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The blood brain barrier (BBB) is central to the neurovascular unit (NVU) where it 
creates a semi-permeable barrier between neuronal tissue and the vascular networks 
that feed the brain. In neurodegenerative conditions and ischaemic stroke, the BBB 
becomes compromised and as a result its permeability increases. This not only 
exacerbates neuronal damage at the site of injury but also causes unwanted 
extravasation of peripheral immune cells into the brain, fuelling the overactivation of 
the immune response. Endocannabinoids and phytocannabinoids have both displayed 
neuroprotective effects, attenuating damage in a range of models including 
Parkinson’s, Huntington’s, amyloid lateral sclerosis and ischaemic stroke. The current 
study aimed to investigate the neuroprotective properties of emerging 
phytocannabinoids; specifically focusing on the BBB and NVU in the context of 
ischaemic stroke pathophysiology. 
 
A four-cell blood brain barrier model was constructed consisting of; human brain 
microvascular endothelial cells (HBMECs), astrocytes, pericytes and neurons. Cells 
were cultured on collagen coated transwell inserts and permeability was assessed 
using transepithelial resistance (TEER). A systematic review was conducted to examine 
work on the neuroprotective properties of minor phytocannabinoids, aside from 
cannabidiol (CBD) and delta 9-tetrahydrocannabinol (Δ9-THC). Following on from this, 
in vitro experiments were conducted using minor phytocannabinoids with the most 
neuroprotective potential; cannabidivarin (CBDV), cannabigerol (CBG) and 
cannabidiolic acid (CBDA). Inserts or monocultures (four cell model and pericyte, 
HBMECs and neuronal monolayers) were subjected to either a 4 h oxygen-glucose 
deprivation (OGD) protocol or an 8 h OGD (astrocyte monocultures), to model 
ischaemic stroke in vitro. Media was analysed for various chemokines and cytokines 





From the systematic review, emerging phytocannabinoids cannabidivarin (CBDV) and 
cannabigerol (CBG) were found to display efficacy in various neurogenerative 
conditions and of the limited available mechanistic data, were found to mediate some 
of their effects through peroxisome proliferator-activated receptor gamma (PPARy). 
Data showed CBDV (300 nM-10 µM) attenuated MCP-1 levels in HBMEC monolayers, 
as well as reducing IL-6 (30 nM, 1 µM and 10 µM; p<0.05) and VEGF (10 nM- 10 µM; 
p<0.01) levels in astrocyte monocultures post OGD. CBG (10 nM-3 µM; p<0.0001) also 
reduced levels of IL-6 secreted by astrocytes and decreased levels of DNA damage 
response proteins including Chk1, Chk2, H2A.X and p53 post OGD. Neither CBG, nor 
CBDV reduced levels of IL-6, VEG or IL-8 in pericytes compared to the vehicle control 
post OGD. Cannabidiolic acid (CBDA) was also investigated and was found to decrease 
IL-6 in pericyte monocultures which was mediated, at least in part, by 5-HT1A 
activation. In a four-cell model of the BBB, CBDA offset increases in permeability vs the 
vehicle control and offered direct protection to neurons, as shown by a lack of 
propidium iodide (PI) staining in CBDA treated cells, indicating live cells are present. 
 
Data presented in this thesis show minor phytocannabinoids CBDV, CBG and CBDA 
provide protection against OGD mediated damage, with CBDA also offering protection 
against increases in permeability of the BBB post OGD. These novel data warrant 
further investigation into the neuroprotective properties of phytocannabinoids, 
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1. General Introduction 
1.1 Prevalence of Neurological disorders with a focus on ischaemic 
stroke 
Globally, neurological disorders such as ischaemic stroke and dementia accounted for 
250.7 million disability adjusted life years in 2015, an increase of 7.45% over the past 
25 years (Cao et al., 2007; Feigin et al., 2019). Of these, stroke is the third leading 
cause of death worldwide; in 2015 6.24 million deaths were reported listing stroke as 
the cause and this number is predicted to rise to 7.8 million deaths by 2030 (Gorelick, 
2019; Lewandowski and Barsan, 2001; Strong et al., 2007). Furthermore, the risk of 
suffering a stroke doubles every 10 years after the age of 55, with around three-
quarters of all strokes occurring in individuals over the age of 65. Similarly, the 
prevalence of dementia in the over 65s is 0.8%, increasing to 28.5% in those aged ≥90 
(Van Der Flier and Scheltens, 2005; Yousufuddin and Young, 2019). As of mid 2019, in 
the UK there are 18.5% of people over 65 and 2.5% aged over 85, with the proportion 
of people over 65 expected to grow to 24.6% by 2045 (Park, 2019). These conditions 
are highly debilitating and place enormous burden on healthcare systems, which is 
only predicted to worsen as the population continues to age and the number at risk of 
suffering from these conditions increases (Feigin et al., 2019).  
 
In recent years, there has been a gradual decline in stroke mortality, thought to be as a 
result of a greater awareness of the risk factors associated with stroke including 
smoking, cardiac disease, physical inactivity, obesity, diabetes, high blood pressure and 
stress (Mozaffarian et al., 2016). Despite this, strokes are still a major public health 
problem exhibiting poor prognosis, high morbidity and mortality, as well as being a key 
cause of chronic adult disability which directly correlates with long term financial 
burden (Moretti et al., 2015). Currently, the only licenced, evidence-based treatments 
for ischaemic stroke are intravenous thrombolysis treatment with tissue-type 
plasminogen activator (tPA) or endovascular thrombectomy (EVT) (Douglas et al., 




however administration is crucially time dependent and not always effective (Bai and 
Lyden, 2015). Recent evidence, however, has led to an extension in the time for a 
viable mechanical clot removal, which may be up to 24 h in certain patients (Douglas et 
al., 2020). Aside from these, no other treatments exist for ischaemic stroke patients 
and there are no interventions that can help with inevitable tissue damage, which is 
inversely proportional to functional recovery. Furthermore, there are several risks 
associated with reperfusion of hypoperfused tissue including post-reperfusion 
haemorrhage, reperfusion injury and haemorrhagic transformation (Bai and Lyden, 
2015). Novel compounds in development for ischaemic stroke have failed to show 
suitable efficacy and potency at both phase 2 and phase 3 clinical trials, either because 
they were found to be toxic to humans or no more efficacious than placebo (Schmidt-
Pogoda et al., 2020). In light of the above, there is a clear need for novel treatments 
for ischaemic stroke as well as therapies to better manage post stoke effects. 
1.2 Pathophysiology of ischaemic stroke and reperfusion injury 
The World Health Organisation (WHO) defines ischaemic stroke as ‘rapidly developing 
signs of focal/global disturbance in cerebral function’ (Howard, 2016). The brain is 
particularly vulnerable to ischaemia due to its high energy dependence and in order to 
maintain normal levels of cellular metabolism it requires 20% of total oxygen and 25% 
of total glucose consumption (Howarth et al., 2012). Therefore, due to the high 
metabolic demand of neuronal tissue, the obstruction of cerebral blood supply causes 
rapid energy depletion with ATP reserves used within minutes. To compensate for the 
absence of oxygen anaerobic glycolysis continues to produce ATP together with lactic 
acid. Early tissue acidosis begins to occur as lactic acid levels rise, causing localised 
tissue damage and inhibition of further ATP production. As a result, ATP dependent ion 
pumps quickly become dysregulated causing cytosolic sodium levels to increase and 
potassium ions to escape to the interstitial space, water then begins to enter cells via 
osmosis resulting in hydroponic cell swelling and oedema (Krause and Edvinsson, 
2002). Ionic imbalances (including high levels of Ca2+ and Na2+) and high levels of 




harmful reactive oxygen species (ROS), hydroxyl radicals (OH-), superoxide (O2- ), as 
well as the particularly damaging peroxynitrite (ONOO-) (Doyle et al., 2008). Oxidative 
stress causes passive DNA damage, including nucleotide base modification as well as 
single and double strand DNA breaks (Chen et al., 1997; Li et al., 2018). 
 
Under physiological conditions the levels of glutamate are carefully regulated, however 
critical ionic imbalances and uncontrolled elevations in Ca2+ as a result of ischaemia-
reperfusion results in membrane depolarisation and the reversal of glutamate 
transporters present in neurones and glial cells (Banati et al., 1993; Nishizawa, 2001). 
Excess extracellular glutamate overstimulates neurons causing a glutamate efflux along 
a concentration gradient and its accumulation within the extracellular spaces of neural 
tissue (Siegal and Sapru, 2011). Increases in Ca2+ ions also activate Ca2+ dependent 
enzymes such as caspases and calpain, a non-lysosomal cysteine protease (Reviewed in 
Momeni, 2011).  
 
Calpains are an abundant family of proteases and early studies have reported the 
presence of calpain mRNA in glia and in the cell body and dendrites of neurons 
(Hamakubo et al., 1986; Perlmutter et al., 1990). More recent studies have implicated 
their activation in post-ischaemic neuronal damage (Bevers and Neumar, 2008; Cao et 
al., 2007) and recent studies have shown calpain inhibitors may offer protection 
against ischaemic damage (Hoang et al., 2011; Potz et al., 2017), but the mechanisms 
in which calpains contribute to ischaemia-reperfusion injury remains to be fully 
elucidated. 
 
During the acute inflammatory phase of ischaemia-reperfusion, a plethora of pro-
inflammatory signals are released in response to oxidative stress, glutamate release 
and tissue damage. These include pro-inflammatory cytokines such as IL-6, IL-8, TNF-⍺ 
and IL-1β as well as adhesion molecules such as ICAM-1, VCAM-1 and MIP-1-⍺, all of 
which are responsible for initiating acute inflammatory phase responses during the 




et al., 2009). TNF-⍺ mediates the early inflammatory response by stimulating the 
synthesis of IL-6 and IL-1. In addition, IL-6 and IL-1 stimulate the vascular endothelium 
increasing the expression of ICAM-1, P-selectin and E-selectin (Chiang et al., 1994; 
Huang et al., 2006). This in turn promotes leukocyte adherence to the endothelium 
and increases endothelial permeability. Meanwhile, IL-8 acts as a potent 
chemoattractant of neutrophils and mediates the diapedesis of peripheral leukocytes 
into the CNS, see Figure 1.1 (Baggiolini et al., 1993; Pieper et al., 2013). Clinically, 
elevations in these cytokines have been found to correlate with stroke severity and 
generally a poorer patient prognosis (Pan and Kastin, 2007; Shaafi et al., 2014). 
 
Reperfusion of hypoperfused tissue is necessary to prevent further damage and 
reinstate normal levels of cellular respiration. However, paradoxically the return of 
blood flow brings with it the potential for further damage to already fragile neuronal 
tissue, hindering neuronal repair mechanisms and overall limiting recovery (Del Zoppo 
and Mabuchi, 2003). The damaging effects of reperfusion injury have been observed in 
animal models of acute stroke and have been linked to increases in infarct volume as 
well as early opening of the BBB. Pivotal features of reperfusion injury include, 
oxidative stress, mitochondrial dysfunction, inflammation and BBB breakdown, which 
is closely followed by peripheral immune cell infiltration (L and X, 2016). Furthermore, 
studies have found that acute ischaemic stroke patients exhibit elevations in 
malondialdehyde (MDA), a marker of oxidative stress as well as reduced antioxidant 
capacity (Menon et al., 2020; Milanlioglu et al., 2016).  
 
In response to elevated levels of ROS and pro-inflammatory cytokines generated 
during ischaemia-reperfusion, stored P-selectin is translocated to the cell surface of 
endothelial cells. Post-reperfusion, levels of P-selectin peak at around 6 h and causes 
rapid activation of the endothelium promoting the adherence and rolling of peripheral 
leukocytes. Meanwhile, the activated endothelium synthesises E-selectin which 




integrins in cerebral ischaemia has been highlighted in several studies (Huang et al., 
2000).  
 
Once blood flow returns to hypoperfused tissue, oxygen becomes a catalyst for 
xanthine oxidase to convert hypoxanthine to uric acid producing superoxide, which is 
subsequently converted to hydrogen peroxide and the hydroxyl radical (Granger, 
1988). These additional elevations in ROS, together with those generated during 
ischaemia, cause lipid and protein peroxidation and the release of fatty acids from 
cellular membranes generating various eicosanoids such as thromboxanes, 
prostaglandins and leukotrienes. In particular, thromboxane-A2 contributes to platelet 
aggregation and blood vessel constriction, exacerbating damage and contributing to 
the no-flow phenomenon. In support of this, studies have shown that antagonising the 
thromboxane-A2 receptor led to a reduction in microglia and macrophage activation in 
mice, as well as the attenuation of pro-inflammatory cytokines (Yan et al., 2016). 
Figure 1.1: Diapedesis of a peripheral neutrophil into the central nervous system (CNS). IL-8 acts as a 
chemoattractant, whilst increased expression of adhesion molecules by human brain microvascular 
endothelial cells (HBMECs), such vascular cell adhesion molecule (VCAM)-1 and (intracellular adhesion 




1.3 The blood brain barrier (BBB) and neurovascular unit (NVU) 
Delicate neuronal tissue is protected by the blood brain barrier (BBB), a specialised 
structure formed by microvascular endothelial cells, pericytes and astrocytes (Abbott 
et al., 2006, 2010). These cells, together with microglia, neurons and various matrix 
components form what is known as the neurovascular unit (NVU)(Blanchette and 
Daneman, 2015; McConnell et al., 2017). The BBB restricts the movement of blood-
borne components into the CNS, maintaining its immune privilege status as well as 
preventing the entry of xenobiotics.  
 
Endothelial cells form the vascular component of the BBB, they help to maintain 
angiogenesis and vasodilation, secreting growth factors such as vascular endothelial 
growth factor (VEGF) and vasodilators such as nitric oxide (NO), ensuring neurons have 
adequate blood flow to meet metabolic demand. Structurally brain endothelial cells 
differ from endothelial cells found in the periphery; they lack fenestrations 
(Fenstermacher et al., 1988), have low pinocytotic activity and a larger mitochondrial 
content (Oldendorf et al., 1977; Stewart et al., 1994), which is essential to maintain the 
large number of ATP dependent transporters. Endothelial cells are also connected by 
specialised tight junctional proteins (TJs) namely, occludins, claudins, zonula occludins 
(ZO) and junctional adhesion molecule (JAMS), see Figure 1.2 (reviewed in Schoknecht 
et al., 2015). TJs maintain low paracellular permeability allowing only small polar 
molecules to cross the barrier unrestricted whilst transporter proteins, namely glucose 
transporter 1 (GLUT-1) and various solute carrier proteins (SLCs), facilitate the entry of 
essential larger molecules such as glucose and amino acids into the CNS (Pardridge et 
al., 1990; Stewart et al., 1994; Zlokovic, 1995 and reviewed in Barar et al., 2016). 
Additionally, efflux transporter proteins such as P-glycoprotein (P-gp) and breast 
cancer resistance protein (BCRP), which are present in the luminal side of the 
endothelium, function to prevent the entry of harmful solutes into the brain (Abbott et 
al., 2010). Pericytes provide mechanical support to endothelial cells, wrapping around 
the endothelium via peg and socket style arrangements covering 70-80% of the 




Zimmermann, 1923). These cells are part of the vascular smooth muscle lineage and in 
the brain they secrete vasoactive substances to generate functional responses to 
changes in the BBB microenvironment (Dore-Duffy, 2008; Von Tell et al., 2006). 
Specifically, these cells help endothelial cells regulate blood flow, capillary diameter, 




Figure 1.2. A schematic of the tight junctional proteins including zonnula occludins (ZO-1,2,3), junctional 
adhesion molecules (JAMs), claudins 3,5 and occludin that are present between endothelial cells which 
form the blood-brain barrier (BBB). Created by the author. 
 
Astrocytes are supportive glial cells and their end feet envelope both pericytes and 
endothelial cells, enabling crosstalk between the vascular component of the BBB and 
neurons. They form connections with all neuronal synapses and although they do not 
propagate impulses themselves, they help to regulate neuronal excitability playing a 
key role in neurotransmitter homeostasis (Ransom and Ransom, 2012). Astrocytes also 
provide metabolic support for neurons and express transporters for glutamate, GABA, 
and glycine to facilitate rapid reuptake of neurotransmitters from the synaptic cleft. 




the extracellular space to prevent excitotoxicity and astrocytes conduct glutamate 
reuptake against a concentration gradient using ATP, sodium-dependent glutamate 
transporters. (Sattler and Rothstein, 2006; Seifert et al., 2006; Sofroniew and Vinters, 
2010).  
 
Microglial cells are resident immune cells of the CNS, participating in immune 
surveillance, neuronal plasticity and CNS homeostasis which is governed by neuronal-
glial crosstalk (da Fonseca et al., 2014; Tremblay et al., 2011). Microglia migrate to the 
brain parenchyma during embryogenesis where they closely associate themselves with 
the brain microvasculature, participating in BBB development and angiogenesis (Alliot 
et al., 1999; Nayak et al., 2014). Normally the activation state of microglia is tightly 
controlled; they are either directed to the ameboid pro-inflammatory M1 phenotype 
or the anti-inflammatory, ramified M2 phenotype (Kettenmann et al., 2011). The M1 
phenotype secrete a variety of proinflammatory mediators such as IL-6 and TNF-⍺ to 
signal to nearby cells of the presence of tissue injury and recruit immune cells. 
Conversely, the M2 phenotype governs anti-inflammatory mechanisms, immune 
surveillance, tissue repair and regeneration, as well as contributing extensively to 
synaptic plasticity and remodelling (Benarroch, 2013). 
1.3.1 Impact of ageing on the BBB and NVU 
Since ischaemic stroke occurs predominantly in the elderly, it is important to recognise 
age-related changes that occur within the NVU. Neuronal loss, cellular senescence, 
oxidative stress and impaired cellular metabolism occur as part of the natural aging 
process, but as they accumulate there are consequences to the normal physiology of 
the brain and NVU.  Thus, not only is the prevalence of neurogenerative conditions and 
ischaemic stroke increased with age, but the capacity of the brain to cope with such 
diseases is also diminished. Senile endothelial cells exhibit reduced secretion of growth 
factors which impairs the ability of the brain microvasculature to maintain 
angiogenesis with age (Lähteenvuo and Rosenzweig, 2012). Pericytes also undergo 
morphological changes with aging which contribute to BBB impairment and 




rats, Hughes et al., (2006) found increases in ⍺-smooth muscle actin as well as 
alterations in the length and orientation of desmin, features typically found pericyte 
senescence. Bell and collegues (2010) showed that there is pericyte loss with aging in 
platelet-derived growth factor receptor (PDGFR)-𝛽 deficient mice, which led to 
microvascular reductions, diminished cerebral blood flow and BBB breakdown. Senile 
astrocytes exhibit marked hypertrophy, increased expression of glial fibrillary acid 
protein (GFAP), decreased density of glucose and glutamate-aspartate transporters 
(GLUT-1 and GLAST), as well as a increases in levels of aquaporin-4 (Berciano et al., 
1995; Ferrer, 2017; Nichols et al., 1993; Owasil et al., 2020; Peinado et al., 1998). 
Therefore, senile astrocytes less equipped to maintain normal physiology and mitigate 
CNS pathologies and are more vulnerable to damage. 
1.3.2 Consequences of ischaemia-reperfusion on BBB physiology 
Ischaemia generates large amounts free radicals triggering oxidative stress, lipid 
peroxidation, protein dysfunction as well as directly downregulating TJs and activating 
MMPs which degrade extracellular matrix (Haorah et al., 2007; Li et al., 2018; 
Schreibelt et al., 2007). Moreover, under normal physiological conditions endothelial 
cells limit immune cell infiltration into the CNS, however post ischaemic BBB 
breakdown, together with increased expression of chemokines and adhesion 
molecules, enables uncontrolled infiltration of peripheral leukocytes into the CNS 
where they secrete matrix metalloproteinases (MMPs) and additional proinflammatory 
mediators, further exacerbating BBB breakdown (Gidday et al., 2005). Following 
ischaemia there is also a significant degree of pericyte loss and remaining pericytes 
have an increased expression of vascular endothelial growth factor (VEGF), which is 
known to contribute to increases in BBB permeability and correlates to poor prognosis 
in stroke patients (Bai et al., 2015; Escudero et al., 2020). Both of these 
pathophysiological responses have been shown to be detrimental to the BBB function 
as even a modest (20%) loss of pericyte coverage induces vascular changes at the BBB. 
Pericyte loss is linked to abnormal astrocyte polarization, increased endothelial 
transcytosis flux and ultimately compromised BBB integrity (Armulik et al., 2010; Bell 





During ischaemia, damaged neurons stimulate the proliferation of astrocytes 
bordering the lesion, as well as the activation of astrocytes in the ischaemic core 
(Barreto et al., 2011; Popa-Wagner et al., 2007). This process, known as astrogliosis, 
triggers alterations in morphology including hyperplasia and hypertrophy, increases in 
the expression of filament proteins such as GFAP and nestin, as well as stimulating the 
secretion of proinflammatory cytokines such as TNF-⍺, IL-1𝛽 and IL-6 (Chiang et al., 
1994; Herx and Yong, 2001; Li and Chopp, 1999; Liu and Chopp, 2016; Sims and Yew, 
2017). Hypertrophic astrocytes exhibit elongated processes which envelope the 
ischaemic region in an attempt to contain the damaged tissue, preventing its spread to 
the penumbral region which is potentially salvageable (Kajihara et al., 2001). After a 
few days post ischaemia, astrocytes begin to form a glial scar which consists of reactive 
astrocytes and extracellular matrix components such as chrondroitin proteoglycans 
(CSPGs) and whilst the scar reduces in size over time, interwoven astrocytic end feet 
and higher levels of GFAP remain present (Sims and Yew, 2017). The development of a 
glial scar can be both beneficial and counterproductive (reviewed in Ferrer, 2017), 
whilst it offers protection to the surrounding salvageable and healthy tissue it can also 
hinder neuronal repair mechanisms. Reactive astrocytes are protective against nitric 
oxide toxicity post ischaemia (Chen et al., 2001) and astrocyte ablation prolonged 
infiltration of CD45-positive leukocytes and the failure of the BBB (Bush et al., 1999). In 
addition, Li and colleagues found that mice lacking in characteristic reactive astrocyte 
markers, GFAP and vimentin, exhibited larger infarct volumes and a 44% lower uptake 
of glutamate vs WT controls, highlighting the protective role of reactive astrocytes in 
ischaemia (Li et al., 2008). On the other hand, prolonged astrocyte activation post 
stroke can increase neuronal damage via excitotoxic damage, increases in 
proinflammatory cytokines, as well as contributing to enhanced BBB permeability and 
preventing axonal sprouting (Li et al., 2014; Silver and Miller, 2004).  
 
Post insult, microglia are rapidly activated by excitotoxic signalling and undergo 




plethora of proinflammatory cytokines and nitric oxide which stimulates surrounding 
cells and recruits other microglia to the site of injury, causing a cycle of uncontrolled 
activation, which can lead to additional tissue damage (Jolivel et al., 2015; Taylor and 
Sansing, 2013). Likewise, quantitative evidence has showed that 24 h post insult,  the 
ischaemic core exhibits marked changes in microglia including increased CD11b 
expression, shorter processes and amoeboid morphology (Morrison and Filosa, 2013). 
Excessive, microglial activation can disrupt BBB integrity post stroke, 
downregulating/redistributing tight-junctional proteins and reorganising the actin 
cytoskeleton (da Fonseca et al., 2014). Despite the clear role of microglia in facilitating 
damage post ischaemia, studies have shown that the absence  of microglia results in a 
larger infarct size and the deletion of microglia can adversely affect the integrity of the 
BBB (Dudvarski Stankovic et al., 2016; Szalay et al., 2016). Thus, some degree of 
microglial activation is necessary to minimise post-stroke injury, but this must be 
adequately controlled to prevent further tissue damage. 
1.4 Endocannabinoids and the endocannabinoid system 
The endocannabinoid system consists of the cannabinoid receptors (CB1 and CB2), 
endogenous lipid ligands that activate them and the enzymes involved in their 
synthesis and degradation. CB1 was first cloned in 1990, followed by CB2 in 1993 which 
shares only 44% homology to CB1 (Howlett et al., 2002; Munro et al., 1993). Both 
receptors are G-protein coupled receptors part of the G1/0 family and as such their 
activation inhibits adenylyl cyclase, a key regulatory enzyme responsible for a diverse 
range of cellular responses, whilst positively activating mitogen-activated protein 
kinases (Pertwee and Ross, 2002). The distribution of the cannabinoid receptors varies 
throughout the body, while CB1 receptors are abundant in the CNS, CB2 receptors are 
present but expressed at a significantly lower level (Howlett et al., 2002; Pertwee, 
1997). CB1 receptors are present within the cortex, basal ganglia, hippocampus and 
cerebellum where they are localised to axon terminals and terminal axon segments 
(Herkenham et al., 1990). Aside from the CNS, CB1 receptors are also found in 




1997). On the other hand, CB2 receptors are expressed by immune cells such as 
resident microglia where they play a role in orchestrating the immune response, 
including the release of pro-inflammatory cytokines.  
 
Shortly after CB1 and CB2 were discovered, the two most studied endocannabinoids 
anandamide (AEA) and 2-arachidonylglycerol (2-AG) were identified from pig brain and 
canine gut respectively (Devane et al., 1992; Mechoulam et al., 1995). They are 
synthesised on demand via the enzymatic hydrolysis of precursors derived from 
phospholipid bilayers in response to cellular stimuli, specifically elevations in 
intracellular calcium. Synthesis of 2-AG occurs when phospholipase C is converted to 
diacylglycerol, which is then converted to 2-AG via the enzyme diacylglycerol (DAG) 
lipase. Conversely, AEA is produced from the phospholipid N-acylphosphadiyl 
ethanolamide. AEA is also synthesised by the same route as two other major 
endocannabinoids oleoylthanolamide (OEA) and palmitoylethanolamide (PEA), which 
in general, are found in higher concentrations than AEA (Di Marzo et al., 2005). 
Altogether these compounds are known as the N-acylethanolamines (NAGEs) and are 
known to exert anti-inflammatory effects. The enzymes fatty acid amide hydrolase 
(FAAH) and monoacylglycerol lipase (MAG-lipase) hydrolase AEA (as well as OEA and 
PEA) and 2-AG respectfully (Reviewed in Di Marzo et al., 2005).  
1.4.1 Endocannabinoid system and neuroprotection 
Modulation of the endocannabinoid system can illicit neuronal plasticity, 
neuroprotection and neurotoxicity, indeed endocannabinoids are known to regulate 
mood, synaptic excitability, hypokinesia and analgesia due to their activity at CB1 and 
other receptors such as 5-HT1A, TRPV1 (Cristino et al., 2020). Moderate increases in 
endocannabinoids post exercise, particularly AEA and 2-AG, may be correlated with 
improvements in neuronal plasticity (Heyman et al., 2012; Raichlen et al., 2012; 
Sparling et al., 2003). Heyman et al., (2012) found that increases in AEA in cyclists was 
positively correlated with increases in brain derived neurotrophic factor (BDNF), and 




increased levels of OEA in healthy volunteers (Stone et al., 2018). Thus, elevations in 
endocannabinoids post exercise could be linked to the positive effects of physical 
activity on cognitive function and mood. Endocannabinoids and endocannabinoid 
receptors are also affected post neuronal injury, for example in a model of stroke CB1 
knockout mice exhibited higher post-ischaemic mortality, greater infarct sizes and 
worse neurological function and studies in humans have found increased levels of AEA 
in stroke and PD patients (Naccarato et al., 2010; Parmentier-Batteur et al., 2002; 
Pisani et al., 2010; Schäbitz et al., 2002). 
1.5 Phytocannabinoids  
Phytocannabinoids are compounds that are naturally present in the cannabis sativa 
herb, with cannabidiol (CBD) and delta 9-tetrahydrocannabinol (Δ9-THC) being the 
most widely studied. Δ9-THC was first identified in by Gaoni and Mechoulam, (1964) 
and later synthesised in 1967 by the same group (Mechoulam et al., 1967). Initial 
studies on cannabis focused on the analgesic and sedative properties of THC (Paton, 
1973) and its psychoactive effects (Pertwee, 1988), which were later found to be 
mediated by its action at CB1 receptors. CBD was first identified in 1963 (Mechoulam 
and Shvo, 1963) and unlike Δ9-THC it has little affinity for CB1 receptors, thus displaying 
no psychotropic activity. Since its discovery, CBD has shown efficacy in a plethora of 
conditions largely due to its promiscuity at different receptors; acting as an 
antioxidant, anti-inflammatory and anticancer agent, as well as displaying anxiolytic 
and anti-convulsant properties (Pisanti et al., 2017; Russo and Marcu, 2017). Other 
phytocannabinoids were discovered not long after Δ9-THC and CBD, including 
cannabigerol (CBG) which was first identified in 1964 (Gaoni and Mechoulam, 1964) 
cannabichromene (CBC) in 1966 (Gaoni and Mechoulam, 1966), cannabidivarin and 
THCV in 1970 (Gill, Paton and Pertwee 1970, Vollner, Bienieke and Korte 1969).  
1.5.1 Other targets for cannabinoids 
Cannabinoids can also modulate a wide range of other receptors aside from the 




peroxisome proliferator activated receptors (PPARs), serotonin receptors and transient 
receptor potential (TRP) channels, as well as orphan GPRs such as GPR55, GPR18 and 
GPR119 (De Petrocellis and Di Marzo, 2010). 
 
PPARs are ligand activated transcription factors that are part of the nuclear hormone 
superfamily and are divided into three subtypes; PPAR⍺, PPARδ and PPAR𝛾. They are 
expressed in almost every cell in the body and are responsible for regulating different 
aspects of gene expression, primarily those involved in fatty acid metabolism and 
inflammation (reviewed in Pistis and O’Sullivan, 2017). Upon activation, for example by 
hormonal or environmental stimuli, PPARs bind to the retinoid X receptor (RXR) 
forming a heterodimer. This triggers the recruitment of coactivators such as PGC-1⍺ or 
E1AS binding protein p300 which have histone acetylase activity (Marion-Letellier et 
al., 2016). The PPAR-RXR heterodimer complex binds along with a cofactor to regions 
of DNA known as peroxisome proliferator response elements (PPREs) which are 
present on the promotor regions of target genes (Berger and Moller, 2002; Osumi et 
al., 1991). It has been deduced that the acetylation of histone proteins alters the 
organisation of the tightly packed chromatin, thus enabling RNA polymerase II to bind 
and imitate gene transcription. In the absence of a stimulus, heterodimers are 
associated with a co-repressor complex which blocks gene transcription (Ziouzenkova 
and Plutzky, 2004). PPAR⍺ is predominantly involved in regulating lipid and lipoprotein 
metabolism and its expression is relatively high in cardiomyocytes, hepatocytes, the 
kidney, brown adipose tissue, the GI tract (enterocytes) and immune cell types 
including monocytes and microglia (Herkenham et al., 1990; Marion-Letellier et al., 
2016; Mottillo et al., 2012). PPARδ expression is ubiquitous but varies from tissue to 
tissue and can be altered in disease states. PPARy is expressed in brown and white 
adipose tissue, the pancreas, large intestine and various immune cells and its 
activation mediates inhibition of helper T-cells responses, as well as having a role in 
glucose metabolism, regulation of fatty acid storage, adipocyte differentiation, insulin 
sensitivity and cell growth (Tyagi et al., 2011). All PPAR isoforms have a central role in 




binding domains which enables them to bind a wide range of ligands, including their 
natural ligands such as fatty acids and eicosanoids (Gervois et al., 2000; Krey et al., 
1997). Not surprisingly, as cannabinoids are lipid-based molecules, a number of 
endocannabinoids and phytocannabinoids have been shown to bind and/or activate 
different PPAR isoforms (O’Sullivan, 2016). PPAR⍺ has been shown to be activated by 
the endocannabinoid like N-acylethanolamines OEA and PEA at concentrations 
achieved under normal physiology (Fu et al., 2003). Further, Sun et al., (2007) 
confirmed that OEA, PEA and AEA bind to the PPAR⍺ binding domain. THC was found 
to increase the activity of PPAR𝛾 (O’Sullivan et al., 2005) and the ability of THC to bind 
to PPAR𝛾 was later confirmed by Granja et al., (2012). Emerging evidence has also 
supported the interaction of PPAR𝛾 with other phytocannabinoids such as 
cannabigerol (CBG) and tetrahydrocannabidiolic acid (THCA) and that interaction with 
this receptor mediates some of their protective effects (Stone et al., 2020). 
 
Transient receptor potential (TRP) channels are a group of membrane spanning 
proteins comprised of four subunits and six transmembrane helices (S1-S6). There are 
six subfamilies of TRP channels; vallinoid type (TRPV), ankyrin type (TRPA), melastatin 
type (TRPM), polycystin type (TRPP), canonical type (TRPC) and mucolipin (TRPML), 
which are further divided into different isoforms. TRP channels are predominantly 
expressed in nociceptive sensory neurons where they mediate the transduction of a 
number of chemical and physical stimuli, including but not limited to pain, pH and 
temperature sensation (Reviewed in Zheng, 2013). Following exposure to a stimulus 
they can gate both mono and divalent cations, including Ca2+, however the full 
mechanisms associated with TRP activation have yet to be fully understood (Gees et 
al., 2010). TRP channels, specifically TRPV1, TRPA1, TRPV4, have been implicated in the 
pathogenesis of several neurodegenerative disorders and ischaemic stroke (Huang et 
al., 2020; Miyanohara et al., 2015; Pires and Earley, 2018). TRPV4 channels expressed 
in astrocytes form complexes with AQP4, contributing to osmotic homeostasis, 
however under ischaemic conductions TRPV4 channels can become overactivated 




activation has also been implicated in exacerbating neuronal injury in ischaemic stroke 
and interestingly, TRPV1 antagonist capsazepine was found to reduce neurological 
deficits and infarct volume in mice post middle cerebral artery occlusion (MCAO) 
(Miyanohara et al., 2015).  
 
To date research has found that endocannabinoids, phytocannabinoids and synthetic 
cannabinoids can activate TRPV1,2,3,4, TRPA1 and TRM8, either as agonists or 
antagonists, with the majority of research focused on their activation of TRPV1 (Muller 
et al., 2019). Table I provides a summary of the roles of the different TRP channels that 

























Table I: Summary of the different TRP channels activated by endo and phytocannabinoids; TRP 
channels of vallinoid type (TRPV1,2,3,4), ankyrin type (TRPA1), melastatin type (TRPM8). 
Endocannabinoids; anandamide (AEA) and oleoylethanolamide (OEA). Phytocannabinoids; 
cannabidiol (CBD), delta-9 tetrahydrocannabinol (Δ9-THC), cannabidivarin (CBDV, cannabigerol 
(CBG), cannabigerolic acid (CBGA), cannabigerovarin (CBGV), cannabichromene (CBC), 
cannabinol (CBN) and tetrahydrocannabidivarin (THCV). 
TRP 
Channel 
Location Role in normal/pathophysiology Activation by 
cannabinoids   
TRPV1 All major classes of 
nociceptive neurons, 
detected in: dorsal root 
ganglion (DRG), 
trigeminal ganglion (TG) 
and nodose ganglion 
(NG).(Nilius et al., 2008) 
• Responsible for strong burning 
sensations and cutaneous pain. 
• Analgesia can be evoked if these 
channels are desensitised  
• Histaminergic itch. 
(Shim et al., 2007) 
AEA  with a binding affinity 
similar to capsaicin (Zygmunt et 
al., 1999). OEA (Ahern, 2003). 
Activated by CBD, CBG and 
CBC,  CBDV can also activate 
and desensitise (Iannotti et al., 







Medium and large 
diameter sensory 
neurons. Heart, GI tract, 
smooth muscle. 
Highly expressed in 
macrophages. (Nilius et 
al., 2008) 
• Insensitive to protons but can be 
activated by high temperatures (>52 
°C) and inflammation.  
• Chronic pain 
• Mechano-sensor in vascular smooth 
muscle cells. (Nilius et al., 2008) 




by CBD (EC50 3.7 μM), THC and 
CBN (Maréchal and Zou, 2013; 










• Responsible for pain and itch 
sensations. 
• Thermosensor between 33-39°C. 
Becomes sensitized in repeated heat 
application. 
Not activated by 
endocannabinoids. CBD and 
THCV were both able to 
activate TRPV3, CBGV and 
CBGA were found to 
desensitise TRPV3 (De 











(Benfenati et al., 2007) 
• Role in vascular function  
• Osmotic pressure in the brain. 
• Skin barrier function and nociception 
• Responds to 25-34 °C (Nilius et al., 
2008) 
CBDV and THCV evoked a Ca2+ 
response in TRPV4 expressing 
cells. Desensitised by CBN, 
CBGV, CBGA, CBG (De 
Petrocellis et al., 2012) 
TRPA1 A subset of peripheral 
sensory neurons. Dorsal 
root, vagal and 
trigeminal ganglion 
neurons. 
(Baraldi et al., 2010) 
• Activated by compounds in mustard, 
garlic etc. and  by temperatures below 
17°C (Bandell et al., 2004; Baraldi et 
al., 2010) 
• Important role in neuropathic pain, 
hyperalgesia, inflammatory pain. 
AEA exhibits a high efficacy.  
CBC (EC50 90 nM), CBD ( EC50 
110 nM), CBN ( EC50 180 nM).  
(De Petrocellis et al., 2008, 
2011, 2012) 
TRPM8 Primary afferent 
neurons (Story et al., 
2003). 
• Activated below 27°C in response to 
cooling compounds, menthol eucalyptus. 
•  Involved in androgen receptor positive 
prostate cancers  
Antagonised by AEA and 
phytocannabinoids 
including  CBD, CBG, THC, and 





Serotonin receptors, otherwise known as 5-hydroxytryptamine (5-HT) receptors are 
involved in the regulation of mood, manifestation of anxiety and depression, as well as 
immune and cardiovascular regulation. Most 5-HT receptors are metabotropic and are 
coupled to G-proteins which mediate their signal transduction. Cannabinoids have 
been shown to modulate the 5-HT1A subtype of these receptors, having effects such as 
neuroprotection, reducing the stress response and acting as anti-emetics. 5-HT1A 
receptors are widely distributed in the brain and areas associated with modulating 
stress and anxiety, such as the raphe nuclei. Resstel et al., (2009) found that CBD (10-
20 mg.kg-1) decreased stress induced cardiovascular responses which was blocked by 
WAY100635, a 5-HT1A receptor antagonist. At low doses (5-10 mg.kg-1) CBD is  an 
effective antiemetic in different models of nausea (Kwiatkowska et al., 2004; Rock et 
al., 2008). Studies have shown that CBDs acidic precursor, cannabidiolic acid (CBDA 
0.1/0.5 mg.kg-1, i.p) acts as a more potent anti-emetic than CBD, reducing nausea in 
three different models in mice, an effect mediated through the 5-HT1A (Bolognini et al., 
2013). CBG has been found to act as a 5-HT1A receptor antagonist (Cascio et al., 2010) 
and recently CBGs neuroprotective effects against rotenone induce neurotoxicity were 
mediated partly by interaction with 5-HT1A receptors (Echeverry et al., 2020).  
 
GPR55/ GPR18 
Despite having a low sequence homology to CB1 (13.4%) and CB2 (14.4%), orphan 
GPCR, GPR55 was postulated to be a third cannabinoid receptor because of its 
activation by some cannabinoid like compounds. It was first identified in 1999 
(Sawzdargo et al., 1999) and is expressed on immune cells, including monocytes, NK 
and microglial cells and is present in both the CNS and the GI tract (Ryberg et al., 
2009). An accumulating body of evidence implicates GPR55 in neuronal 
hyperexcitability and epilepsy, corroborated by recent findings indicating that GPR55 
expression is elevated in the epileptic hippocampus (Gray and Whalley, 2020; 
Rosenberg et al., 2018). Ryberg et al., (2007) showed that cannabidiol displayed 
antagonist properties at GPR55 and that anandamide stimulated GTPγS binding with 




antiepileptic effects; Kaplan and colleagues (2017) found that GPR55 was responsible 
for CBDs effects on increasing inhibitory neuronal excitability. Despite these promising 
advances regarding the biological roles of GPR55 and its cannabinoid ligands, the link 
between the role of GPR55 and other pathologies that affect the CNS, such as 
neuroinflammation, remains unclear. Saliba et al., (2018) found that activation of 
GPR55 by antagonists mediated protective effects in microglial cells and Hill et al., 
(2018) found that GPR55 activation led to an increase in the proliferation rate of 
human neuronal stem cells in vitro.  
 
GPR18, another orphan GPCR, has been found to be activated by Δ9-THC and abnormal 
cannabidiol. Early studies showed GPR18 is richly expressed in the testis and spleen 
(Gantz et al., 1997) and was later found to also be expressed in peripheral leukocytes, 
microglia and lymph nodes (McHugh, 2012). GPR18 is also involved in the action of N-
arachidonoylglycine, the carboxylic metabolite of anandamide, in the modulation of 
the immune response and the cross talk between microglia and neurons (Burstein et 
al., 2011).  
1.5.2 Phytocannabinoids, ischaemic stroke and neuroprotection 
Accumulating evidence supports the neuroprotective effects of phytocannabinoids in 
various models of neurodegeneration and neurological dysfunction (Cristino et al., 
2020; Fernández-Ruiz et al., 2013). Due to their lipophilic nature they readily penetrate 
the BBB (Deiana et al., 2012) and recently Brzozowska et al., (2016) found that CBD 
was not a substrate for P-gp or BCRP, thus these transporters do not limit CBD uptake 
into the brain. Preclinical studies on Δ9-THC and CBD have been conducted in models 
of AD, PD, ALS, MS, traumatic brain injury (TBI) and stroke. In an animal model of AD, 3 
mg.kg Δ9-THC + COX-2 inhibitor was shown to reduce amyloid beta plaques (Maroon 
and Bost, 2018). In vitro CBD attenuated the damaging effects of amyloid beta (AB) 
peptide and in a murine model of AD CBD attenuated reactive gliosis and decreased 
the production of pro-inflammatory mediators (Esposito et al., 2006, 2007; Iuvone et 




the immune response; including microglial activity and T-cell proliferation (Kozela et 
al., 2010). In PD patients, CBD decreased PD associated psychosis symptoms and 
improved patient well-being (Chagas et al., 2014; Zuardi et al., 2009). In ischaemia, Δ9-
THC and CBD have also displayed neuroprotective effects in various in vitro and in vivo 
models (Alvarez et al., 2008; Castillo et al., 2010; Louw et al., 2000; Zani et al., 2007). 
Pre-treatment with CBD (100 and 200 ng/rat) for five days prior to initiating a 60 
minute MCAO resulted in a significant decrease in infarct size (Khaksar and Bigdeli, 
2017). Ceprián et al., (2017) found that CBD administration ameliorated excitotoxic 
associated damage and improved neurological outcome post MCAO. Other 
phytocannabinoids have also exhibited neuroprotective potential (Reviewed in Stone 
et al., 2020), CBDV and Δ9-THCV have displayed efficacy an antiepileptics (Amada et al., 
2013; Hill et al., 2010, 2013; Ma et al., 2008), CBG as an anti-neuroinflammatory agent 
(Carrillo-Salinas et al., 2014; Rodríguez-Cueto et al., 2018) and Δ9-THCA as a 
neuroprotectant (Nadal et al., 2017).  
 
Clinical studies assessing the therapeutic potential of cannabinoids and neurological 
disorders have been predominantly in epilepsy, MS and Parkinson’s. In a human trial 
with MS patients, Δ9-THC ameliorated urinary incontinence, spasticity and tremors in 
MS, but no effect on disease progression was observed (Baker et al., 2000; Freeman et 
al., 2006; Zajicek et al., 2003). So far, CBD alone (Epidiolex, GW Pharmaceuticals, 
Cambridge, UK) and as a 1:1 formulation with Δ9-THC (Sativex, GW Pharmaceuticals, 
Cambridge, UK) are the only licenced cannabis-based medicines and are prescribed to 
treat Dravet syndrome and Lennox-Gastaut syndrome, both rare forms of childhood 
epilepsy. There are, however phase 3 trials in the pipeline to assess whether CBD oil is 
effective in ALS (Urbi et al., 2019), as well as phase 2 trials to assess the efficacy of 
Sativex in spasticity associated with motor neuron disease and multiple sclerosis (MS) 
(Markovà et al., 2019; Riva et al., 2019). The aforementioned findings emphasise the 
neuroprotective potential of cannabinoids, the role of the endocannabinoid system in 




1.6 Summary  
Most therapies targeting stroke and other neurodegenerative conditions have only 
targeted neurons in order to preserve functionality. However, from the high number of 
failed neuroprotective agents, it is clear that protecting neurons alone is insufficient to 
improve neurological outcome in these conditions. Various compounds have displayed 
efficacy in animal models of ischaemic stroke, however there has been little success 
when these compounds reach clinical development (Schmidt-Pogoda et al., 2020). 
O’Collins et al., (2006) highlighted the importance of only taking worthy drugs to 
clinical trial and only if the animal study data is robust, valid and relevant to the clinical 
cause. In order to be a successful treatment in conditions such as ischaemic stroke, 
multiple facets of the disease need to be targeted. The unique pharmacology of 
cannabinoids makes them particularly desirable as novel therapies as they can 
potentially target multiple areas of dysfunction, as well as modulate different cells that 
constitute the NVU. 
1.7 Thesis aims 
1.7.1 Rationale 
In vitro models to simulate stroke are useful tools to screen neuroprotective agents 
and determine which compounds look the most promising to be taken to in vivo 
studies (Antonic et al., 2012). We aimed to develop a more clinically relevant four-cell 
NVU model consisting of primary human cells to model ischaemic stroke in vitro using 
a previously described oxygen-glucose deprivation (OGD) protocol (Hind et al., 2015, 
2016). Using OGD to model stroke exhibits the majority of effects associated with in 
vivo ischaemia-reperfusion injury and is therefore a relevant methodology to simulate 
stroke in vitro (Holloway and Gavins, 2016). Secondly, we aimed to gain insight into the 
neuroprotective properties of CBG, CBDV and CBDA or lack thereof and to establish 
whether these compounds may be useful as potential treatments for ischaemic stroke. 
CBG and CBDV effects in ischaemia are largely unknown but were found to be 




on the results of our systematic review; Chapter 4). In light of these data, we 
hypothesised that CBDV and CBG would also prove to be protective in a model of 
ischaemic stroke. CBDA has been found to exhibit similar biological and 
pharmacological properties to CBD, but is significantly overlooked compared to its 
neutral derivative (Reviewed in Formato et al., 2020). Given that previous work from 
our group found CBD prevented increases in BBB permeability in an OGD model (Hind 
et al., 2016), we hypothesised that CBDA may also be protective against BBB 
permeability, perhaps by a similar mechanism to CBD. 
1.7.2 Objectives 
Therefore, the aim of this thesis was to assess the neuroprotective properties of minor 
phytocannabinoids, CBG, CBDV and CBDA, on cells of the NVU and to assess whether 
CBDA, like CBD, was able to modulate BBB permeability in an in vitro model of 
ischaemic stroke. To achieve this, we set out to test CBG, CBDV and CBDA in 
monocultures of cells of the NVU and to test CBDA in a BBB model of our own design. 
To simulate ischaemic stroke in vitro we used an oxygen-glucose deprivation (OGD) 
protocol.  
 
Specifically, our objectives were as follows: 
1. To develop a more clinically relevant in vitro BBB model comprised of primary 
human cells to study permeability. 
Based on evidence from previous studies on CBD, results from our systematic review 
and the wider literature: 
2. To investigate the neuroprotective properties of minor phytocannabinoids, 
CBG, CBDV and CBDA in cells of the NVU using an OGD protocol. 
3. To investigate whether CBDA modulates BBB permeability when administered 
before an OGD protocol.  
4. To explore the potential mechanisms of action by which CBDV, CBG and CBDA 




In addition to my central thesis aims, during my PhD studies we also investigated the 
levels of endocannabinoids on volunteers who underwent exercise activities and 
singing. This provided additional lab training, academic publication writing and clinical 
study design experience. Specific aims of this project were: 
 
1. To assess whether different activities influenced mood as measured by visual 
analogue score (VAS) questionnaire. 
2. To establish whether changes in mood were correlated with levels of circulating 























2. General Methods 
Cell culture 
All cell culture work was performed under sterile conditions within a biological class II 
cabinet (HEPA filtered). Personal protective equipment (PPE) was worn during cell 
culture and aseptic technique was used throughout. Surfaces were disinfected with 1% 
distel, followed by 70% ethanol. Each item was disinfected with 70% ethanol before 
placing in the safety cabinet. Cell cultures were maintained in an incubator; 37°C with 
5% CO2 and 95% air. 
Cell types 
Primary cell cultures included human astrocytes (HA; SC-1800), human pericytes (HP; 
SC-1200), human brain microvascular endothelial cells (HBMECs; SC-1000) and human 
neurons (HN; SC-1520). All cells were purchased from Caltagmedsystems (UK), 
originally sourced from Sciencell (USA) in vials of 1x10^6 cells per mL. In order to 
prevent de-differentiation, cells were not used beyond passage 6, as per 
manufacturer’s recommendations. 
Specialised medium 
Cells were maintained in their respective recommended specialised medium 
purchased from Caltagmedsystems (UK), originally sourced from Sciencell (USA). Media 
was supplied as a basal phenol red formula containing essential nutrients along with a 
bullet pack consisting of foetal bovine serum (FBS), 10,000 units/mL penicillin and 
streptomycin (pen-strep, 1% final volume). Endothelial cell medium was supplemented 
with 5% FBS, pericyte and astrocyte medium were supplemented with 1% FBS. 
Neuronal medium was not supplemented with FBS. A growth supplement mix specific 
to each cell type was added to each of the different media (Caltagmedsystems (UK). 
These were originally formulated and sourced from Sciencell (USA). 
Revival, Sub-culturing and cryopreservation 
To initiate cell cultures vials of cells in freezing medium containing 5% 




thawed in a water bath at 37°C. Once vial contents were approximately 50-75% 
thawed they were pipetted into T75 cell culture flask (75cm2) containing 13 mL of the 
appropriate pre-warmed medium. The flask was then placed in an incubator (37°C, 5% 
CO2) and the cells were allowed to adhere to the flask surface for a minimum of 6 h 
before replacing the medium. Upon reaching 80-90% confluency cells were passaged 
depending on each cell types doubling number and experimental demand. Typically, 
astrocytes and HBMECs were passaged in a 1:3 ratio of cells to fresh medium and 
pericytes in a 1:5 ratio cells to fresh medium. Cells were either passaged into new 
flasks (to increase cell populations), into cell culture plates or inserts, or cryopreserved 
for future use.  
 
Cells were passaged as follows: medium was aspirated and discarded; 8 mL of pre-
warmed phosphate buffered saline (PBS, Gibco) was used to rinse the cell monolayer 
to remove any excess medium containing FBS. This was then aspirated and discarded 
and 2 mL of trypsin-EDTA (0.25% in 1x PBS) was pipetted into the T75 flask. For 
HBMECs 2 mL StemPro™ accutase (Gibco, ThermoFisher Scientific) was used instead of 
trypsin. The flask was gently rocked from side to side to ensure full coverage of the 
cells with Trypsin-EDTA, then placed into the cell culture incubator (37°C, 5% CO2) for 
1-2 minutes. The flasks were removed from the incubator and firmly tapped. The flasks 
were observed under a light microscope to ensure cells were detached. If cells were 
still adhering to the flask, cells were placed back in the incubator for 1-2 minutes and 
the process repeated until cells were detached. Once cell detachment was confirmed, 
5-7 mL of cell culture medium was added to neutralise the trypsin. Media was rinsed 
over any remaining cells left on the bottom of the flask and repeated to ensure the 
maximum number of cells were re-suspended in the media. Then medium was 
aliquoted into a falcon tube. Cells were centrifuged at 1000 rpm (320 xg) for 5 minutes 
to form a cell pellet. The supernatant was carefully aspirated and discarded. The cell 
pellet was gently re-suspended in 1 mL of medium. The cell suspension was 




each T75 flask), to be seeded into cell culture plates (i.e 12 mL, 500 µL each well for a 
24 well plate), or to be cryopreserved for later use. 
 
To cryopreserve cells, cells were pelleted in the procedure described above, then 
resuspended in their recommended medium containing 5% DMSO. DMSO acts as a 
cryopreservative, preventing unwanted crystals forming in the freezing process and 
preserves cell viability. Then the cell suspension was aliquoted into 1 or 2 mL cryovials 
and placed on ice for 10 minutes before being transferred to a Mr Freeze 
cryocontainer to be stored at -80°C overnight, cooling at approximately 1 °C /minute. 
The following day cryovials were transferred to liquid nitrogen for long term storage 
until required. 
Oxygen-glucose derivation (OGD) protocol 
To simulate ischaemia in vitro, an oxygen-glucose deprivation (OGD) protocol was 
followed (Hind et al., 2015, 2016). Normal cell culture medium (specific to each cell 
type, detailed previously) was removed and replaced with glucose-free RPMI medium 
(ThermoFisher, UK). Cell culture plate were placed in an anaerobe BD GasPack (UK) for 
4 h for HBMECs, pericytes and neuron or 8 h for astrocytes and placed back into the 
cell culture incubator (37°C, 5% CO2). Following this, plates were removed from the 
anaerobic bags and glucose-free medium was aspirated and replaced with normal cell 
culture medium. Cell culture plates were then returned to the cell culture incubator for 
either a 20 h or 16 h reperfusion period.  
Sample collection; media and lysates 
Post OGD experiments, medium samples were collected from cell culture plates into 1 
mL Eppendorf tubes and analysed immediately or stored at -80°C until subsequent 
analysis. During analysis all samples were kept on ice (approximately 4°C) to minimise 
sample degradation. Once cell medium had been removed, cell monolayers were 
gently washed with 1X PBS. Ice cold RIPA buffer (Sigma-Aldrich R0278) containing 




was added to each well. Cell culture plates were then placed on a plate shaker in the 
cold room (4°C) for 30-60 minutes to lyse the cells. The cell lysis mixture was then 
either immediately analysed, or frozen at -80°C and stored in liquid nitrogen. 
Phytocannabinoids 
Cannabidiol (CBD) was purchased from Tocris, UK. Cannabidiolic acid (CBDA) was 
purchased from Sigma, UK. Cannabigerol (CBG) and cannabidivarin (CBDV) were gifts 
from STI pharmaceuticals, UK. CBD, CBG and CBDV were dissolved in 100% ethanol at 
stock concentrations of 10 mM and CBDA was dissolved in 100% acetonitrile at a stock 
of 10 mM. All stocks were stored at -20°C. Fresh dilutions were prepared daily as 
required. 
Antagonists 
All antagonists were purchased from Tocris, UK and were used at the following 
concentrations AM251 (100 nM), AM630 (100 nM), GW6471 (100 nM), GW9962 (100 
nM), (S)-WAY 100135 (300 nM), capsazepine (1 µM), O1918 (1 µM), CID16020046 (1 
µM), SB366791 (1 µM) (Hind et al., 2016). All antagonists except for (S)-WAY 100135 
were dissolved in dimethyl sulfoxide (DMSO), (S)-WAY 100135 was dissolved in 
deionised water. All antagonists were prepared as stock solutions of 10 mM and stored 
at -20°C. Dilutions were prepared fresh as required. 
Microplate spectrophotometer 
A microplate spectrophotometer (Thermo Scientific, UK) with SkanIt Software was 
used to colorimetrically measure optical density to determine protein concentration. 
illuminating samples and measure the light intensity returned relative to its specific 
wavelength. A standard curve was created using samples at known protein 
concentrations. Samples of unknown protein concentrations were determined using 
the equation of the line created by the standard curve, unknowns were interpolated 




Bicinchoninic acid (BCA) assay  
A bicinchoninic acid (BCA) assay was performed on cell lysates to quantify the amount 
of protein present. This was to enable normalisation of data from multiplex and ELISA 
assays to compensate for any cell variation between wells. An 8-point standard curve 
was constructed using samples of known concentrations of BSA protein (0-2 mg/mL). 
10 µL of sample or standard was pipetted into a clear, flat bottomed 96 well plate 
(Griener, UK). A solution of Cu2+ and BCA was prepared at a 1:50 ratio and 100 µL 
added to respective wells. This was incubated for 20 minutes at 37°C and for a further 
10 mins at room temperature before reading absorbance at 562 nm using VarioskanTM 
LUX platereader, (Thermofisher, UK) using SkanIt Software. Unknowns were 
interpolated from the 8-point standard curve in µg/mL using Prism Software 
(GraphPad, USA).  
Enzyme-linked immunoassays (ELISA) 
Human DUOset sandwich enzyme-linked immunosorbent assays (ELISAs) were used to 
measure the presence and concentration of secreted cellular proteins and used as per 
the manufacturer’s instructions. The following kits were used over the course of the 
project: vascular cell adhesion molecule-1 (DY809), human intracellular adhesion 
molecule-1 (DY720), interleukin-8 (DY208), monocyte chemoattractant protein-1 
(DY279) and interleukin-6 (DY206).  To assay: clear, flat-bottomed, high-binding 96-
well microplates (Greiner Bio-One, 655061) were incubated with capture antibody (see 
specific kit for details on concentrations used) diluted in 1xPBS overnight at room 
temperature. The next day plates were washed 3x with wash buffer (0.05% TWEEN in 
PBS) and blotted on clean absorbent towels to remove excess liquid. Next, 300 µL of 
blocking solution (1% BSA in PBS) was added to the wells for 1 h at room temperature 
to prevent any non-specific binding of protein to the plate wells. The supplied standard 
was reconstituted and diluted, then an 8-point standard curve was constructed by 
serial dilution. Quality controls were prepared at low and high concentrations based on 




third wash plates were blotted on absorbent towels. 100 µL of standard, QC or 
samples was pipetted into the plate and incubated for 2 h at room temperature to 
allow the protein of interest to bind to the capture antibody coated on the plate 
bottom. After this incubation step plates were washed 3x again with wash buffer and 
blotted on absorbent paper, then a biotinylated secondary antibody solution (1% BSA 
in PBS, see specific kit for concentration details) was added to the wells and incubated 
for 1 h at room temperature. Plates were washed with wash buffer and blotted, and 
horseradish peroxidase (HRP; prepared in 1% BSA in 1X PBS) was added to the wells 
and plates were incubated at room temperature for 20 minutes. For this step and the 
last step plates were wrapped in foil as these steps are light sensitive. Following a final 
wash with wash buffer and blotting of the plates, a colour forming solution (which 
consisted of mixing equal amounts of colour reagent A (H2O2) and reagent B (3,3’,5,5’-
tetramethylbenzidine, TMB) was added to the plates and incubated at room 
temperature for a further 20 minutes. Stop solution consisting of 2N sulphuric acid 
(H2SO4) was added to each well to end the reaction. Optical density was determined 
using a spectrophotometer at the wavelengths 450 nm and 570 nm. Readings were 
determined by subtracting values at 570 nm from 450 nm. Sample concentrations 
were determined by extrapolating unknowns from the 8-point standard curve 
comprised of known concentrations. A plate wash was conducted between each step 
to prevent any non-specific binding of excess protein and ensure consistency and 
robust data each time the kit was performed. Fresh reagents were prepared every 
three months or as required. In every plate, QCs were included to ensure inter and 
intra batch consistency and were deemed acceptable if their interpolated values were 
within a variance of <15% of the desired concentration. 
Multiplex immunoassays  
Multiplex immunoassays enable the simultaneous detection of more than one analyte 
within an individual sample where fifty distinct coloured beads can be created from 
the combination of two fluorescent dyes which are then pre-coated with capture 




Millipore were used alongside a MILLIPLEX MAP DNA Damage/Genotoxicity Magnetic 
Bead Panel kit (48-621MAG) to detect DNA damage response (DDR) proteins: ataxia-
telangiectasia mutated (ATR-Total), checkpoint kinases 1, 2 (Chk,1 Ser345 and Chk2, 
Thr68), histone family member X (H2AX, Ser139), mouse double minute 2 homolog 
(MDM2, total), cyclin-dependent kinase inhibitor 1 (p21, total), tumour protein (p53, 
Ser15). Internally labelled fluorescent dyes with magnetite encapsulated functional 
polymer outer coating with a surface of carboxyl groups to enable covalent coupling of 
ligands. Samples and the beads were pipetted into the supplied black, clear bottomed 
96 well plates. Plates were incubated overnight on a plate shaker at a speed in which 
beads were in a constant motion but avoiding splashing (as per manufacturer’s 
recommendations) and in the absence of light to enable antibody-analyte binding. The 
next day a mixture of specific biotinylated secondary antibodies were added. The 
biotinylated secondary antibodies bind to the analytes of interest, forming an 
antibody-antigen sandwich. Following this, phycoerythrin (PE)-conjugated streptavidin 
was added to bind the biotinylated detection antibodies. Samples were either re-
suspended in sheath fluid or assay buffer depending on manufacturer’s instructions for 
individual kits before reading on the MAGPIXTM analysing system. The system uses two 
distinct light emitting diodes (LEDs): one to classify the bead based on its fluorescence 
and determine the analyte being detected and one to determine level of analyte 
bound by the extent of the PE signal. Depending on the specifications for individual 
kits, mean fluorescent intensity (MFI) data were exported into PRISM software 
(GraphPad, USA) and if required, interpolated from a standard curve of known 
concentrations to determine concentration of unknowns (cytokine panel kits). All data 
were normalised to total protein determined by a BCA assay. 
Cell Viability assay 
A resazurin reduction assay was performed to determine astrocyte viability. 10 µL of 
resesazurin was added directly to cells cultured in 96 well plates and incubated for 4 h 




metabolically active) are able to convert resazurin substrate, which is deep blue in 




Figure 2.1: Conversion of resazurin to resorufin, this process occurs in mitochondria of metabolically 
active cells and correlates to cell viability. 
 
After a 4 h incubation period, the resorufin product was measured using a microplate 
fluorometer (VarioskanTM LUX, Thermofisher, UK) with filters set to 560 nm excitation 
and 590 nm emission. The accumulation of product is proportional to the number of 
viable cells in each well. 
LDH Assay 
A colorimetric lactate dehydrogenase (LDH) assay was used to evaluate cytotoxicity 
(Abcam, UK). LDH is a stable cytosolic enzyme present in all cell types and if cell 
membrane integrity is compromised (i.e. as a result of damage), LDH is rapidly 
excreted into the extracellular space. Therefore, the LDH quantification is a reliable 
measure of cellular apoptosis and necrosis in cultured cells. Cell culture medium or 
standard was pipetted into a 96 well plate (Griener, UK) and WST substrate mix was 
added, as per manufacturer’s instructions. If LDH is present in the sample NAD is 




sample was read at 450 nm using a plate reader (VarioskanTM LUX, Thermofisher, UK) 
every 15 minutes up to 1 h. The yellow colour generated is proportional to the number 
of damaged (lysed) cells and LDH activity was determined by interpolating unknown 
values from a standard curve of known NADH concentrations. 
Transepithelial resistance (TEER) 
Transepithelial resistance (TEER) is a useful, relatively non-invasive technique and is 
used to evaluate barrier integrity of cells grown in a four-cell culture model (REF). The 
tips of STX-3 chopstick electrodes were firstly placed in 70% ethanol for 5 minutes, 
then placed into endothelial cell culture medium to equilibrate for 15 minutes. When 
cells reached full confluency, the four-cell model cell culture plates were removed 
from the cell culture incubator, sterilised with 70% ethanol and placed inside the 
biological safety cabinet. Plate lids were removed, and the electrodes were placed 
either side of the cell layer, ensuring the shorter electrode was placed in the upper 
compartment (apical) and the longer electrode was placed in the lower compartment 
(basolateral). The ohmic resistance of the inserts was determined by applying a current 
to STX-3 chopstick electrodes (which have silver chloride pellets for passing 
current)(Srinivasan et al., 2015).The resistance of the monolayer was then measured 
and calculated according to Ohm’s law using an Epithelial Voltohmmeter (EVOM™, 
World Precision Instruments). A background ‘blank’ well containing medium but no 
cells was used as a control and measured. Each experimental well was measured twice 
and an average of the two readings was calculated. The blank well was subtracted 
from the average reading and multiplied by the surface area (SA) of the insert (1.12). 
An equation summarising this is shown below: 
 
TEER reported in Ohms (Ω.cm2) = ((R1+R2*)/2) x SA**(cm2) 
 
Where * is the measured reading in Ohms (Ω) and **SA is specific to the model of insert 





In order to ensure reproducible TEER measurements, the electrodes were placed in the 
same location in each well for every measurement. Particular care was also taken 
when placing electrodes into each well as to not disturb the cell monolayer on the 
apical surface of the insert, or the coverslip containing neurons on the plate bottom. 
For details on full BBB methodology, refer to Chapter 3 (Stone et al., 2019). 
Propidium Iodide (PI) Staining  
A life/death assay utilising propidium iodide (PI) staining was conducted to determine 
the fraction of dead neurons post OGD. At 72 h post OGD, neurons were washed with 
1X PBS and incubated with a 100 μL/mL solution of PI prepared in PBS for 1-2 minutes 
at room temperature in the absence of light. As PI is a membrane impermeant dye, it is 
excluded from live cells but can bind to double stranded DNA of dead or dying cells by 
intercalating between base pairs. Images were obtained immediately using a Nikon DS-
Fi1 digital camera linked to an upright fluorescence microscope (Nikon Eclipse 50i) with 
a 20x objective. Images were visually assessed to determine proportion of dead cells.  
Statistical Analysis 
Statistical analysis was conducted using GraphPad prism software (USA), versions 7-8. 
Data were tested for normality using the D’Agostino & Pearson omnibus normality test 
to determine whether a non-parametric (non-normal data) or parametric test (normal 
data) were to be applied. In general, when data compared three or more groups, e.g 
vehicle vs various drug concentrations, a one-way analysis of variance (ANOVA) test 
was used. Multiple comparisons were adjusted using Dunnett’s or Sidak’s statistical 
tests. If a data set was looking a response affected by two independent factors, e.g 
TEER measurement and time, then a two-way ANOVA was used and multiple 
comparisons adjusted for using Turkey’s statistical test. Typically, data are presented 
as mean ± standard error of the mean (SEM) of two or three experimental repeats, 















































1. A Novel Transwell Blood Brain Barrier Model Using Primary 
Human Cells 
 
The following chapter is presented in its final manuscript format and is published in 
Frontiers in Cellular Neuroscience (Stone et al., 2019). 
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A Novel Transwell Blood Brain
Barrier Model Using Primary
Human Cells
Nicole L. Stone*, Timothy J. England and Saoirse E. O’Sullivan
Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham,
Nottingham, United Kingdom
Structural alterations and breakdown of the blood brain barrier (BBB) is often a primary
or secondary consequence of disease, resulting in brain oedema and the transport
of unwanted substances into the brain. It is critical that effective in vitro models
are developed to model the in vivo environment to aid in clinically relevant research,
especially regarding drug screening and permeability studies. Our novel model uses only
primary human cells and includes four of the key cells of the BBB: astrocytes, pericytes,
brain microvascular endothelial cells (HBMEC) and neurons. We show that using a larger
membrane pore size (3.0 µM) there is an improved connection between the endothelial
cells, astrocytes and pericytes. Compared to a two and three cell model, we show
that when neurons are added to HBMECs, astrocytes and pericytes, BBB integrity was
more sensitive to oxygen-glucose deprivation evidenced by increased permeability and
markers of cell damage. Our data also show that a four cell model responds faster
to the barrier tightening effects of glucocorticoid dexamethasone, when compared to
a two cell and three cell model. These data highlight the important role that neurons
play in response to ischaemia, particularly how they contribute to BBB maintenance
and breakdown. We consider that this model is more representative of the interactions
at the neurovascular unit than other transwell models and is a useful method to study
BBB physiology.
Keywords: blood-brain barrier, transwell, in vitro, BBB model, BBB permeability, primary human cells, stroke
INTRODUCTION
The blood brain barrier (BBB) is a unique interface that separates the peripheral blood supply and
neuronal tissue. Structurally, the BBB is comprised of specialized brain microvascular endothelial
cells (HBMECs), perivascular cells (pericytes) and astrocytes (Abbott et al., 2006, 2010). Neurons
and microglia also contribute to the maintenance of the BBB and form what is known as the
neurovascular unit (NVU) (Abbott et al., 2006). Pericytes contribute 22–32% of the cerebral
vasculature and together with vascular smooth muscle cells and endothelial cells they maintain
vascular function (Martini and Bartholomew, 2017). In the CNS, pericytes are present at a higher
ratio to HBMECs in the brain compared to the periphery and recent studies have shown the
extensive role of pericytes in BBB development and maintenance (Kacem et al., 1998; Armulik
et al., 2011; Sweeney et al., 2016). As well as o ering mechanical support, they also regulate
vessel contractility, endothelial proliferation, blood flow and angiogenesis (Bergers and Song, 2005;
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Dore-Du y, 2008). Pericytes have also been shown to secrete
angiogenic factors such as vascular endothelial growth factor
(VEGF), that support endothelial cell survival and proliferation
(Darland et al., 2003). In pathologies such as ischaemic stroke,
large gaps can develop between adjacent pericytes, increasing
barrier permeability and vessel leakage. These alterations in
pericyte morphology, coupled with an upregulation in the
expression of adhesion molecules and leukocyte integrin ligands,
contribute to the extravasation of peripheral leukocytes into
the brain following ischaemic insult (Pieper et al., 2013).
Thus, pericytes play a large role in cerebral vascular function
under normal physiological conditions as well as vascular
dysfunction in hypoxia.
Several studies have also highlighted the roles of neurons and
glia in BBB development and maintenance. Neural progenitor
cells present in the ventricular neuroepithelium have been
shown to aid endothelial cell recruitment during early BBB
development, which is largely governed by the Wnt signaling
pathway (Risau et al., 1986). Specifically, Wnt signaling in early
CNS development is responsible for vascular stabilization and
angiogenesis (Liebner et al., 2008). Further to this, early neuronal
signaling has been shown to be essential for the maturation of
the BBB, specifically, tight junction (TJ) organization. A study
carried out using rat microvascular endothelial cells and neuronal
progenitor cells, showed that in the presence of neural progenitor
cells, endothelial cells established regular TJ formation including:
claudin 5, zonula occludens (ZO-1) and occludin (Weidenfeller
et al., 2007). After maturation, maintenance of the BBB and
preservation of brain homeostasis is largely dependent on
adequate perfusion to neuronal tissue and neuronal signaling
to cerebral vessels, a process known as hyperaemia (Attwell
et al., 2010). Studies have shown that neuronal-astrocyte crosstalk
is important for appropriate vessel contractility and blood
flow, depending on metabolic demand (Zonta et al., 2003;
Attwell et al., 2010; Macvicar and Newman, 2015). In cerebral
ischaemia, astrocytes sense elevations in Ca2+ ions and increases
in extracellular glutamate released by neurons and respond
accordingly, secreting a range of vasoactive substances to help
mitigate the e ects of the blood vessel occlusion (Macvicar and
Newman, 2015). Altogether, interactions between both neural
and vascular cells within the NVU is considered to be paramount
in BBB functionality because together they induce and strengthen
barrier properties; helping to maintain its key features including
low paracellular permeability and functional tightness (Abbott
et al., 2010). Breakdown of the BBB in conditions such as
ischaemic stroke can lead to severe consequences to brain
homeostasis, therefore, modeling these interactions is necessary
to understand the complex signaling networks between these cell
types and how they are influenced in disease states.
To date, a number of BBB models have been developed
ranging from HBMEC monolayers to more sophisticated
spheroid and chip style models, see Table 1. After the successful
isolation of brain endothelial cells, the first, most simplistic
BBB models were developed utilizing HBMECs as a single
monolayer in the abluminal side of transwell inserts, see Table 1
(Borges et al., 1994; Hartz et al., 2010). Later addition of other
BBB cell types (namely astrocytes and pericytes), led to the
development of co-culture transwell systems which exhibited
greater barrier strength, exhibited by higher transepithelial
resistance (TEER) and lower permeability than single HBMEC
models, see Figure 1. More recent transwell systems typically use
three cell types originating from either bovine, porcine or rodent
origin, see Table 1 (Gaillard et al., 2000; Nakagawa et al., 2009;
Thomsen et al., 2015).
Whilst modeling using non-human cells is cheaper and easier
to obtain, they are not comparable to human cells, with many
studies showing key di erences in morphology and function,
particularly their sensitivity to glutamate and expression of e ux
transporter proteins (Oberheim et al., 2009; Warren et al., 2009;
Zhang et al., 2016). More complex BBB models are also available,
such as spheroid or microfluidic models and o er a closer
representation of the in vivo environment. However, these set
ups are di cult and expensive to assemble (Ruck et al., 2015).
Therefore, there is a need to develop a multicellular transwell
model that incorporates multiple NVU cell types to study their
interactions, particularly the role of neurons and their influence
on barrier strength in both physiological and disease states.
Transwell systems still o er a distinct advantage in that they are
relatively easy to setup and control, as well as o ering a range of
endpoints to study. Measuring TEER in these types of models is
commonplace as it provides a reliable, non-invasive quantitative
measure of barrier integrity, enabling repeated measurements
to be taken over the desired time period with minimal damage
to cells (Srinivasan et al., 2015). Further to this, transwell
models enable access to both the apical and basolateral (basal)
compartments for drug application andmedium sampling as well
as being able to visualize cells over the course of the experiment.
Our aim was therefore to create a novel four cell human
BBB model to study changes in permeability post oxygen-glucose
deprivation (OGD) and for use in in vitro pharmacology. We
initially focused on model development, refining a protocol first
outlined by Hind (2014) by optimizing the inserts themselves,
insert coating, cell seeding densities and cell culture timelines.
Finally, we incorporated a method of seeding neurons on plastic
coverslips which were placed on the bottom of 12 well cell culture
plates. Thus, our model maintains the ease of the transwell
setup but utilizes four primary human cells, making it a closer
representation of the human in vivo environment.
MATERIALS AND METHODS
Primary cells (astrocytes, pericytes, HBMECs, and neurons)
and specialized cell culture medium (astrocyte medium,
pericyte medium, endothelial cell medium, and neuronal
medium) were obtained from ScienCell, United States
supplied by Caltag Medsystems, United Kingdom. Poly-L-
lysine and porcine fibronectin were also obtained from ScienCell,
United States supplied by Caltag Medsystems, United Kingdom.
Collagen coated inserts, 3.0 µm, 12 mm were obtained from
Corning, United Kingdom. Plastic coverslips (Thermanox R 
13 mm diameter), Accutase dissociation reagent and glucose
free RPMI medium were obtained from Thermo Fisher
Scientific, United Kingdom.
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TABLE 1 | Different models of the blood brain barrier; their features, advantages, and disadvantages.






A monolayer of HBMECs
cultured in the apical
compartment of the
transwell insert.
Very easy to set up.
Minimal cost.
Low labor intensity.
Useful if wanting to study
endothelial cells alone.
TEER is typically low. Cobblestone appearance of
HBMECs, barrier formation.
Little information on the
impact of additional cell
types.
Borges et al., 1994;
Hartz et al., 2010
Co-culture /multicellular
transwell systems
HBMECs cultured on the apical
side of the transwell insert and
astrocytes and/or pericytes
cultured on the underside of
the transwell insert.
Time and cost effective.
Higher TEER.
Greater barrier stability.
Some models are not
fully in contact.
Closer representation of the
BBB with the addition of
important cell types. Able to
study interactions between






Spheroid 3D organization of cells typically
using matrigel.
Typically consists of HBMECs
and astrocytes and/or pericytes














Helps to induce tight
junction proteins. Closely
represents the in vivo set
up with cells in direct




Cho et al., 2017;
Nzou et al., 2018
Microfluidic systems/3D
chip-style models
3D organization of cells with the
added benefit of a “flow”
system to mimic cerebral blood
flow. Typically consists of
HBMECs and astrocytes and/or
pericytes with some models
containing neuronal cell types.
Advantage of mimicking
sheer stress which is
essential for HBMECs
optimum phenotype.
Difficult to set up and
maintain adequate
flow unless linked to
a computer system.
Useful to assess the impact
of blood flow on cell
development and optimum
phenotype.
Also useful in studying cell
migration and metastatic
progression.
Yeon et al., 2012;
Wang et al., 2017
HBMECs = human brain microvascular endothelial cells, TGF  = transforming growth factor beta, TEER = transepithelial resistance, BBB = blood brain barrier.
FIGURE 1 | Schematic representation of the BBB model development. (A) A co-culture cell model containing HBMECs and astrocytes. (B) HBMECs seeded on the
apical side, astrocytes seeded on the underside of the insert and pericytes seeded on the plate bottom. (C) HBMECs seeded on the apical side of the insert,
pericytes seeded on the underside of the insert and astrocytes seeded on the plate bottom. (D) HBMECs seeded on the apical side of the insert with mixed culture
of astrocytes and pericytes on the underside of the insert. (E) HBMECs seeded on the apical side of the insert with mixed culture of astrocytes and pericytes on the
underside of the insert and neurons seeded on a poly-L-lysine coated coverslip on the plate bottom.
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Cells were maintained in a humidified incubator (37 C,
5% CO2). Astrocytes and pericytes were cultured and used
between passages 4 and 6. Human brain microvascular
endothelial cells (HBMECs) were used between passages 3 and
5 and neurons were used at passage 1. During subculture,
flasks containing HBMECs were coated with 2 µg·cm2 of
fibronectin before reviving or splitting cells as per manufacturers
recommendations. Cells were passaged at 80–90% confluency.
Inserts contained 1.2 mL of medium in the basolateral
compartment and 800 µL in the apical compartment.
STX-3 probes and Ohms meter were obtained from World
Precision Instruments, United Kingdom. Dexamethasone was
obtained from Sigma, United Kingdom and dissolved in DMSO
at a stock concentration of 10 mM and subsequently diluted in
cell culture medium. GasPakTM EZ anaerobe container systems
were obtained from BD, United Kingdom.
Model Validation
Our model was based on an initial co-culture set up established
by Hind (2014) and previous models by Allen and Bayraktutan
(2009). Our model was modified and developed in a number
of preliminary experiments including comparison of insert
pore sizes, insert coating, cell organization and addition of
multiple cell types.
Pore Size, Insert Size and Coating
Initially, pore sizes of Corning, United Kingdom inserts were
compared (0.4 µm vs. 3.0 µm) as well as cell culture plates
(12 well vs. 24 well). This was to determine the best initial setup
that provided the highest and most stable barrier resistance,
as well as giving the best cell contact. During protocol
development, we found addition of pericytes in the smaller 24
well plates yielded poor results and insu cient TEER, suggesting
inadequate barrier formation. Possibly as a result of inadequate
cellular growth in such a small surface area and environment.
Therefore, 24 well plates were switched back to 12 well plates,
which resulted in substantially higher TEER readings. Following
work carried out by Niego and Medcalf (2013), we also found
that inserts with a 3.0 µm pore size had higher TEER values
than 0.4 µm inserts, suggesting that increased contact between
the cells in the apical and basolateral sides of the insert resulted
in greater barrier strength, see Figure 2A.
Addition of Multiple Cell Types and
Cell Positioning
Despite these improvements on the co-culture model, the
need for additional cell types was critical to create a closer
representation of the in vivo BBB. We established three di erent
set ups as shown in Figure 1. In one, astrocytes were seeded on
the basolateral side of the inserts and pericytes on the bottom of
the culture dish (Figure 1B), in another pericytes were seeded on
the basolateral of the inserts whilst astrocytes were seeded on the
bottom of the culture dish (Figure 1C) and finally the last set up
involved a mixed culture of astrocytes and pericytes seeded on
the basolateral side of the insert (Figure 1D). In all models tested,
HBMECs were seeded in the apical side of the transwell insert.
FIGURE 2 | Model protocol development (A) measured transepithelial
resistance (TEER) as a marker of barrier tightness comparing a 12 well plate
transwell set up vs. a 24 well plate transwell set up and insert pore size
3.0 µm vs. 0.4 µm. HBMECs seeded on the apical side of the insert,
astrocytes underneath and pericytes on the plate bottom. (B) The
organization of cells was optimized by comparing the TEER generated by a
mixed culture of astrocytes and pericytes, pericytes or astrocytes alone on the
underside of transwell inserts and astrocytes or pericytes on the cell culture
plate bottom. HBMECs were seeded on the apical side of the insert. Data
given as mean ± SEM, n = 4–6 from two experimental repeats. Statistical
analysis conducted using 2-way ANOVA with Turkey’s multiple comparisons
test, ⇤⇤P < 0.01 and ⇤⇤⇤P < 0.001 mixed culture astrocytes and pericytes vs.
pericytes underside the insert and astrocytes on plate bottom. #P < 0.05
mixed culture astrocytes and pericytes vs. astrocytes underside the insert and
pericytes on plate bottom.
The final set up o ered a closer replication of the organization
held at the in vivo BBB, as cells would be in direct contact allowing
them to exchange vital growth factors required for cellular growth
and development. We found that mixed culture of pericytes
and astrocytes exhibited significantly higher TEER values when
compared to the set-up with pericytes seeded on the plate bottom
and astrocytes underneath the insert or astrocytes on the plate
bottom and pericytes underneath the insert on days 3 and 4,
P < 0.05 and P < 0.01, respectively (Figure 2B). Furthermore,
this set up was also considered the most stable, as shown by
steadier TEER readings and was altogether more physiologically
relevant. This set up was therefore taken forward in subsequent
four cell protocol development.
To test the viability of adding neurons to the model,
we originally seeded neurons on the bottom of the 12 well
plate in which the inserts were hung. This, however, was
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not feasible as the TEER probes touched the bottom of
the plate causing unwanted damage to the cells. Therefore,
we decided to utilize coverslips that could be positioned
on the plate bottom, but not take up the entirety of the
well, allowing the probe to sit where the cells were not
present. After testing both poly-L-lysine coated glass and plastic
coverslips, we found that plastic coverslips coated were the most
e ective in neuronal adhesion and this method was used in
the final model.
Four Cell Method Overview
After optimization, our four cell BBB model consisted of four
major NVU cell types arranged in a transwell permeability set-up
(see Figure 1E). The assembly of this involves seeding di erent
cell types at di erent times on the apical and basolateral sides
of the transwell insert. During this time, neurons are seeded
on plastic coverslips placed on the bottom of a separate 12
well plate to develop neurite before putting both parts of the
model together on the final day of model establishment. Cell
culture medium in both compartments was replaced every other
day and the final set up was left to equilibrate for 2 days
before commencing experiments. Greater than 85% of inserts are
feasible for use in experiments and the model remained viable
for up to 5 days.
Insert Coating and Astrocyte Seeding
On day one, the basolateral side of transwell inserts were
coated with poly-L-Lysine and astrocytes were seeded on the
basolateral side of the inserts, see Figure 3. Briefly, 3.0 µm,
12 mm collagen coated inserts (Corning, United Kingdom) were
carefully removed from outer packaging and placed into 12 well
cell culture plates using sterile forceps. A solution of poly-L-
Lysine (2 µg/cm2) was prepared in sterile water, homogenously
mixed and carefully pipetted using a Pasteur pipette to just cover
the basolateral of the insert, see Figures 4A,i. Plates containing
inserts were then returned to the incubator, 37 C, 5% CO2
for 1 h as per supplier recommendations. After 1 h, plates
were removed from the incubator and washed twice with sterile
water to remove any residual poly-L-lysine. All remaining liquid
was removed by careful aspiration. Transwell inserts were then
flipped inside the plate and the lid removed (Figure 4B). On
the newly coated inserts, 100 µL of astrocyte cell suspension
in astrocyte medium (3.13 ⇥ 105 cells) was pipetted quickly
onto the basolateral side of the transwell and the lid carefully
replaced (see Figures 4C,ii). Plates were returned to the cell
culture incubator for 2–3 h for the cells to adhere. After this
time, transwell inserts were reverted and any excess medium was
removed by aspiration. Medium was topped up in the apical
and basolateral compartments, see Figure 4iii. Again, plates were
returned to the incubator.
Pericyte Seeding
On day 2, plates were removed from the incubator and the
astrocyte medium was removed with care so as to not disturb the
layer of cells on the basolateral side of the insert. Inserts were then
inverted again and 100 µL of 6.25 ⇥ 104 pericyte cell suspension
was added to the astrocyte cell layer on the basolateral side of the
transwell inserts, giving an approximate ratio of 5:1 astrocytes to
pericytes (Pardridge, 1999). Plate lids were quickly replaced and
returned to the incubator for 2–3 h. After this time, transwell
inserts were reverted and any excess medium was removed by
aspiration and a mixture of astrocyte and pericyte medium (1:1)
was added to the apical and basolateral compartments.
HBMEC Seeding
Once astrocytes and pericytes reached 90% confluency (approxi-
mately day 4 from model initiation, see Figure 3), the
astrocyte:pericyte (1:1) medium in the apical compartment was
removed and 100 µL of HBMEC cell suspension (7.5 ⇥ 104)
in HBMEC medium was added to the apical compartment of
transwell inserts and cells were left to adhere for a minimum of
5 h, then medium was topped up to 700 µL with endothelial cell
medium and plates returned to the incubator.
Neuronal Seeding
On the same day as HBMEC seeding, plastic coverslips (13 mm
diameter) were coated with poly-L-lysine and placed in the
cell culture incubator for a minimum of 1 h, as per supplier
recommendations. Plates containing coverslips were carefully
removed from the incubator and coverslips were washed twice
with sterile water and left to air dry in the cell culture hood.
Following this, cryopreserved neurons were revived into 3 mL
of neuronal medium (to give a total cell suspension of 4 mL)
and 100 µL of cell suspension was added to each coverslip (thus
seeded at a density of approximately 2.5 ⇥ 104 cells per cm2
within the optimum range according to the manufacturer’s
FIGURE 3 | Timeline showing stages of model establishment. On day 1, inserts were coated and astrocyte seeded on the basolateral side of transwell inserts and
on day 3 pericytes were seeded on the basolateral side of inserts to form a mixed culture. On day 6 HBMECs were seeded on the apical side of inserts and neurons
were seeded on coated plastic coverslips in a separate 12 well plate. On day 10/11, inserts are carefully lifted out of their current plate and placed into the second
12 well plate containing the neurons seeded on coverslips. After 2 days, TEER measurements are taken to ensure adequate barrier formation. ⇤ In our lab OGD
experiments were commenced at this point and were viable for 4–5 days.
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FIGURE 4 | Model setup (A–D) and (i–v). (A/i) Inserts are placed into 12 well plate, coated with poly-L-lysine and washed, ensuring all of the liquid is removed.
(B/ii) Inserts are carefully flipped inside the plate and the plate removed. 100 µL of relevant cell suspension is carefully placed on the underside of the insert.
(C/ii) The bottom of the cell culture plate acts as a “lid” and is replaced as quickly as possible, plates are then returned to the incubator for the cells to adhere for
3–4 h. (iv) In a separate 12 well plate, coverslips are placed in the bottom of the culture dish, coated with poly-L-lysine and seeded with neuronal cell suspension.
(v) Once all cells have been seeded on transwells, inserts are carefully transferred to plates containing neurons on coverslips.
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recommendations) (Figures 4D,iv). Medium was topped up
after 2 h and half of the medium replaced every 2–3 days.
After light microscope observation, neurons began showing
extensive neurite growth at approximately day 5. At this point
HBMECs will have almost formed a confluent monolayer above
the astrocytes and pericytes. Transwells were then carefully lifted
out of their current 12 well plate using sterile forceps and
placed into the 12 well plate containing the neuronal coverslips.
Fresh HBMEC medium was applied to the apical compartment
and a mix of pericyte, astrocyte and neuronal medium (1:1:2,
respectively) was added to the basolateral compartment. This was
to maintain a low concentration of fetal bovine serum optimum
for neuronal maintenance, whilst also preserving growth of
astrocytes and pericytes. As all cells were confluent and the
barrier was adequately formed, conditions were able to be
maintained in the di erent compartments.
Oxygen-Glucose Deprivation
(OGD) Protocol
An oxygen-glucose deprivation (OGD) protocol was used
to increase barrier permeability, simulating the e ects of
ischaemic stroke in vitro (Hind et al., 2015, 2016). Normal
cell culture medium was removed from transwell inserts
and replaced with glucose free RPMI medium (Thermo
Fisher Scientific, United Kingdom) and placed in a 0% O2
environment (GasPakTM anaerobe pouch Beckton Dickinson,
Oxford, United Kingdom) for 20 min to ensure anaerobic
conditions for a further 4 h. There was no initial pre-
conditioning period. Reperfusion was initiated by removing
plates from the anaerobe pouch and returning cells to their
normal medium (HBMEC medium in the apical compartment
and in the basolateral compartment a mix of pericyte, astrocyte
and neuronal medium, 1:1:2, respectively). TEER was measured
at baseline (0 h), immediately post OGD (4 h), 24, 48, and 72 h.
Evaluation of Barrier Integrity
Transepithelial resistance (TEER) was measured prior to
commencing OGD experiments to ensure model barrier
integrity; inserts should exhibit a TEER value of  45 /cm2
(Figure 4v). Light microscope observation was also carried out
to ensure cell confluency and successful neurite formation. To
ensure consistency, TEER measures should always be read at
least 24 h after a medium change. Briefly, STX3 electrodes were
sterilized by placing the tips of the probe in 70% ethanol, and
then equilibrated for 15 min in endothelial cell culture medium
at room temperature. The STX probe was then connected
to an EVOM2 meter (Both World Precision Instruments,
United Kingdom) and inserted into the transwell insert. The
electrode has two parts that are uneven in length, the longer part
of the electrode was placed so it gently touched the bottom of
the cell culture plate, whilst the shorter electrode rested slightly
above the insert dish, not quite making contact the HBMEC
cell layer. Care should be taken to avoid disrupting the neurons
on the bottom of the cell plate, see technical comments and
limitations. As TEER values are very susceptible to change, it is
important to keep the electrode upright and avoid tilting as
this can cause fluctuation in the TEER values. A background
reading for an insert with just cell culture medium was taken
and subtracted from each reading (readings were repeated twice
to ensure reproducibility), this was then multiplied by 1.12 to
address the cell culture insert area (cm2) (Hind, 2014).
Dexamethasone Protocol
Dexamethasone is a synthetic glucocorticoid and several groups
have shown that is able to artificially improve barrier strength
(Shi and Zheng, 2005; Pyrgos et al., 2010; Hind, 2014). Therefore,
we used dexamethasone as a positive control to investigate any
potential di erence in the response of the three versus four
cell model to a drug application. Baseline TEER readings were
recorded and medium replaced, then dexamethasone was added
to the apical compartment of the transwell insert, giving a final
concentration of 1 µM. TEER was measured at 2, 4, and 24 h.
Data Analysis
Data analysis was carried out using GraphPad prism software
(La Jolla, CA, United States). Data are presented as mean ± SEM
and analyzed using two-way ANOVA, followed by Sidak’s
or Turkey’s multiple comparisons test. ⇤P < 0.05 was
considered significant.
Technical Comments and Limitations
A critical step for setting up the four cellular model is timing
and the revival and seeding of human neurons. Addition of the
cells at incorrect timings will result in the model not working
as e ectively and TEER values will be lower than anticipated.
We have therefore outlined a timeline for setting the model up
(Figure 2), steps 4 and 5 can vary depending on the time taken for
barrier formation to take place and for neurons to form neurite.
Improper technique when seeding neurons on the coverslips will
result in a lack of uniformity and inadequate neurite formation.
Ensure coverslips are adequately air dried and neuronal cell
suspension is carefully but adequately mixed during the revival
and seeding process. Avoid removing neurons from the incubator
for long periods.
When taking TEER values, ensure that the larger part of
the STX probe does not touch the neurons cultured on the
coverslip. This is especially important if multiple readings are
beingmade (recommended). Utilization of neurons after primary
experiments have been completed is also possible. Staining can
be done on the coverslips using a variety of techniques including
propidium iodide (PI) and DAPI staining, neurons can be lysed
and intracellular assays can be performed.
RESULTS
Protocol Development
During BBB model development various set ups were compared
including; insert pore size, plate size, and cell organization.
Figure 2 highlights stages in protocol development and their
respective TEER values, prior to the addition of neurons into
the model. Figure 2A shows that a larger pore size (3.0 µm)
exhibited greater barrier integrity (as shown by greater TEER
readings) than the smaller pore size (0.4 µm). Furthermore, the
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12 well inserts displayed considerably greater TEER readings
than the 24 well inserts. Continuing model development using
12 3.0 µm inserts, Figure 2B compares three di erent cell
culture set-ups days after model establishment. On days three
and four, the inserts containing a mixed culture of astrocytes and
pericytes displayed significantly higher TEER readings than set-
ups containing astrocytes or pericytes seeded on the underside
of the inserts or the cell culture plate bottom, P < 0.05 and
P < 0.01, respectively.
OGD Model Simulation
To assess the e ect of having di erent cells present, changes
in TEER from models D and E shown in Figure 1, were
compared following an OGD protocol. Figure 5A highlights
the di erent responses of a three cell and four cell model in
response to a 4 h OGD protocol, followed by a reperfusion
period. The three-cell mode exhibited approximately a 30%
drop in TEER from baseline after 4 h OGD. This contrasts
to the four-cell model which exhibited a 50% drop in TEER
post OGD and was significantly di erent to the three-cell
model P < 0.05. After OGD, when reperfusion was initiated,
TEER was able to return to baseline in the three-cell model,
however, BBB permeability only marginally recovered by 20%
in the four-cell model. This was significantly di erent at 24 h
(P < 0.01) but not 48 or 72 h. Images 5B and C show
FIGURE 5 | (A) Effect of a 4 h oxygen-glucose deprivation (OGD) protocol on
transepithelial resistance (TEER) as a marker of barrier tightness in a three cell
model (HBMECs, astrocytes, and pericytes) and a four cell model (HBMECs,
astrocytes, pericytes, and neurons). Neuronal images taken from the four cell
model (B) before OGD 40⇥ and (C) neuronal images immediately post OGD
40⇥. Data given as mean ± SEM, n = 3–6 from two experimental repeats,
calculated as a % change from baseline TEER readings. Statistical analysis
was conducted using 2-way ANOVA with Sidak’s multiple comparisons test,
⇤P < 0.05 and ⇤⇤P < 0.01 was considered significant.
light microscope images of neurons in the four-cell model
before and immediately after the OGD protocol, respectively.
In Figure 5C neuronal clumping is clearly visible along with
apparent neurite fragmentation compared to Figure 5B showing
healthy neurons prior to OGD.
Dexamethasone Application
Dexamethasone increased barrier tightness in all three models, as
shown by increases in TEER and exhibiting overall significance
as a result of drug interaction in the three cell and four cell
model, P < 0.05. The two-cell model was the most unstable
out of the three models, as shown by greater fluctuations and
variability in TEER measurements (Figure 6A). The three-cell
model was considerably more stable but di erences in TEER
between dexamethasone treated and control were only observed
after 2 h (Figure 6B). The four-cell model was the fastest to
exhibit an increase in barrier tightness (i.e., increased TEER)
as a result of dexamethasone application (Figure 6C) and
this reached significance compared to the vehicle control at 2
and 24 h (P < 0.05).
DISCUSSION
The BBB can be compromised in a range of di erent conditions,
including but not limited to ischaemic stroke, Alzheimer’s
disease, cancer, and multiple sclerosis (MS). Research into
these disorders that a ect the BBB is plagued by translational
di culty, resulting in many potential compounds and/or
therapies failing to surpass phase I/II clinical trials. This is
at least partly due to a lack of suitable in vitro models that
can predict drug e ectiveness pre-clinically. Most, if not all,
current BBB models exhibit “pitfalls” whether that be cost,
time or resources. Models that o er the closest representation
of the BBB are often complex and expensive to replicate,
adding to the cost of the drug screening process. To help
improve the translatability of in vitro data, we developed a
transwell style model that incorporates four primary human
cell types, representing the NVU more than other BBB models
currently available. We found that our novel four-cell model
was superior in modeling ischaemic stroke and drug application
in vitro compared to a three-cell and a two-cell model as shown
through changes in TEER as a measure of barrier integrity and
dexamethasone application.
Implications for Drug Testing
The e ect of dexamethasone was assessed in three transwell
models; a two cell, three cell and four cell model. Greater
instability in barrier strength and a slower response was
exhibited by the two-cell model after dexamethasone application.
This could also suggest that models containing just two
cell types, in this case astrocytes and HBMECs, would also
react di erently to other drug applications and are therefore
are not su cient to truly model drug interactions at the
BBB. Whilst the three-cell model shared the same trend in
increasing barrier strength, it exhibited more stable TEER
values compared to the two-cell model and dexamethasone
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FIGURE 6 | The effect of dexamethasone on transepithelial resistance (TEER)
as a measure of barrier tightness in (A) a two cell (astrocytes and HBMECs),
(B) three cell (astrocytes, HBMECs, and pericytes), and (C) four cell model
(astrocytes, HBMECs, pericytes, and neurons). Dexamethasone (1 µM) was
added to the luminal side and used as positive control that is known to
decrease permeability, thus increase TEER. Data represented as
mean ± SEM, n = 4 from two experimental repeats. Statistical analysis was
conducted using 2-way ANOVA with Sidak’s multiple comparisons test,
⇤P < 0.05 was considered significant.
treated wells were overall significantly di erent to the vehicle
control. Also, by introducing pericytes (generating a three
cell model) there was a large increase in baseline TEER
from 30 to 40 , again highlighting the role of pericytes
in strengthening vascular stability at the BBB and the need
for their presence in BBB models (Bergers and Song, 2005;
Dohgu et al., 2005; Nakagawa et al., 2007; Ferland-McCollough
et al., 2017) Interestingly, the four-cell model exhibited a
significant increase in barrier tightness (as shown by an increase
in TEER) compared to the vehicle control at just 2 h after
dexamethasone application. Although neurons in this model
do not directly interact with the BBB, neurons have been
shown to secrete a number of vasoactive substances, including
VEGF, which influence barrier forming properties and early
angiogenesis (Engelhardt, 2003; Eichmann and Thomas, 2013).
These comparison data highlight the variations in data obtained
from models containing di erent cell types and the impact this
can have on drug screening. This stresses the importance of
having a more representative BBB model containing additional
cells present at the NVU.
Implications for Protocol Testing
Currently there are a wide range of in vitro BBB models
available, but despite promising developments in modeling
the BBB, there are still gaps in model design, primarily the
inability to include all cell types present in the NVU. Whilst
most transwell systems incorporate astrocytes and HBMECs,
only more recent studies have introduced pericytes or neurons
into these model designs. To gain a better understanding
of how these cells contribute to the breakdown of the BBB
in ischaemic conditions, we subjected our three cell and
four cell models to an OGD protocol and measured TEER
overtime to assess changes in barrier integrity. Interestingly,
we found that with the presence of neurons our model
exhibited a larger decrease in TEER compared to the three-
cell model, which only contained astrocytes, pericytes and
HBMECs. Similarly, whilst the three-cell model was able to
recover 24 h post OGD the four-cell model only marginally
recovered by approximately 20%, highlighting the role of
and sensitivity of neurons in the level of damage ensued by
the OGD protocol. Altogether, we have shown that with the
addition of neurons our model became more vulnerable to
damage; exhibiting a greater loss of barrier strength shown by
a decrease in TEER, supporting previous work which showed
that ischaemic neurons disrupt the endothelial barrier through
increasing VEGF secretion (Li et al., 2014). Thus, omitting
neurons from a BBB modeling stroke would underestimate the
damage caused and contribution of neurons to the breakdown of
the BBB post ischaemia.
Limitations and Future Development
Although our model now includes four cell present in the
NVU, our model does not incorporate flow which is an
important feature to maintain the BBB phenotype in vitro.
Studies have shown that sheer stress is critical to increase
cell longevity and influence cell phenotype, regulate BBB
transport, preventing de-di erentiation (Desai et al., 2002;
Chiu et al., 2005; Partyka et al., 2017). Culturing HBMECs
under physiological shear stress, is particularly important in
a ischaemic stroke setting because there is an interruption in
blood flow. Microfluidic systems that mimic physiological flow
have the advantage in that they can simulate continuous flow
improving translation to the environment (Partyka et al., 2017;
Wang et al., 2017).
Equally, there is increasing evidence of the role of microglial
cells in BBB breakdown. These resident brain immune cells
have been shown to release pro-inflammatory mediators that
increase barrier permeability and reduce levels of certain TJs,
thus playing a key role in BBB breakdown in pathological states
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(da Fonseca et al., 2014; Shigemoto-Mogami et al., 2018)
Therefore, future work should assess whether additional cells and
shear stress can be incorporated into transwell style models.
CONCLUSION
The overall function of the NVU is the perfusion of brain tissue
to supply neurons with essential nutrients and the ability of
neurons to regulate this blood flow. Glia, namely astrocytes, act
as mediators between the vascular and neural compartments (Lo
et al., 2015). Pericytes provide an extra level of communication
between the endothelia and astrocytes as well as serving a
prominent immune function (Darland et al., 2003; Armulik
et al., 2011; Kovac et al., 2011). During cerebral ischaemia, these
complex interactions are disrupted, and homeostasis is lost as a
consequence of functional, morphological andmetabolic changes
within the NVU (Lo et al., 2015). It is important to model how
these cells interact in both normoxic and ischaemic conditions to
study the pathophysiology of ischaemic stroke. Finally, transwell
systems o er noticeable advantages over the more complex
models as they maintain the ease simpler cell culture set up
and often use minimal resources. We believe our model o ers a
closer representation of the BBB, whilst maintaining the ease of a
transwell setup.
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3.1 Four-cell model method development and supplemental information 
During model development there were several challenges that required many 
troubleshooting experiments and method validation. Cells were required to be 
passaged on specific days to seed cells onto the inserts and the model itself could only 
be used for a maximum of five days. This posed several logistical issues, and some 
cultures were lost during the process of finding optimal days to passage for model set-
up. Overall, the model development was very challenging, and it is important to 
appreciate it has limited applications given the expense of using primary human 
neurons, complex assembly, and the finite lifespan of the model in culture. The model 
is aimed for use only after preliminary screening of compounds has been completed 
and lead compounds have been identified. 
 
Cell morphology was difficult to assess due to the material and coating of the transwell 
inserts and staining of individual cell types on the inserts was not possible due to the 
porous nature of the inserts. Whilst the increase in TEER is suggestive of barrier 
development, interactions between individual cell types were not assessed and could 
merely have been endothelial cells blocking the transwell pores. In vitro OGD protocols 
to model stroke have been adapted and used by numerous research groups because it 
recapitulates many of the cellular pathways associated with ischaemia-reperfusion 
injury (Holloway and Gavins, 2016). Specifically, the OGD protocol used in this study 
was based on previous work conducted by Hind and colleagues (Hind et al., 2015, 
2016) and was found to successfully increase barrier permeability, as well as increase 
levels of damage and inflammatory markers. It is worth noting that the OGD protocol 
oxygen conditions are classed as ‘anoxia’ not ‘hypoxia’, effectively modelling a ‘worst-
case’ scenario. Therefore, it would be useful for future studies to perform experiments 
with varying levels of hypoxia, for example between 0.5 and 2% oxygen, to model the 
in vivo environment more closely and to ascertain whether different levels of hypoxia 




assessment barrier permeability under both physiological and pathophysiological 






























2. A Systematic Review of Minor Phytocannabinoids with 
Promising Neuroprotective Potential 
 
The following chapter is presented in its final manuscript format and is published in 
The British Journal of Pharmacology (Stone et al., 2020). 
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Embase and PubMed were systematically searched for articles addressing
the neuroprotective properties of phytocannabinoids, apart from cannabidiol
and Δ9-tetrahydrocannabinol, including Δ9-tetrahydrocannabinolic acid,
Δ9-tetrahydrocannabivarin, cannabidiolic acid, cannabidivarin, cannabichromene,
cannabichromenic acid, cannabichromevarin, cannabigerol, cannabigerolic acid,
cannabigerivarin, cannabigerovarinic acid, cannabichromevarinic acid, can-
nabidivarinic acid, and cannabinol. Out of 2,341 studies, 31 articles met inclusion
criteria. Cannabigerol (range 5 to 20 mg!kg−1) and cannabidivarin (range 0.2 to
400 mg!kg−1) displayed efficacy in models of Huntington's disease and epilepsy. Can-
nabichromene (10–75 mg!kg−1), Δ9-tetrahydrocannabinolic acid (20 mg!kg−1), and
tetrahydrocannabivarin (range 0.025–2.5 mg!kg−1) showed promise in models of
seizure and hypomobility, Huntington's and Parkinson's disease. Limited mechanistic
data showed cannabigerol, its derivatives VCE.003 and VCE.003.2, and
Δ9-tetrahydrocannabinolic acid mediated some of their effects through PPAR-γ, but
no other receptors were probed. Further studies with these phytocannabinoids, and
their combinations, are warranted across a range of neurodegenerative disorders.
K E YWORD S
Alzheimer's, epilepsy, Huntington's, neurodegeneration, neuroprotection, phytocannabinoids
1 | INTRODUCTION
According to the World Health Organization (WHO), neurodegenera-
tive diseases will be the second most prevalent cause of death by
2040 (Gammon, 2014). The cellular mechanisms of these diseases
typically overlap with neuronal dysfunction and a common thread is
neuronal cell death, regardless of definitive clinical presentations.
Typically, neurodegenerative diseases are categorized as amyloidoses,
which includes Alzheimer's disease and British familial dementia; syn-
ucleinopathies, which includes Lewy body disorders such as
Parkinson's; and proteinopathies, which includes amyotrophic lateral
sclerosis and tauopathies (Kovac, 2018). Other common neurological
disorders include epilepsy and stroke, characterized by recurring,
unprovoked seizures and vascular pathology, respectively. Recently,
stroke was reclassified as a neurological disease by the International
Classification of Disease (ICD) 11, highlighting that while strokes pre-
dominantly have a vascular origin, the neurological consequences are
often severe (Shakir, 2018).
Current treatments for neurodegenerative and neurological con-
ditions are often limited and usually rely on managing symptoms
Abbreviations: 3-NP, 3-nitropropionic acid; 6-OHDA, 6-hydroxydopamine; Δ9-THCA, Δ9-
tetrahydrocannabinolic acid; Δ9-THCV, Δ9-tetrahydrocannabivarin; BBB, blood–brain barrier;
CBC, cannabichromene; CBCA, cannabichromenic acid; CBCV, cannabichromevarin; CBDA,
cannabidiolic acid; CBDV, cannabidivarin; CBDVA, cannabidivarinic acid; CBG, cannabigerol;
CBGA, cannabigerolic acid; CBGV, cannabigerivarin; CBGVA, cannabigerovarinic acid; CBM,
cannabis-based medicine; CBN, cannabinol; CNCVA, cannabichromevarinic acid; MS, multiple
sclerosis; RTT, Rett syndrome; TBZ, tetrabenazine; VMAT, vesicular monoamine transporter.
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rather than having a significant effect on delaying disease progression
(Kiaei, 2013). For example, Huntington disease is managed with
tetrabenazine (TBZ) 75–200 mg per day to alleviate chorea (involun-
tary movement), but because it acts as a vesicular monoamine
transporter (VMAT) inhibitor, interfering with both 5-HT and
dopamine degradation, patients can develop neuropsychiatric symp-
toms along with other side effects (Hayden, Leavitt, Yasothan, &
Kirkpatrick, 2009; Kaur, Kumar, Jamwal, Deshmukh, &
Gauttam, 2016; Wyant, Ridder, & Dayalu, 2017). Other first-line treat-
ments, for example, L-Dopa in Parkinson's disease, often cause side
effects and do not delay disease progression. Finally, cholinesterase
inhibitors such as donepezil are only minimally effective in improving
cognition for the treatment of Alzheimer's disease. In light of this,
there is clearly an urgent need to develop new therapies with more
tolerable side effect profiles to combat these debilitating conditions
and increase the quality of life of the ageing population.
Over 120 different phytocannabinoids have been isolated
from Cannabis sativa (ElSohly & Gul, 2015). Of these,
Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the
most abundant and widely studied. Δ9-THC is responsible for the
psychoactive effects of cannabis, which are mediated through
the cannabinoid CB1 receptor (Pertwee, 2008). Δ9-THC also inter-
acts with other targets including transient receptor potential (TRP)
channels, the orphan G-protein receptor, GPR55, and peroxisome
proliferator-activated receptors (PPARs; Pertwee & Cascio, 2015).
CBD has also been shown to modulate a wide range of pharmaco-
logical targets including 5-HT1A receptors, PPARγ and TRPV1
channels, but has no psychotropic effects because it does not acti-
vate central CB1 receptors (see Ibeas Bih et al., 2015, and Russo &
Marcu, 2017). Interaction with these targets has given CBD status
as a neuroprotectant, anti-inflammatory agent and antioxidant
(Fernandez-Ruiz et al., 2013; Maroon & Bost, 2018). These
features, along with its favourable safety profile in humans (Millar
et al., 2019; World Health Organization, 2017) has made CBD, in
many respects, a more desirable drug candidate than Δ9-THC. CBD
has shown promise in several animal models of neurodegeneration
as well as clinical trials for Parkinson's, Alzheimer's and
amyotrophic lateral sclerosis (Iuvone, Esposito, de Filippis,
Scuderi, & Steardo, 2009). Furthermore, a fixed combination of
CBD and Δ9-THC (1:1) is currently licenced by GW Pharmaceuti-
cals under the brand name Sativex® to treat pain and spasticity
associated with multiple sclerosis (MS), and Epidiolex® (pure CBD)
is licensed to treat Lennox–Gastaut syndrome and Dravet
syndrome, which are severe forms of childhood epilepsy. Other
cannabis-based medicines (CBMs) are also under development. GW
Pharmaceuticals has four compounds (structures are not disclosed)
in the pipeline for neurological conditions including glioblastoma,
schizophrenia and neonatal hypoxic-ischaemic encephalopathy
(GW Pharmaceuticals, 2019).
Phytocannabinoids are highly unique compounds, they are pro-
miscuous in action, modulating a range of pharmacological targets as
well as exhibiting high antioxidant capability due to their phenolic
structures and the presence of hydroxyl groups (Borges et al., 2013;
Hampson, Grimaldi, Axelrod, & Wink, 1998; Yamaori, Ebisawa,
Okushima, Yamamoto, & Watanabe, 2011). These features, along with
their lipophilicity and ability to act as anti-inflammatory agents, makes
them desirable therapeutic candidates for the treatment of CNS disor-
ders, as they can effectively cross the blood–brain barrier (BBB), mod-
ulate the immune response, and target the many aspects of
neurodegeneration (Deiana et al., 2012). These characteristics have
been well established for Δ9-THC and CBD but are less well known
for some of the minor constituents of the plant. Thus, in order to
understand the full therapeutic potential of Cannabis sativa, the phar-
macology of the lesser-known components of the plant should be elu-
cidated (Turner, Williams, Iversen, & Whalley, 2017). Given the wide-
ranging neuroprotective effects of Δ9-THC and CBD already
established, it is not unreasonable to suggest other phytocannabinoids
may exhibit similar or more potent neuroprotective properties. There-
fore, the aim of this systematic review was to collate all available data
on the neuroprotective effects of Δ9-tetrahydrocannabinolic acid
(Δ9-THCA), Δ9-tetrahydrocannabivarin (Δ9-THCV), cannabidiolic acid
(CBDA), cannabidivarin (CBDV), cannabichromene (CBC),
cannabichromenic acid (CBCA), cannabichromevarin (CBCV),
cannabigerol (CBG), cannabigerolic acid (CBGA), cannabigerivarin
(CBGV), cannabigerovarinic acid (CBGVA), cannabichromevarinic acid
(CBCVA), cannabidivarinic acid (CBDVA), and cannabinol (CBN).
These phytocannabinoids were selected based on their abundance in
the plant, ease of synthesis, efficacy in other fields (e.g., as anticancer
agents or treatments for inflammatory bowel disease), and similarities
in their structure to CBD and Δ9-THC (which have already shown
promise as a neuroprotectants and displayed safety in humans) and
are therefore more likely to have neuroprotective potential and
exhibit human translatability.
2 | METHODS
2.1 | Data sources and search strategy
An electronic search was conducted using the search engines PubMed
and Embase from its inception to June 2019. This was carried out in
accordance with the PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analyses) guidelines (Moher, Liberati, &
Tetzlaff, 2009; Shamseer et al., 2015; Tóth, Schumacher, Castro, &
Perkins, 2010) Search terms included Δ9-tetrahydrocannabinolic acid,
Δ9-tetrahydrocannabivarin, cannabidiolic acid, cannabidivarin, can-
nabichromene, cannabichromenic acid, cannabichromevarin, can-
nabigerol, cannabigerolic acid, cannabigerivarin, cannabigerovarinic
acid, cannabichromevarinic acid, cannabidivarinic acid and cannabinol
(and their corresponding abbreviations), phytocannabinoids, neuro-
vascular unit, pericytes, neurons, astrocytes, human brain microvascu-
lar endothelial cells, brain, neuroinflammation, hyperexcitability,
neurodegeneration, Huntington's, Alzheimer's, Parkinson's, epilepsy,
and stroke. Two independent reviewers carried out the searches by
November 2019, and the reference lists of the final papers were hand
searched for any additional studies.
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2.2 | Eligibility and exclusion criteria
Conference abstracts and review articles were excluded. No
restrictions were applied to type of study, publication year, or
language. Inclusion criteria were as follows: an original, peer
reviewed article that involved the application of emerging
phytocannabinoids in an in vivo or in vitro model of neu-
rodegeneration or neuronal damage. Studies that looked at two
derivatives of CBG, known as VCE-003 or VCE-002.3 were also
included because current research is focused on these compounds,
based on their increased affinity for PPARγ. Studies that assessed
CBD, Δ9-THC, Δ9-THC:CBD 1:1 (Sativex®), or similar combinations
of phytocannabinoids (i.e., different ratios of phytocannabinoids)
were excluded from this review. After duplicates and irrelevant
articles were removed, the full text was obtained for the remaining
articles, and studies were examined for data regarding Δ9-THCA,
Δ9-THCV, CBDA, CBDV, CBC, CBCA, CBCV, CBG, CBGA, CBGV,
CBGVA, CBCVA, CBDVA, and CBN application in an in vitro and/or
in vivo model of neuroprotection or neuronal damage. Dose and
route of administration were extracted from in vivo studies and
where possible range and average were calculated. If studies
reported mechanistic data, this was also described in Section 3.
3 | RESULTS
The preliminary search retrieved 2,341 studies, which after duplicates
were removed left 1,851. A total of 107 cannabinoid studies were
retrieved; once exclusion criteria were applied, 26 articles were
considered to be potentially relevant and their full texts obtained.
After additional screening (including reviewing reference lists for any
potential studies), 28 studies were included in this review; see
Figure 1. Table 1 summarizes the in vitro data included in this review,
and Table 2 summarizes the in vivo data.
Within the 28 studies, the neuroprotective models were epilepsy
(n = 7), Huntington's disease (n = 6), Parkinson's (n = 4), amyotrophic
lateral sclerosis (n = 3), neuroprotection (not disease specific, n = 2),
multiple sclerosis (MS; n = 1), Rett syndrome (n = 2), neuroinflammation
(n = 1), Alzheimer's (n = 1), and oxidative stress (n = 1). Fifteen papers
studiedCBGor its derivatives, five studies usedCBN, eight studies used
CBDV, and four studies used CBC. Only two studies used Δ9-THCV,
and three used Δ9-THCA. CBDA was only included in one study. No
data on the neuroprotective effects of CBGA, CBGV, CBCA, CBCV,
CBCVA, CBGVA, or CBDVA were identified. Figure 2 shows some of
the minor phytocannabinoids structures with CBD and Δ9-THC for
reference, and Table 3 summarises the neurological conditions for
which emerging cannabinoids have shown therapeutic potential.
3.1 | Cannabigerol (CBG) and its derivatives
Nine studies included in vitro data, and eight included in vivo data on
CBG and its derivatives that are formed by the oxidation of CBG
(Carrillo-Salinas et al., 2014; Díaz-Alonso et al., 2016; García
et al., 2018). VCE-003 and VCE-003.2 have displayed increased
affinity for PPARγ, thus maintaining their anti-inflammatory properties
while having little affinity for CB1 and CB2 receptors (VCE-003
Ki > 40 μM for CB1 and Ki > 1.76 μM CB2, Granja et al., 2012, and
VCE-003.2 Ki > 40 μM for both CB1 and CB2, García et al., 2018). All
studies except one reported a positive effect of CBG, VCE-003, or
VCE-002.3, compared with control in the disease model being
studied. In an in vivo model, using 3-nitropropionic acid (3-NP)
to induce Huntington's disease, CBG (10 mg!kg−1 per day i.p.)
significantly attenuated the up-regulation of COX-2, iNOS, IL-6, and
TNF-α (Valdeolivas et al., 2015). CBG treatment also prevented
3-NP-induced neuronal loss, recovered catalase, SOD and GSH, com-
pared with control, and down-regulating genes that were directly
associated with Huntington's disease including sgkl, Cd44, and nor-
malized levels of huntingtin-associated protein-1. Aggregation of
mutant Huntingtin protein was diminished, and motor deficits such as
hindlimb clasping and dystonia and general locomotor activity were
also improved (Valdeolivas et al., 2015). Hill et al. (2014) assessed the
anti-convulsant potential of CBG (50–200 mg!kg−1 i.p.) when
F IGURE 1 Overview of methodology used in the search process,
identification, screening, eligibility, and inclusion
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administered prior to the initiation of pentylenetetrazole (PTZ)
seizures; however, despite being able to block Nav channel activity,
CBG had no effect on seizure severity. No antagonist experiments
were conducted in these studies, but Valdeolivas et al. (2015) did
show that CBG dose-dependently activated PPARγ in cultured striatal
cells (WT and mutant huntingtin; supplementary data). Four studies
reported that the CBG derivatives VCE-003 (5 mg!kg−1 i.p.) and
VCE-003.2 (10 mg!kg−1 p.o./i.p.) successfully reduced immune cell
activation in macrophages, microglia, and infiltrating neutrophils in
models of EAE (to model MS) and Huntington's and LPS-induced
Parkinson's disease (PD; Aguareles et al., 2019; Carrillo-Salinas
et al., 2014; Díaz-Alonso et al., 2016; García et al., 2018). In the in vivo
Parkinson's disease model, García et al. (2018) found that PPARγ
antagonist T0070907 (5 mg!kg−1) blocked VCE-003.2-mediated
decreases inTNF-α, IL-1β, and iNOS mRNA levels, but no other antag-
onists were investigated. In a follow-up study by the same group,
20 mg!kg−1 (but not 10 mg!kg−1) oral VCE-003.2 promoted a trend
towards recovery in the basal ganglia of LPS-lesioned mice and was
associated with decreases in IL-1β gene expression, lysosomal-
associated membrane protein-1 (LAMP-1), and glial fibrillary acidic
protein (GFAP) immunostaining (Burgaz et al., 2019). Orally dosed
VCE-003.2 (10 mg!kg−1) promoted neurogenesis in mice subjected to
mutant Huntingtin expression in a Huntington's disease model
(Aguareles et al., 2019). In another model of Huntington's disease
VCE-003.2 (10 mg!kg−1 i.p.) prevented neuronal loss, indicated by
increases in Nissl and NeuN staining and at the same dose improved
RotaRod performance and reduced astrogliosis in mice, measured by
attenuated levels of GFAP and ionized calcium binding adaptor mole-
cule 1 (Iba-1; Díaz-Alonso et al., 2016). Rodríguez-Cueto et al. (2018)
found that VCE-003.2 10 mg!kg−1 i.p. successfully improved neuro-
pathological deterioration and normalized CB2 receptor and IL-1β
levels, in an experimental model of amyotrophic lateral sclerosis, but
again no mechanisms of action were probed.
In vitro, Schubert et al. (2019) reported that CBG (100 nM)
prevented MC65 neurons from accumulating toxic amyloid β (Aβ) pro-
tein in an Alzhiemer's disease model. CBG also preserved neuronal
trophic factors in primary rat cortical neurons (EC50 1.5 μM) and
prevented oxytosis in mouse HT22 hippocampal nerve cells (EC50
1.9 μM). Although no mechanisms were explored in this study, neither
MC65 neurons nor HT22 cells express CB1 or CB2 receptors, leading
the authors to conclude that these effects were mediated indepen-
dently of these receptors. In N2a cells, VCE-003.2 (10 and 25 μM)
prevented excitotoxicity induced by glutamate and in models of LPS
induced Parkinson's disease and amyotrophic lateral sclerosis (García
et al., 2018; Rodríguez-Cueto et al., 2018). Similarly, VCE-003
(0.1–25 μM) dose dependently protected neuronal cells in a model of
MS, while VCE-003.2 (500 nM) promoted neuronal differentiation
when dosed for 21 days in an in vitro model of Huntington's disease,
but no antagonist experiments were conducted to explain these
effects (Aguareles et al., 2019; Granja et al., 2012). In a model of neu-
roinflammation, pretreatment with CBG (7.5 μM) improved viability in
cells treated medium from LPS-stimulated macrophages and, while
F IGURE 2 Structured and pharmacological profiles of
some of the minor phytocannabinoids with cannabidiol
(CBD) and tetrahydrocannabidiol (∆9-THC) included for
reference: ∆9-tetrahydrocannabinolic acid (∆9-THCA), ∆9-
tetrahydrocannabinolic (∆9-THCV), cannabidivarin (CBDV),
cannabidiolic acid (CBDA), cannabichromene (CBC),
cannabigerol (CBG), and cannabinol (CBN)
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authors reported that CBG treatment resulted in PPARγ down-
regulation, no direct mechanistic probing was conducted (Gugliandolo,
Pollastro, Grassi, Bramanti, & Mazzon, 2018). Granja et al. (2012) and
Carrillo-Salinas et al. (2014) found that treatment with VCE-003
(1 and 2.5 μM and 1, 10, and 25 μM) blocked the secretion of a
number pro-inflammatory mediators including IL-6, TNF-α, IL-1β, and
CCL3 in macrophages and primary microglia. VCE-003.2 also
attenuated TNF-α and L-1β secretion but from BV2 mouse microglial
cells (5 μM) and astroglial cells (1 and 5 μM; Díaz-Alonso et al., 2016;
García et al., 2018; Rodríguez-Cueto et al., 2018). Díaz-Alonso
et al. (2016) and García et al. (2018) deduced that VCE-003.2 did not
mediate its protective effects via CB1 or CB2 receptors due to poor
binding affinity (Ki > 40 μM) and both groups found that VCE-003.2
was an agonist at PPARγ (IC50 of 1.2 μM).
3.2 | Cannabidivarin (CBDV)
All in vivo cannabidivarin (CBDV) studies evaluated the anti-epileptic
properties of the compound in models of Rett syndrome and MES
seizures (Amada, Yamasaki, Williams, & Whalley, 2013; Hill
et al., 2012; Hill et al., 2013; Vigli et al., 2018; Zamberletti
et al., 2019). Doses in these studies ranged from 0.2 to 400 mg!kg−1
per day in rodents with efficacy in reducing tremors was observed
between 2 and 200 mg!kg−1 per day. Two studies reported that
200 mg!kg−1 i.p. CBDV significantly decreased PTZ seizure severity
and mortality in rats (A. J. Hill et al., 2012; Hill et al., 2013). Hill
et al. (2012) found that 90% of animals remained seizure free at a
dose of 200 mg!kg−1 CBDV i.p. per day; however, lower concentra-
tions of CBDV were ineffective (0.2 mg!kg), and CBDV had no
effect on the severity of pilocarpine convulsions at any tested
concentration (50–200 mg!kg−1 per day). CBDV (400 mg!kg−1 oral
gavage) suppressed PTZ seizures, significantly decreasing seizure
severity but had no effect on expression of epilepsy related genes
(Amada et al., 2013). Another study reported that 20 mg!kg−1
i.p. CBDV dosed for 14 days improved brain weight in Rett
syndrome (RTT) mice, compared with WT mice, but had no effect
on neurotrophin levels (Vigli et al., 2018). None of these in vivo
studies conducted antagonist experiments to further elucidate the
anticonvulsant effects of CBDV.
In HEK293 cells transfected with TRPV1, 2, and 3 channels,
CBDV caused a concentration-dependent bidirectional current at
TRPV1 channels similar to capsaicin, and capsazepine (TRPV1 channel
antagonist) blocked this effect. Furthermore, 5'-iodoresiniferatoxin
(5'-IRTX), a selective antagonist of TRPV1 channels counteracted the
effect of CBDV in the duration but not amplitude of neuronal burst.
These data suggest that CBDV acts as an agonist at these channels,
but some of CBDVs effects are mediated independently of this chan-
nel. However, no other antagonists were tested to establish which
receptors were responsible for the other effects of CBDV (Iannotti
et al., 2014). Hill et al. (2012) reported that CBDV (10 and 100 μM)
decreased the amplitude and duration of local field potentials in hip-



































































































































































































































































































































































































































































STONE ET AL. 4343
CA1 region (100 μM). CBDV also showed efficacy in an in vitro model
of Alzheimer's disease, preventing oxytosis and energy loss in HT22
cells (EC50 1.1 μM and 90 nM, respectively), as well as reducing Aβ
toxicity (EC50 100 nM) and trophic withdrawal (EC50 350 nM);
however, no mechanistic data were reported to determine how these
effects were mediated (Schubert et al., 2019).
3.3 | Cannabichromene (CBC)
In a model of electroshock seizure, CBC (10–75 mg!kg−1 i.p. per day)
significantly depressed motor activity during the first 10-min interval,
but subsequently only the highest dose was effective (Davis &
Hatoum, 1983). In vitro, Shinjyo and Di Marzo (2013) found that 1μM
CBC increased viability of adult nestin-positive neuronal stem cells
when applied in medium without growth factors (B27 medium), by
inducing ERK phosphorylation. No antagonist data were presented in
these studies.
3.4 | Cannabinol (CBN)
Only one in vivo study assessed CBN (5 mg!kg−1 per day) in an
SOD1 model of amyotrophic lateral sclerosis. CBN delayed motor
abnormalities at Day 17 in the chronic treatment regimen,
compared with vehicle control, but disease progression was not
affected (Weydt et al., 2005). In a model of Huntington's disease,
Aiken et al. (2004) found that CBN reduced LDH activity in PC12
cells (20 and 100 μM), but the authors did not investigate the
mechanism(s) of this effect. CBN displayed potent antioxidant
activity in primary cerebral granule cells under oxidative stress
conditions; however, no antagonist data were presented on this
cannabinoid (Marsicano et al., 2002).
3.5 | Δ9-THCV
Male Sprague–Dawley rats and CB2 receptor knockout mice were
dosed with 2 mg!kg−1 per day Δ9-THCV over a period of 14 days in a
model of Parkinson's disease, induced by 6-hydroxydopamine
(6-OHDA) or LPS (García et al., 2011). Δ9-THCV reduced slow motor
movements induced by 6-OHDA and enhanced mean velocity of
movement with a potency similar to rimonabant. Chronic Δ9-THCV
dosing reduced microglial activation and preserved nigrostriatal dopa-
minergic neurons after 6-OHDA application and in the LPS model of
Parkinson's disease, Δ9-THCV preserved TH positive neurons,
mirroring the effects of the CB2 receptor agonist HU-308. Thus,
authors speculated that Δ9-THCV mediated at least some of its
effects in the LPS model via CB2 receptors (García et al., 2011). Also,
2 mg!kg−1 Δ9-THCV blocked the effects of the CB1 receptor agonist,
CP55,940, suggesting it acts as an antagonist at this receptor. How-
ever, no data were presented assessing if such antagonistic properties
of Δ9-THCV at CB1 receptors mediated its protective effects in the
6-OHDA or LPS models of Parkinson's disease. Hill et al. (2010) stud-
ied Δ9-THCV in a seizure model induced by 80 mg!kg−1 PTZ and
found that at a dose of 0.25 mg!kg−1 i.p. Δ9-THCV, with 33% of
animals having a complete absence of seizures. Although no direct
mechanistic probing was investigated, receptor binding assays were
performed on rat cortical membranes, and Δ9-THCV was found to act
as a CB1 receptor ligand (CB1 Ki " 290 nM; [3H]SR141716A displace-
ment but no agonist stimulation using [35S] GTPγS binding; Hill
et al., 2010).
3.6 | Δ9-THCA
In an acute 3-NP model of Huntington's disease, Nadal et al. (2017)
observed a significant improvement in hindlimb dystonia (uncontrolla-
ble hindlimb muscle contraction) and locomotor activity in male,
C57BL/6 mice treated with Δ9-THCA (20 mg!kg−1 per day i.p.). Δ9-
THCA also prevented astrogliosis and microgliosis and attenuated the
up-regulation of pro-inflammatory mediators induced by 3-NP. These
effects were blocked when mice were co-administered with the
PPARγ antagonist T0070903 (with the exception of IL-6; Nadal
et al., 2017). In vitro, N2a cells infected with the huntingtin polyQ
repeats resulted in toxicity, which was significantly reduced by treat-
ment with ∆9-THCA, as well as decreased expression of inflammatory
mediators: TNF-α, iNOS, IL-6, and COX-2. Δ9-THCA also improved
neuronal viability post-serum deprivation, and this effect was
prevented by GW9662, a PPARγ antagonist. No other antagonists
were used in this study (Nadal et al., 2017).
Δ9-THCA (0.01–10 μM) displayed no pro-survival effect on
dopaminergic neurons but had a significant, positive effect on cell
count (123%) when compared to the control, in an in vitro model of
Parkinson's disease (Moldzio et al., 2012).
4 | DISCUSSION
To our knowledge, this is the first systematic review on the neuro-
protective effects of lesser-known, minor phytocannabinoids in
various models of neurological disease. Data obtained from our search
revealed that CBG, VCE.003, VCE.003.2, and CBDV were the
most promising candidates as neuroprotectants, while Δ9-THCV,
Δ9-THCA, CBC, and CBN have limited but encouraging data as
neuroprotectants. CBG, VCE.003, VCE.003.2, and Δ9-THCA mediated
their neuroprotective effects at least in part by the nuclear receptor
PPARγ. CBDV was found to mediate some of its antiepileptic effects
via TRPV1 channels, and Δ9-THCV was found to be a CB1 receptor
ligand and a possible CB2 receptor agonist, but no experiments were
conducted to establish whether its neuroprotective action was
mediated by CB1 or CB2 receptors. No other receptors were investi-
gated, and no studies assessed the neuroprotective potential of
CBDA, CBGA, CBGV, CBCV, CBGVA, or CBDVA.
CBG was first isolated in 1964 by the same group that reported
the structure of Δ9-THC (Gaoni & Mechoulam, 1964). It exhibited
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antioxidant and anti-inflammatory properties, while displaying no
psychotropic effects, as it is a poor CB1 receptor agonist (Gauson
et al., 2007; Navarro et al., 2018; Rosenthaler et al., 2014). CBG is a
partial agonist at CB2 receptors, a potent α2-adrenoceptor agonist
(EC50 0.2 nM) and a moderate 5-HT1A receptor antagonist, as well as
interacting with various TRP isoforms including TRPV1 and 2 channels
(Cascio, Gauson, Stevenson, Ross, & Pertwee, 2010; De Petrocellis
et al., 2012). Studies included here show that these compounds have
significant anti-inflammatory effects, including attenuating cytokine
release and decreasing the activation of immune cells, an effect
observed in both in vitro and in vivo models.
CBG and its derivatives were particularly effective in models of
Huntington's disease, targeting multiple facets of the disease including
gene expression, easing motor symptoms, reducing microglial
activation, and attenuating the inflammatory response. Huntington's
disease pathophysiology, like other neurodegenerative disorders,
exhibits uncontrolled microglial activation, which is a key part of the
neuroinflammatory response. In early stages of this disease, PET
imaging has revealed marked microglial activation, which was corre-
lated with impairments of neuronal activity (Tai et al., 2007). Micro-
glial activation along with increases in pro-inflammatory mediators
has also been detected in post-mortem Huntington's disease brains
(Palpagama, Waldvogel, Faull, & Kwakowsky, 2019). Interestingly,
microglial mediated neuroinflammation was suppressed with the acti-
vation of CB2 receptors (Ehrhart et al., 2005). However, given VCE-
003 and VCE.003.2's protective effects were likely to be CB1 and CB2
receptor-independent, their effects on microglial activation are likely
to be via a different mechanism, possibly through the activation of
PPARγ, which has an important role in regulating the inflammatory
response, especially in the CNS (see Bright, Kanakasabai, Chearwae, &
Chakraborty, 2008; Villapol, 2018). It is also worth noting that micro-
glial activation can be protective, preserving neurons by secreting
anti-inflammatory cytokines such as IL-4 and IL-10 as well as various
trophic factors (see Le, Wu, & Tang, 2016, and Pöyhönen, Er, Doma-
nskyi, & Airavaara, 2019). In line with these observations, there effec-
tively needs to be a balancing act between enabling some degree of
microglial activation to protect neurons, while limiting their over-
activation that would ultimately lead to damage. Given that the symp-
toms of Huntington's disease are currently managed using VMAT
inhibitors (such as TBZ) to decrease levels of monoamines, it would be
useful to assess whether CBG and its derivates have any efficacy as
VMAT inhibitors, or whether their protective effects in models of
Huntington's disease are independent of this mechanism. If the latter
is the case, future studies should investigate low-dose VMATs
(to minimize neuropsychiatric side effects) together with CBG or its
derivatives as an adjuvant therapy to assess if there is an additive, or
even synergistic, protective effect of these compounds.
Long-term dose tolerability and a lack of accumulation in tissue
are both essential features of neuroprotective agents as these drugs
are typically taken for life after disease onset. In a study conducted by
Deiana et al. (2012), CBG was found to have similar PK profiles in rats
and mice but exhibited slower brain penetration in mice. Both animals
also had higher concentrations of CBG following i.p. injection
compared to oral administration, but interestingly in rats, this did not
equate to higher concentrations in brain tissue (Deiana et al., 2012).
From the results in our review, treatment with CBG, VCE-003, and
VCE.003.2 was well tolerated and ranged from just 3 days to 10 weeks
with two studies dosing CBG orally and seven studies dosing intraper-
itoneally. Deiana et al. (2012) reported that animals tolerated CBG
better after i.p. administration, compared with the oral route. In
humans, i.p. dosing is not a viable means of regular administration,
and all drugs given orally have a larger side effect profile. Moreover,
patients receiving certain oral therapies for neurological conditions,
such as levodopa for Parkinson's disease, must also take medications
to minimize peripheral effects (Fahn, 2008). Therefore, dose
formulation and route of administration for these compounds should
be carefully assessed, based on thorough ADME profiling and feasibil-
ity of long-term dosing.
CBG exhibited positive effects in two Huntington's disease
models, despite one study using oral and the other i.p., administration.
Of note, CBD has already been trialled in Huntington's disease
patients; CBD (10 mg!kg−1; 700 mg average daily dose) was given for
6 weeks and resulted in a consistent plasma level of 5.9–11 ng!mL-1.
Once treatment had stopped, elimination was between 2 and 5 days,
suggesting CBD did not accumulate and remain in plasma longer than
5 days in these Huntington's disease patients (Consroe et al., 1991).
Further studies should elucidate whether CBG and its derivatives dis-
play efficacy in humans and clarify whether their activation of PPARγ
corresponds to their neuroprotective properties and if other receptors
are involved. More data are also needed on the PK profiles of CBG
and its derivatives in older mice and larger mammals and to establish
whether it exhibits a similar elimination to CBD in humans. These fac-
tors would aid in the translation of this compound as a treatment for
neurodegenerative conditions.
Cannabidivarin (CBDV) is a structural analogue of CBD, with the
molecule shortened by two methylene bridges (Morales, Hurst, &
Reggio, 2017; Vollner, Bieniek, & Korte, 1969). From our search, in vivo
studies consistently reported 200 mg!kg−1 i.p. CBDV having anti-
epileptic effects and a 400 mg!kg−1 oral dose also showing promise.
Like CBD, CBDV is a agonist at TRPV1/2 and TRPA1 channels, and
an antagonist at TRPM8 channels, which may explain similarities in
their neuroprotective properties, particularly the action of CBDV as
an agonist at TRPV1 channels (De Petrocellis et al., 2011; Iannotti
et al., 2014; Scutt & Williamson, 2007). In our review, studies showed
that CBDV did not affect neurotrophic levels or epilepsy-related gene
expression. Thus, it can be assumed that CBDV mediates its protec-
tive effects independent of these pathways (Amada et al., 2013; Vigli
et al., 2018). Deiana et al. (2012) reported that CBDV was rapidly
absorbed in mice and rats, but there was a higher drug concentration
in plasma and brain following oral treatment in rats compared to mice.
Furthermore, while i.p. injection resulted in similar PK profiles in the
two species, brain concentrations in rats were higher. This brings into
question the differences in the amount of CBDV delivered to the
brain in the studies conducted in mice compared with rats presented
in this review and whether this influenced study outcomes. Only two
studies reported chronic CBDV dosing both in models of Rett
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syndrome, highlighting the need for future studies to assess the long-
term tolerability of CBDV as an anti-epileptic agent and how different
species exhibit different bioavailability of this compound, as these will
both affect the translatability of CBDV to humans.
Although out of the scope of this review, it is worth noting that
CBDV has already been trialled as an anti-convulsant by GW Pharma-
ceuticals in a phase IIa, placebo-controlled study of 162 adult patients
(clinical trial number: NCT02369471/NCT02365610). The drug
GWP42006 (which contains CBDV as its main ingredient) was dose
titrated (over 2 weeks) up to a 800 mg twice daily dose for a 6-week
stable treatment period. However, focal seizures were inadequately
controlled with this dose and GWP42006 displayed no difference in
efficacy to the placebo control group (Schultz, 2018). While this may
cast doubt on the translatability of the evidence presented in this
review, it is worth highlighting that the maximum dose in humans
from the GW study would be considerably less than if the same dose
regimens as the in vivo studies were followed for a 60-kg human. Fur-
thermore, Morano et al. (2020) have suggested that the inability of
CBDV to control seizures was in part due to an extremely high
response from the placebo group and that the use of purified CBDV
may have also influenced the study outcome. Therefore, it is impor-
tant to exercise caution when extrapolating the findings from the
in vitro and in vivo data presented here and what doses may be effec-
tive in clinical trials.
Cannabichromene (CBC) was first isolated in 1966 by Gaoni and
Mechoulam and is a non-psychotropic cannabinoid that does not
interact with CB1 receptors (Gaoni & Mechoulam, 1966). CBC is an
agonist at CB2 receptors and TRP channels, acting potently at TRPA1
as well as displaying some activity at TRPV3 and TRPV4 channels
(Cascio & Pertwee, 2015; De Petrocellis et al., 2008, 2011; de
Petrocellis et al., 2012; Udoh, Santiago, Devenish, McGregor, &
Connor, 2019). CBC (0.001–1 μM) exhibited promising anti-
inflammatory effects in an in vitro model of colitis, decreasing LPS
increased nitrite levels and attenuating IFN-γ and IL-10 secretion in
peritoneal macrophages (Romano et al., 2013). More recently CBC
acted as a CB2 receptor agonist in AtT20 cells transfected with these
receptors and was confirmed by application of the CB2 receptor
antagonist AM630, which blocked the effects of CBC (Udoh
et al., 2019). We found only two papers related to neuroprotective
effects of CBC; in vivo CBC suppressed motor activity while in vitro
CBC improved viability of neural stem cells (Davis & Hatoum, 1983;
Shinjyo & Di Marzo, 2013). The anti-inflammatory effects of CBC may
play a pivotal role in its ability to act as a neuroprotectant, as inflam-
mation and overactivation of the immune response are important fea-
tures of neurodegenerative conditions.Thus, further research should
assess this compound in neuro-inflammatory conditions, where it may
have potential.
Cannabinol (CBN) is an oxidation product of ∆9-THC and was
the first cannabinoid to be discovered and isolated (Wood, Spivey, &
Easterfield, 1899). Like ∆9-THC, it has been shown to activate CB1
receptors (Ki 211.2 nM) but with lower potency, as well as acting as
an agonist at TRPV2 channels (Rhee et al., 1997; Russo &
Marcu, 2017). CBN (1 mg!mL−1) was recently shown to reduce
mechanical sensitization and sensitivity of afferent muscle fibres in
an in vivo model of myofascial pain, but no mechanism of action
was investigated (Wong & Cairns, 2019). From our search, limited
data showed that CBN decreased cell damage and acted as a potent
antioxidant in a cell-based Huntington's disease model (Aiken et al.,
2004). The antioxidant activity of CBN is a characteristic feature of
cannabinoids, which as previously mentioned, is thought to be due
to the presence of the phenolic ring and carboxyl moieties, as well
as the ability to increase antioxidant defences. CBD has already
shown extensive antioxidant properties, including increasing the
levels and activity of antioxidants, capturing ROS, and transforming
them into less active forms, as well as activating nuclear erythroid
2-related factor (NrF2) that governs the transcription of many anti-
oxidant genes (see Atalay, Jarocka-karpowicz, &
Skrzydlewskas, 2020). Oxidative stress is a key feature of neurode-
generative disorders including Parkinson's and Alzheimer's disease.
In the latter condition, Aβ deposits contain a significant number of
binding sites for biometals (zinc, copper, and iron) that contribute to
oxidative stress in patients (Huang, Zhang, & Chen, 2016; Kozlowski
et al., 2009). Furthermore, Alzheimer's disease patients have
decreased levels of antioxidant enzymes and increased products of
oxidative stress, such as peroxidised lipids and oxidized proteins in
brain tissue (Kim et al., 2006; Sultana et al., 2011). Also, large
amounts of ROS are generated by reactive microglial cells, with
studies showing superoxide produced by microglia directly contrib-
uting to the death of dopaminergic neurons in Parkinson's disease
(Hernandes, Café-Mendes, & Britto, 2013). It is clear that more
information is needed on the pharmacology of CBN, especially its
antioxidant potential. Moreover, the ability of CBDV, CBG, CBC,
and CBN to reduce Aβ deposits in vitro is also noteworthy and it is
clearly of interest to examine the antioxidant and anti-inflammatory
potential of these compounds in Alzheimer's disease models in vivo
and whether these compounds act through mechanisms, similar to
those of CBD.
∆9-THCV is a homologue of ∆9-THC differing by just a propyl
side chain, and studies have suggested that ∆9-THCV acts as a CB1
receptor agonist, sharing properties with ∆9-THC, albeit with less
potency (Gill, Paton, & Pertwee, 1970; Pertwee, 2008). They exhibit
similarities in their in vivo effects such as inducing catalepsy in mice
and ∆9-THC-like effects in humans (Gill et al., 1970; Hollister, 1974).
We found two studies where ∆9-THCV showed promise as an anti-
epileptic agent and protected neurons in two models of Parkinson's
disease, while García et al. (2011) suggested ∆9-THCV mediated some
of its protective effects by acting at CB1 and CB2 receptors, the possi-
ble mechanisms of action of ∆9-THCV was largely unexplored (García
et al., 2011; Hill et al., 2010). In an earlier study, ∆9-THCV displaced
[3H]CP55940 from specific sites in mouse brain and CHO-hCB2 cell
membranes (Ki values 75.4 nM and 62.8 nM, respectively), and along
with data from GTPγS-binding experiments, the authors concluded
∆9-THCV acted as a CB1 and CB2 receptor antagonist (Thomas
et al. 2005). Other groups have shown ∆9-THCV can block CB1 recep-
tor activity in murine cerebellar slices and, at 5.8 μM, increased GABA
release from neurons, sharing the same properties as AM251, a CB1
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receptor antagonist (Ma, Weston, Whalley, & Stephens, 2008;
Pertwee, 2008). Thus, while there is evidence to suggest ∆9-THCV
mediates some of its protective effects via CB1 and CB2 receptors,
the data remain largely unclear, and there is also a lack of investigation
into the potential of ∆9-THCV to act at other known cannabinoid
targets.
Microglial activation and the presence of neuroinflammatory fac-
tors are well known characteristics of Parkinson's disease and well
documented among patients (Mogi et al., 1994; Qian et al., 2011).
Moreover, studies have demonstrated that microglial overactivation
leads to deleterious effects and the exacerbation of the immune
response, especially the release of pro-inflammatory mediators. As
observed with the CBG derivative VC-003.2, microglial activation was
decreased by ∆9-THCV, inducing a protective effect by dampening
the immune response. Studies have already demonstrated the ability
of CBD to modulate the immune response by acting an agonist of
PPARγ and altering NF-κB signalling, which is up-regulated in both
microglia and astrocytes of Parkinson's disease patients. Furthermore,
activation of PPARγ leads to inhibition of NF-κB signalling and
decreases mRNA levels of proinflammatory mediators TNF-a, IL-1β,
IL-6, and iNOS (Vallée, Lecarpentier, Guillevin, & Vallée, 2017). There-
fore, it would be of interest to determine whether ∆9-THCV is able to
reduce microglial activation through the same mechanism as CBD,
involving the activation of PPARγ.
Limited pharmacokinetic data on Δ9-THCV have shown it exhibits
rapid absorption in rats and mice when administered either i.p. or
orally but is rapidly eliminated when orally administered (<1.5 h) com-
pared to i.p administration where its elimination rate is >5 h (Deiana
et al., 2012). Interestingly, Δ9-THCV exhibited extensive brain pene-
tration (exceeding plasma levels), regardless of the route of adminis-
tration, meaning it can effectively cross the BBB. At 24 h, Δ9-THCV
was no longer detected, suggesting that it exhibits a lack of accumula-
tion in brain tissue (Deiana et al., 2012). Altogether, these features,
along with evidence collected in this study, support Δ9-THCV as a
neuroprotective agent. However, clearly, more data with Δ9-THCV
are needed, especially to assess safety after chronic dosing and
whether this compound exhibits tolerance with long-term use.
∆9-THCA is the acidic precursor of ∆9-THC, and competition
binding assays revealed that this compound was unable to achieve
displacement of [3H]-CP55,940 (CB1 and CB2 receptor agonist) up to
10 μM, suggesting ∆9-THCA exhibits poor affinity for CB1 or CB2
receptors (McPartland et al., 2017). Results from this study also
showed that ∆9-THCA has little efficacy at these receptors as it
exhibited no inhibition of forskolin-mediated cAMP, compared to ∆9-
THC that acted as an agonist in this assay. Our search revealed that
∆9-THCA had anti-inflammatory effects that improved neural viability
in a model of Huntington's disease, but interestingly, it did not affect
the survival of dopaminergic neurons in a model of Parkinson's dis-
ease (Moldzio et al., 2012; Nadal et al., 2017). In a recent study,
Anderson, Low, Banister, McGregor, and Arnold (2019) reported that
∆9-THCA had extremely poor brain penetration (an optimistic brain–
plasma ratio of 0.15) in both vehicles tested. Furthermore, studies
have shown that ∆9-THCA has poor stability and rapidly
decarboxylates to ∆9-THC, bringing into question whether the ability
of ∆9-THCA to act as a neuroprotectant in the studies presented here
is actually due to nearly unavoidable contamination with ∆9-THC
(Anderson et al., 2019; McPartland et al., 2017). Overall, these data
warrant further investigation into ∆9-THCA as a potential neuro-
protective and anti-inflammatory agent, but with caution, and such
studies should include purity data on ∆9-THCA to enhance the
robustness of the experimental data.
There were no studies identified in this review that looked at the
potential neuroprotective effects of other cannabinoid varins or their
acidic forms such as CBGV, CBGVA, CBDVA, CBCV, and CBCVA. This
may be due to the lack of commercial availability of these compounds
due to their low concentrations in the plant, costly synthetic production
or that these compounds are not very stable. CBDA was only used in
one study on Huntington's disease, where it had no protective effects.
This compound, however, has shown promise in other conditions
including breast cancer migration, inflammatory pain and nausea
(Bolognini et al., 2013; Rock, Limebeer, & Parker, 2018; Takeda
et al., 2012), with groups suggesting that CBDA is 1,000 times more
potent at the 5-HT1A receptor than CBD (Bolognini et al., 2013). Activa-
tion of the 5-HT1A receptor is protective both in vitro in Parkinsonian
models and in vivo in models of hypoxia ischaemia (Miyazaki
et al., 2013; Pazos et al., 2013). Although Anderson et al. (2019) con-
cluded that CBDA displayed poor brain penetration in an oil-based for-
mulation, uptake was increased when CBDA was formulated in a
Tween-based vehicle. Also, CBDA was anti-convulsant at 10 and
30mg!kg−1 displaying greater potency compared toCBD (100mg!kg−1).
These data support CBDA's efficacy in the brain, as well as highlighting
its potential as an anticonvulsant (Anderson et al., 2019). Considering
these points, CBDA may be also protective in conditions such as
ischaemic stroke and Parkinson's disease and warrants further investi-
gation. Recent studies have also shown that CBDA, CBGV, and CBGA
interact with various TRP channel isoforms including TRPV1, TRPV2,
TRPA1, and TRPM8 channels. Of note, CBGV and CBGA were also
potent desensitizers of TRPV3 and TRPV4 channels, respectively
(De Petrocellis et al., 2012). While the extent of the role of TRP chan-
nels in neuroprotection has yet to be fully understood, these receptors
are involved in a wide range of neurological disorders. For example,
TRPA1-deficient mice were more likely to sustain damage post ischae-
mia and TRPA1 channel activation in Alzheimer's disease may have a
crucial role in regulating astrocyte-mediated inflammation (Lee
et al., 2016; Pires & Earley, 2018). Conversely, TRPV1 channel activity
has been implicated in epilepsy having a role in neuronal excitability and
synaptic transmission (Nazıroglu, 2015). Therefore, CBDA, CBGV, and
CBGA interactions at TRP channels may be beneficial in conditions that
involve these channels in their pathophysiology.
Translatability of these data and the viability of minor
phytocannabinoids as neuroprotectants will also rely on understand-
ing and perhaps manipulating their bioavailability and pharmacokinetic
properties. In a recent systematic review conducted by our group, Mil-
lar, Stone, Yates, and O'Sullivan (2018) highlighted discrepancies
regarding CBD bioavailability, Cmax, Tmax, and half-life (t1/2) in humans
depending on the route of administration and formulation and
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whether CBD was dosed in a fed or fasted state. That being said,
studies conducted in piglets (Garberg et al., 2017) and rodents
(Hammell et al., 2016; Long et al., 2012) have shown a dose-
dependent relationship between CBD administration and brain and
plasma concentrations. Limited data extracted by Millar et al. (2018)
showed that administration of CBD in humans also led to dose-
dependent increases in plasma concentrations, suggesting the same
may apply to brain concentrations in man.
Information on the human metabolites of CBD, ∆9-THC, and
other phytocannabinoids is scarce, with the majority of research
focusing on the extensive first pass metabolism of CBD and the iden-
tification of its urinary metabolites. Of interest, a patent filed by
Mechoulam et al. (2010) described that two major metabolites of
CBD, 7-hydroxy (7-OH) CBD and 7-carboxy (7-COOH), are both anti-
inflammatory and dose dependently inhibit TNF-а, NO, and ROS.
However, these data have yet to be confirmed in academic studies or
found to be true of other phytocannabinoids. In addition, the cyto-
chrome P450 (CYP) superfamily is responsible for metabolizing 60%–
80% of CNS-acting drugs, 23% by CYP3A4 and 38% CYP2C19, both
of which accept CBD as a substrate (Cacabelos, 2010; Iffland &
Grotenhermen, 2017). Altogether, these findings highlight that there
are major gaps in the ADME of phytocannabinoids, as well as a lack of
identification of metabolites and whether they have biological effects.
In phase II trials, the minor phytocannabinoids presented in this
review will, in all likelihood, be used alongside current therapies to see
if they can augment survival of neurons and/or symptom burden,
rather than being used as a single agent. In light of the above, it will
be essential to consider the interactions that these compounds may
have when administered in conjunction with conventional drug thera-
pies (where they exist) and to establish potential synergistic or delete-
rious effects. Looking forward, initial ADME data will be essential to
determine whether these compounds have true clinical potential and
for their subsequent formulation and administration.
5 | CONCLUSIONS
This review aimed to collate and summarise all current data on the
neuroprotective potential of phytocannabinoids other than ∆9-THC
and CBD. Despite the lack of studies available in this area, we found
that all phytocannabinoids tested displayed neuroprotective proper-
ties in a range of disorders. CBG and its derivatives displayed signifi-
cant anti-inflammatory effects and were particularly effective in
Huntington's disease models. CBDV, ∆9-THCV, and CBC were effec-
tive as anti-seizure agents, while CBN displayed antioxidant activity
and ∆9-THCA had anti-inflammatory effects. CBG and ∆9-THCA, like
CBD, mediate their anti-inflammatory effects through PPARγ. Many
of the studies were screening studies that conducted no mechanistic
probing, suggesting that research into these compounds is still in its
early stages. Extensive pharmacokinetic and pharmacodynamic data in
larger mammals are also necessary on these compounds, given that all
in vivo studies in this review were conducted in mice and rats. This
would provide more evidence for the facilitation of these compounds
as therapies in humans. Further studies are required to investigate the
full neuroprotective potential of these compounds particularly the
mechanisms underlying their protective effects, as well as exploring
whether their combinations may enhance their capabilities as
neuroprotectants. While we have focused on a select number of
minor phytocannabinoids, based predominantly on their shared physi-
cal and biological similarities to CBD, there are over
100 phytocannabinoids and terpenes present in the Cannabis plant
that could potentially display neuroprotective potential.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (http://www.guidetopharmacology.org), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, Christopoulos et al., 2019; Alexander, Cidlowski et al.,
2019; Alexander, Fabbro et al., 2019; Alexander, Mathie, et al., 2019).
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Protective Effects of Cannabidivarin and Cannabigerol
on Cells of the Blood–Brain Barrier
Under Ischemic Conditions
Nicole L. Stone,1,* Timothy J. England,1,2 and Saoirse E. O’Sullivan2,3
Abstract
Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic
stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuro-
protective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier
(BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes.
Experimental Approach: Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model is-
chemic stroke and cell culture medium was assessed for cytokines and adhesion molecules post-OGD. Astrocyte
cell lysates were also analyzed for DNA damage markers. Antagonist studies were conducted where appropriate
to study receptor mechanisms.
Results: In astrocytes CBG and CBDV attenuated levels of interleukin-6 (IL-6) and lactate dehydrogenase (LDH),
whereas CBDV (10 nM–10 lM) also decreased vascular endothelial growth factor (VEGF) secretion. CBDV
(300 nM–10 lM) attenuated levels of monocyte chemoattractant protein (MCP)-1 in HBMECs. In astrocytes,
CBG decreased levels of DNA damage proteins, including p53, whereas CBDV increased levels of DNA damage
markers. Antagonists for CB1, CB2, PPAR-c, PPAR-a, 5-HT1A, and TRPV1 had no effect on CBG (3 lM) or CBDV
(1 lM)-mediated decreases in LDH in astrocytes. GPR55 and GPR18 were partially implicated in the effects of
CBDV, but no molecular target was identified for CBG.
Conclusions: We show that CBG and CBDV were protective against OG mediated injury in three different cells
that constitute the BBB, modulating different hallmarks of ischemic stroke pathophysiology. These data enhance
our understanding of the protective effects of CBG and CBDV and warrant further investigation into these com-
pounds in ischemic stroke. Future studies should identify other possible neuroprotective effects of CBG and
CBDV and their corresponding mechanisms of action.
Keywords: blood–brain barrier; cannabidivarin; cannabigerol; cannabinoids; ischemia; neuroprotection
Introduction
The blood–brain barrier (BBB) is a unique interface
that separates the central nervous system (CNS) and
the periphery, protecting the brain from damaging
components found in general circulation, namely pe-
ripheral leukocytes, macromolecules, and xenobiot-
ics.1,2 The barrier itself is formed by microvascular
endothelial cells, which are encompassed by pericytes,
and altogether surrounded by astrocyte end feet, which
cover 99% of BBB endothelia.3 Cerebral ischemia–
reperfusion (IR) initiates a plethora of inflammatory
signaling pathways, cytotoxic glutamate release, and
oxidative stress, all of which contribute to increases
in BBB permeability.4 This loss of BBB integrity
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ultimately causes uncontrolled immune infiltration
into the CNS that perpetuates neuronal injury and hin-
ders poststroke recovery. Although administration of
tissue plasminogen activator (tPA) and mechanical
thrombectomy are effective licensed therapies to dis-
solve or remove the culpable clot, at present, there
are no available approved therapies that mitigate post-
stroke injury.5
Cannabidiol (CBD), one of the chemicals found in
Cannabis sativa, has displayed a range of neuroprotec-
tive qualities, preventing neuronal loss,6,7 attenuating
astrocyte reactivity,8 and dampening the neuroinflam-
matory response.9 Unlike delta9-tetrahydrocannabinol
(D9-THC), CBD does not activate the central cannabi-
noid receptors, CB1 or CB2, but activates a plethora of
other targets including PPAR-c, TRPV1, and 5-HT1A
receptors.10–13 CBD has formulations (alone and with
D9-THC) licensed by GW pharmaceuticals to treat
rare childhood epilepsies and spasticity associated
with multiple sclerosis. The protective effects of CBD
in stroke models has been well documented,14 specifi-
cally CBD has been shown to reduce infarct volume,15,16
reduce glutamate toxicity,9,17 attenuate mitochondrial
dysfunction18 and glial activation.6,19 In a co-culture
BBB model CBD preserved barrier integrity after oxygen-
glucose deprivation (OGD), which was mediated at
least in part by PPAR-c and 5-HT1A receptors.
12
Cannabigerol (CBG) and cannabidivarin (CBDV)
are neutral cannabinoids present in cannabis and stud-
ies have found these compounds share similar pharma-
cological characteristics to CBD. Like CBD, they do not
produce feelings of euphoria and display antioxidant
and anti-inflammatory properties, as well as interacting
with a range of target proteins including TRPV1,13
PPAR-c,20 5-HT1A, and CB2.
21 Recently our group
conducted a systematic review focusing on the neu-
roprotective properties of minor phytocannabinoids
(other than D9-THC or CBD) and found that CBG
and CBDV show efficacy in models of Huntington’s
disease, Alzheimer’s, and epilepsy, with CBG mediating
its protective effects through PPAR-c activation,22 the
same mechanism by which we have shown that CBD
protects BBB integrity.12 However, despite these com-
pounds having neuroprotective effects in other models,
no studies have been conducted to test whether CBG
or CBDV are protective in IR injury.
In light of the above, we hypothesized these com-
pounds may exhibit protective properties at the
BBB in a stroke model. To test this, we treated cells of
the BBB with CBG or CBDV in vitro before an OGD
protocol and measured various proinflammatory cyto-
kines, adhesion molecules, and cell damage markers.
Materials and Methods
Materials
CBG and CBDV were kindly gifted by STI pharmaceu-
ticals. Both compounds were dissolved in 100% ethanol
to 10 mM and were stored at !20!C. AM251, AM630,
GW6471, GW9962, O1918, CID16020046, SB366791
(Tocris, United Kingdom) were dissolved in dimethyl
sulfoxide as stock solutions of 10 mM. (S)-WAY100135
was dissolved in deionized water. Antagonists were stored
at !20!C and dilutions were made fresh as required.
General cell culture
Human brain microvascular endothelial cells (HBMECs),
astrocytes, and pericytes (passages 3–6) were grown in
their respective medium and maintained at 37!C in a
humidified incubator supplemented with 5% CO2.
HBMECs were cultured on fibronectin-coated plastic-
ware (2 lg/cm2), as per supplier recommendations.
Primary cells and medium were purchased from Scien-
Cell, United Kingdom.
OGD protocol
To simulate ischemic conditions, normal medium was
replaced with glucose free RPMI medium (Gibco,
United Kingdom) containing either CBG or CBDV
(10 nM to 10 lM), alongside a vehicle control (0.01%
ethanol). Cell culture plates were then placed in an
anoxic bag (BD GasPak", anaerobe) for 4 h (8 h for
astrocyte experiments) plus an additional 20 min to en-
sure anaerobic conditions. For vehicle normoxia, etha-
nol (0.01%) was added to the respective medium of
each cell type (ScienCell) and maintained in normal
oxygenated conditions. After OGD, medium was
aspirated and replaced with each cell types respective
medium (ScienCell) containing the relevant concentra-
tions of CBG or CBDV for a 20-h/16-h reperfusion pe-
riod. At 24 h, the medium was sampled, and cells were
lysed with RIPA buffer containing protease and phos-
phatase inhibitors (Sigma, United Kingdom; Thermo-
Fisher, United Kingdom). Medium and lysates were
stored at !80!C for future analysis.
Total protein
To quantify total protein, a bicinchoninic acid (BCA)
protein assay was performed on cell lysates. A working
reagent of copper II sulfate and BCA (Sigma-Aldrich)
was prepared in a 1:50 ratio and added to wells. After
a 30-min incubation at 37!C, plates were read at
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562 nm. Unknowns were extrapolated from a standard
curve of known concentrations of bovine serum album.
Unless otherwise stated, all secreted and intracellular
proteins were normalized to total protein.
Enzyme-linked immunosorbent assay
Medium samples were analyzed for various proinflamma-
tory cytokines including interleukin (IL)-6, IL-8, and adhe-
sion molecules including intracellular adhesion molecule
(ICAM)-1, vascular endothelial growth factor (VEGF),
monocyte chemoattractant protein (MCP)-1 using duo-
set enzyme-linked immunosorbent assay (ELISA) by
R&D systems, United Kingdom (DY206, DY208, DY720,
DY293B, and DY279). Raw values at 570 nm were sub-
tracted from values obtained at 450 nm, sample concentra-
tions were determined by extrapolating unknowns from
the 8-point standard curve (known concentrations).
Lactate dehydrogenase assay
A lactate dehydrogenase (LDH) assay was performed
to determine nonspecific damage induced by the
OGD protocol. A standard curve of known concen-
tration of nicotinamide adenine dinucleotide was
constructed as per manufacturer’s instructions. Fifty
microliters of standard or sample was aliquoted into
a 96-well plate and 50 lL of assay mix was added.
Plate absorbance was read at 450 nm and unknown
values were obtained from a standard curve.
DNA damage/genotoxicity assay
Astrocyte lysates post-OGD were analyzed using the
Milliplex DNA damage/Genotoxicity multiplex as-
say kit (Millipore, 48–621MAG) to detect changes in
DNA damage markers ataxia-telangiectasia mutated
(ATR-Total), checkpoint kinases 1, 2 (Chk1, Ser345
and Chk2, and Thr68), histone family member X
(H2A.X, Ser139), mouse double minute 2 homolog
(MDM2, total), cyclin-dependent kinase inhibitor 1
(p21, total), tumour protein (p53, Ser15). Kits were
performed according to manufacturer’s instructions.
Statistical analysis
All data are represented as the mean –standard error of
the mean, data were assessed for normality using the
D’Agostino–Pearson normality test and subsequently
analyzed using one-way analysis of variance with Dun-
nett’s post hoc analysis. All statistical analyses were
conducted using GraphPad prism (7/8) (Version 7.01;
GraphPad Software, Inc.), comparing either vehicle
normoxia or vehicle OGD with all other treatments.
A value of p < 0.05 was considered significant.
Results
HBMEC monocultures
Protein levels from HBMEC lysates were significantly
lower post-OGD compared with vehicle normoxia
wells ( p < 0.001). This was not affected by pretreatment
with CBDV or CBG (Supplementary Fig. S1C, F).
IL-6, ICAM-1, and MCP-1 were significantly in-
creased in cell culture medium 24 h after 4-h OGD
compared with normoxia vehicle ( p < 0.05; Fig. 1A–
F). Pretreatment with CBG (10 nM–10 lM) displayed
an overall trend to decrease IL-6 and 100 nM,
300 nM, and 10 lM CBG-treated wells were not statis-
tically significant to vehicle normoxia (Fig. 1A). CBG
pretreatment did not alter ICAM-1 and MCP-1 secre-
tion in response to OGD (Fig. 1B, C).
Pretreatment with CBDV (10 nM–1 lM and 10 lM)
did not attenuate IL-6 levels 24-h post-OGD. However,
3 lM CBDV was not significantly different from
vehicle normoxia (Figure 1D). Pretreatment with 3
and 10 lM CBDV significantly increased levels of
ICAM-1 24-h post-OGD ( p < 0.05, Fig. 1E). CBDV
(100 nM–10 lM) concentration-dependently reduced
levels of MCP-1, an effect that was significantly differ-
ent to vehicle OGD at 3 and 10 lM ( p < 0.05; Fig. 1F).
Pericyte monocultures
Protein levels from pericyte monocultures were not
significantly altered by the OGD protocol or drug treat-
ment (Supplementary Fig. S1A, D). A 4-h OGD in-
creased levels of IL-6, VEGF, and IL-8 measured in
cell culture medium 24-h post-OGD (Fig. 2A–F).
In pericyte monocultures, neither CBG nor CBDV
(10 nM–3 lM) altered IL-6 levels post-OGD; however,
both compounds increased IL-6 levels at 10 lM
( p < 0.0001; Fig. 2A, D). Pretreatment with CBG and
CBDV (10 nM–10 lM) did not alter levels of VEGF
(Fig. 2B, E).
At the lowest and highest concentrations tested,
CBG pretreatment increased IL-8 levels compared
with vehicle normoxia and vehicle OGD ( p < 0.05;
Fig. 2C). At 100 and 300 nM, CBG did not alter in-
creased levels of IL-8 produced by OGD (Fig. 2C).
CBDV did not affect IL-8 levels post-OGD, although
there was a trend to produce an increase in IL-8 at
10 lM (Fig. 2F).
Astrocyte monocultures
IL-6 levels were not statistically different to vehicle nor-
moxia 24 h after 4-h OGD (70.03 pg$mL normoxia vs.
65.29 pg$mL OGD, data not shown), but levels of IL-6
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FIG. 1. The effects of CBG and CBDV on HBMEC monocultures. Medium was analyzed for IL-6 (A, D),
ICAM-1 (B, E), and MCP-1 (C, F) 24 h after 4-h OGD. Data were normalized to total protein (calculated using
a BCA assay) and are given as a % change from the normoxia vehicle presented as means with error bars
representing SEM. n = 6–9 from three experimental repeats. *, Significant difference compared with
vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01,
$$$p < 0.001, and $$$$p < 0.0001) significant difference to vehicle OGD, one-way ANOVA with Dunnett’s post
hoc analysis. ANOVA, analysis of variance; BCA, bicinchoninic acid; CBDV, cannabidivarin; CBG, cannabigerol;
HBMEC, human brain microvascular endothelial cell; ICAM-1, intracellular adhesion molecule-1; IL-6,
interleukin-6; MCP-1, monocyte chemoattractant protein-1; OGD, oxygen-glucose deprivation; SEM, standard
error of the mean.
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FIG. 2. The effects of CBDV and CBG on pericyte monocultures. Medium 24 h after 4-h OGD was analyzed
for IL-6, VEGF, and IL-8 (A–F). Data were normalized to total protein and are given as a % change from the
normoxia vehicle, presented as means with error bars representing SEM. n = 6–9 from 3 experimental
repeats. *, Significant difference compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001, and $$$$p < 0.0001) significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis. VEGF, vascular endothelial growth factor.
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were significantly increased 24 h after 8-h OGD
( p < 0.01; Figure 3A and C). Therefore, subsequent ex-
periments in astrocytes were conducted using an 8-h
OGD protocol.
An 8-h protocol significantly decreased protein
levels in astrocyte cell lysates ( p < 0.01 versus vehicle
normoxia; Supplementary Fig. S1B, E). Treatment
with 10 lM CBG decreased protein content com-
pared with both vehicle OGD and vehicle normoxia
( p < 0.0001; Supplementary Fig. S1B). Pretreatment
with CBDV did not prevent the decrease in pro-
tein content caused by the 8-h OGD protocol ( p <
0.05 vs. vehicle normoxia); however, 30 nM, 1 and
10 lM CBDV did not exhibit a significant differ-
ence compared with vehicle normoxia (Supplemen-
tary Figure S1E).
Pretreatment with CBG 10 nM–3 lM attenuated astro-
cytic IL-6 levels ( p > 0.0001 vs. vehicle OGD; Fig. 3A);
however, at 10 lM CBG significantly increased IL-6
(Supplementary Fig. S2A). CBDV reduced levels of IL-6
compared with vehicle OGD at 30 nM ( p < 0.05), 1 lM
( p < 0.01), and 10 lM ( p < 0.05; Fig. 3C). CBDV at
300 nM and 3 lM also appeared to decrease IL-6 levels,
exhibiting no statistical difference to vehicle normoxia.
Astrocytic VEGF levels were significantly increased
post-OGD ( p < 0.0001; Fig. 3B, D). CBG pretreatment
appeared to attenuate VEGF levels at 100 nM and
3 lM, but this did not reach significance to vehicle
OGD (Fig. 3B). Conversely, 10 lM CBG significantly
increased VEGF compared with both vehicle normoxia
and vehicle OGD ( p < 0.001; Supplementary Fig. S2B).
Pretreatment with CBDV (10 nM–10 lM) decreased
FIG. 3. The effects of CBG and CBDV on astrocyte monocultures. (A-D) Medium 24 h after 8-h OGD were
analyzed for IL-6 and VEGF. Data were normalized to total protein and are given as a % change from the
normoxia vehicle, presented as means with error bars representing SEM. n = 5–9 from 3 experimental
repeats. *, Significant difference compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001, and $$$$p < 0.0001) significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis.
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VEGF levels in a concentration-dependent manner. At
10 lM this was not significantly different to vehicle
normoxia and significantly different to vehicle OGD
( p < 0.0001; Fig. 3D).
LDH was significantly elevated in astrocyte medium
post-OGD ( p < 0.01; Fig. 4A, C). Pretreatment with 1
and 3 lM CBG significantly attenuated LDH activity
( p < 0.05; Fig. 4A); however, at 10 lM CBG signifi-
cantly increased LDH activity (Supplementary Fig. S2C).
CBDV exhibited a biphasic concentration response, de-
creasing LDH activity at lower (10 nM; p < 0.01) and
higher concentrations ( p < 0.05; 1 and 3 lM), but in-
creasing levels at 100 nM ( p < 0.001; Fig. 4C).
None of the antagonists tested blocked CBG (3 lM)-
mediated decreases in LDH; however, application of
CID1602 (antagonist for GPR55) appeared to potenti-
ate the effects of CBG ( p < 0.001; 3 lM CBG + CID1602
vs. vehicle OGD; Fig. 4B). In the presence of an-
tagonists for GPR55, CID1602 and O1918, CBDV
(1 lM)-mediated decreases in LDH were no longer
significantly different to vehicle OGD (Fig. 4D). In
addition, SB366791 appeared to potentiate the LDH-
reducing effects of CBDV ( p < 0.01; 1 lM CBDV
SB366791 vs. vehicle OGD, Fig. 4D).
As CBDV and CBG reduced cell damage in astro-
cytes, we next investigated whether these compounds
FIG. 4. The effects of CBG and CBDV treatment alone (A, B) and with antagonists (C, D) on LDH release
from astrocyte monocultures. Medium 24 h after 8-h OGD were analyzed LDH. Data were normalized to
total protein and are given as a % change from the normoxia vehicle, presented as means with error bars
representing SEM. n = 5–6 from 3 experimental repeats. *, Significant difference compared with vehicle
normoxia (vehicle N) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001,
and $$$$p < 0.0001) significant difference to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis.
LDH, lactate dehydrogenase.
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(at the most efficacious lower and higher concentrations
tested) influenced levels of DNA damage proteins. Lev-
els of DNA damage proteins, ATR, Chk1, Chk2,
H2A.X, and p53 were increased in astrocyte cell lysates
24 h after 8-h OGD. MDM2 showed a trend for in-
creasing post-OGD, but levels of p21 were not affected
(Fig. 5A–N). Application of CBG (1 lM) before OGD
significantly reduced levels of Chk1 and Chk2 com-
pared with OGD vehicle ( p > 0.01, p < 0.05; Fig. 5B,
C). In addition, CBG pretreatment at 10 nM, 1 lM,
and 3 lM decreased H2A.X levels that displayed
trend for increasing post-OGD ( p > 0.05; Fig. 5D). Lev-
els of p53 were also increased post-OGD ( p > 0.05) and
attenuated by CBG in a concentration-dependent man-
ner that was significant at 1 lM ( p > 0.05; Fig. 5K). By
contrast, CBDV (10 nM, 100 nM) increased levels of
ATR (p > 0.0001, p < 0.01; Fig. 5E) as well as increas-
ing levels of Chk1 at 100 nM (p < 0.05) and Chk2 at
10 nM (p < 0.01; Fig.5F). CBDV (100 nM and 1 lM)
also increased levels of H2A.X, p53 and MDM2
(p < 0.05; Fig. 5H, L, N).
Discussion
In this study we assessed whether non-euphoric phyto-
cannabinoids CBG and CBDV protected cells of the
BBB in a cellular model of ischemic stroke. Despite
promising preclinical data, drugs developed for one
or more of the hallmarks of stroke have failed once
they have reached clinical trials.23,24 Poor translational
efficacy is likely to stem from the multifactorial patho-
physiology of ischemic stroke and complicating factors
among elderly patients, which are often overlooked
in ischemic stroke modeling.25 These points empha-
size the need to generate new, effective therapies
for patients, which target multiple aspects of stroke
pathogenesis.26
CBD has been widely studied as a neuroprotectant,
partly because of its promiscuous pharmacology, toler-
able safety profile in humans and absence of euphoric
effects.10,27,28 However, other phytocannabinoids are be-
ginning to gain significant interest as therapeutic agents.
CBG has displayed prominent anti-inflammatory and
antioxidant capabilities20,29,30 and the antiepileptic
properties of CBDV have been well documented.31–33
Recently, CBDV has been shown to reduce inflamma-
tory cytokine release in a model of intestinal inflam-
mation.34 Our results demonstrate that CBDV and
CBG exhibit protective properties against OGD-induced
damage in astrocytes and HBMECs, modulating a range
of biochemical parameters measured post-OGD. For
CBDV, its cytoprotective effects appeared to partially in-
volve GPR55, but a target for CBG was not identi-
fied. These data warrant their further investigation
into these compounds as neuroprotectants and to assess
their clinical applicability, specifically, their efficacy in
in vivo models of ischemic stroke and whether they
are protective when applied post-OGD.
Post-cerebral ischemia and elevated levels of proin-
flammatory cytokine IL-6 are associated with increased
neuronal cell necrosis and are correlated with stroke se-
verity, increases in mortality rate, poor performance,
and functional disability.35–38 In this study, CBG and
CBDV significantly decreased levels of IL-6 in astro-
cytes, suggesting that like CBD, CBDV and CBG may
offer protection against inflammation caused by ische-
mic stroke.12 Increases in IL-6 post-ischemia have also
been implicated in BBB breakdown and tight junc-
tion remodeling, including reduced expression of VE-
cadherin, occludin, and claudin-5.39 Although there
was a trend for CBDV and CBG to attenuate IL-6 levels
in HBMECs, more pronounced reductions in IL-6 were
observed in astrocytes. Astrocytes provide biochemical
and mechanical support that help to maintain the BBB,
as well as providing neurovascular crosstalk between
neurons and cerebral blood vessels.40 Unlike in mono-
culture, in vivo, astrocyte endfeet are in direct contact
with endothelial cells; thus, modulating the astrocyte
inflammatory response in situ may act to preserve
BBB integrity indirectly by soluble factors secreted by
astrocytes or by preserving normal astrocyte function.
Mice lacking the receptor for adhesion molecule,
MCP-1 (CCR2), have significantly reduced infarct sizes
together with reduced BBB permeability and similarly,
MCP-1 knockout mice have a reduced influx of hema-
togenic cells from systemic circulation and improved
neurological outcome.41,42 Bonifa!cić et al. found a rela-
tionship between patients with poor outcomes 90 days
after stroke and elevated levels of MCP-1 and a recent
meta-analysis revealed that higher baseline circulating
levels of MCP-1 correlated with a higher risk of ische-
mic stroke.43,44 Our data show that CBDV concentra-
tion dependently decreased levels of MCP-1 secreted
by HBMECs when applied at the same time as initiating
OGD, suggesting that CBDV might offer protection
against MCP-1-related damage post-stroke and/or
offer protection in individuals at a higher risk of ische-
mic stroke. These data are also consistent with that of a
recent study showing that CBDV treatment attenuated
MCP-1 mRNA levels in colonic tissue post-colitis.34 Of
interest, this study also showed that CBDV was able to
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FIG. 5. The effects of CBG and CBDV on DNA damage markers (ATR [A,E] , Chk1 [B,F] , Chk2 [C,G] , H2A.X
[D,H] , MDM2 [I,L] , p21 [J,M] , and p53 [K,N] from astrocyte cell lysates, 24 h after 8-h OGD. Data were
normalized to total protein and are given as MFI as a % change from the normoxia vehicle (vehicle N);
means with error bars represent SEM. n = 6–8 from 3 experimental repeats. *, Significant difference
compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01). $p < 0.05, $$p < 0.01 significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis. MFI, mean fluorescent intensity.
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reduce intestinal permeability, an effect that may be
replicated at the BBB, but this has yet to be investigated.
We also measured VEGF secreted by pericytes and
astrocytes post-OGD reperfusion as elevations in
VEGF are correlated with increased endothelial barrier
permeability post-ischemia.45–47 Li and co-authors
found that astrocyte-derived VEGF mediated endo-
thelial barrier disruption, which was associated with
decreases in occludin and claudin-5.47 Interestingly,
whilst CBG and CBDV did not affect pericyte-derived
VEGF, CBDV decreased VEGF secretion in astrocytes
in a concentration-dependent manner and CBG
exhibited a trend for decreasing VEGF at 100 nM and
3 lM. As VEGF is known to facilitate BBB opening
these compounds may offer protection against BBB
breakdown post-ischemia; however, the mechanisms
in which these compounds decrease VEGF remains
to be elucidated.
During IR injury cells undergo a combination of ap-
optosis and necrosis, causing various cellular compo-
nents to be released into the extracellular space. One
of these components, LDH, is often used as a marker
of cell damage. Previous studies have shown that IR
models cause LDH leakage into cell culture medium48,49
and clinically, LDH has been trialled as a marker of
ischemic severity.50,51 Pretreatment with CBDV and
CBG offset increases in LDH, suggesting both com-
pounds mitigate cellular damage produced by OGD
reperfusion. Application of receptor antagonists revealed
that CBDV appeared to mediate its effects on LDH lev-
els by GPR55; however, none of the antagonists tested
blocked the effect of CBG. This could be explained by
the nonspecific antioxidant properties of cannabinoids,
namely owing to their phenolic rings and hydroxyl
moieties.17,52 Indeed, previous studies have shown
that CBD increases antioxidant enzymes in BV2 micro-
glial cells,53 as well as attenuating oxidative stress
and increasing mitochondrial bioenergetics in OGD
reperfusion-damaged neurons.18 Similarly, CBD, CBDV,
and CBG were able to prevent oxytosis in a preclinical
drug screen for Alzheimer’s disease and CBG exhibited
antioxidant capacity in neuroblastoma cells.54,55 More
data are clearly needed on the specific and nonspecific
mechanisms in which these compounds mediate their
protective effects, particularly whether their antioxi-
dant status is responsible for reducing cell damage in
the context of ischemia.
Ischemia is a pathophysiological stressor and as a
consequence, nonspecific single- and double-strand
DNA breaks (ssDNA/dsDNA breaks) and replication-
associated DNA damage responses (DDRs) occur. DNA
damage can activate the DDR pathway and DDR re-
sponse proteins ATR, Chk1, Chk2, H2A.X, MDM2,
p21 and p53 that govern elements of DNA repair, cell
cycle arrest, apoptotic and necrotic cell death.56–59
These processes are central in IR injury and early stud-
ies found that neurons are the first to exhibit signs of
DNA damage (0.5–8 h reperfusion) followed by astro-
cytes (24 h reperfusion).60 Thus, we next investigated
the effect of CBDV and CBG on DDR proteins post-
OGD in astrocytes.
In support of previous studies, our OGD protocol
(and subsequent reperfusion period) increased levels
of almost all measured DDR proteins in astrocyte
monoculture lysates.61 In stroke patients, Huttner
and colleagues found evidence of ATM/ATR activity
in the penumbra of cortical neurons 7–10 days post-
ischemia.62 Studies have also shown p53 activation is
implicated in ischemia-induced neuronal cell death,
with elevated levels of p53 also present in reactive as-
trocytes and microglia.63,64 Ahn and colleagues found
that inhibition of p53 by pifithrin-a reduced OGD-
induced cell death in cultured astrocytes, and as a sec-
ondary effect reduced elevated levels of glutamate and
glial fibrillary acidic protein (GFAP), which were also
increased post-OGD.65 To our knowledge, this is the
first study to show that CBG pretreatment reduced lev-
els of Chk1, Chk2, H2A.X, and p53 in astrocytes post-
OGD. It is likely that these decreases in DNA damage
proteins were caused indirectly, possibly because of the
overall reductions in cellular damage and inflamma-
tion, as well as the known antioxidant properties of
CBG that have both been demonstrated in other stud-
ies.20,66 Nevertheless, direct modulation of these pro-
teins should not be ruled out particularly as PPAR-c,
a known target for phytocannabinoids, has been impli-
cated in ATM signaling and the DDR.67
Pretreatment with CBDV significantly increased ex-
pression of the majority of DNA damage proteins in as-
trocytes and exhibited a trend for increasing p21. CBD
was recently found to increase protein expression of
ATM and p21, but not p53 in an in vitro model of gas-
tric cancer, suggesting CBD promotes cell cycle arrest
at the G0–G1 phase.
68 Our data suggest that CBDV
acts in a similar manner; however, it is important to
emphasize that p21 has roles in both enhancing and
inhibiting apoptosis depending on the type of stressor;
thus, generating this response in a cancer cell model
will be different to responses of astrocytes subjected
to OGD. Low dose N-methyl-D-aspartate (NMDA) to
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simulate ischemic preconditioning was shown to increase
MDM2 protein expression, preventing p53 stabilization
in mouse cortical neurons and ischemia-induced apopto-
tic cell death.69 CBDV significantly increased levels of
MDM2, which is a key protein involved in p53 deg-
radation and thus promotion of cell survival. Future
studies should clarify the implications of CBDVs abil-
ity to increase levels of DNA damage proteins in ische-
mia and establish whether modulating DNA damage
and repair in astrocytes can influence post-stroke in-
jury and recovery.
Conclusions
This study provides novel data on the neuroprotective
and anti-inflammatory properties of CBG and CBDV
in an in vitro model of IR. These data, together with ev-
idence from other studies, corroborate the protective
properties of these compounds and further studies
are needed to elucidate the mechanism of action of
CBG and CBDV and whether they can modulate
BBB permeability in more clinically relevant in vivo
models of ischemic stroke. There is lack of effective
treatments for ischemic stroke, a condition that will in-
crease in prevalence in coming years, to which canna-
binoids may offer a unique therapeutic strategy.
Acknowledgments
The authors specially thank STI Pharmaceuticals for
providing the test compounds CBDV and CBG.
Authors’ Contributions
S.O.S. and N.S. designed the experiments that were car-
ried out by N.S. N.S. wrote the article with input from
S.O.S. and T.J.E. T.J.E. and S.O.S. supervised the project.
Author Disclosure Statement
S.O.S. is director of CanPharmaConsulting, scientific
advisor to pharmaceutical companies developing
cannabinoid-based medicines. None of these compa-
nies were involved in this research.
Funding information
This work was supported by the Biotechnology and






1. Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function
of the blood-brain barrier. Neurobiol Dis. 2010;37:13–25.
2. McConnell HL, Kersch CN, Woltjer RL, et al. The translational significance
of the neurovascular unit. J Biol Chem. 2017;292:762–770.
3. Sosunov AA, Wu X, Tsankova NM, et al. Phenotypic heterogeneity and
plasticity of isocortical and hippocampal astrocytes in the human brain.
J Neurosci. 2014;34:2285–2298.
4. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke.
J Neuroimmunol. 2007;184:53–68.
5. Douglas DR, Luoma V, Reddy U. Acute management of ischaemic stroke.
Anaesth Intensive Care Med. 2020;21:1–7.
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66.09 191.10 226.59 1037.36 
285.33 509.77 
SD 11.46 80.32 71.53 359.27 55.13 168.85 
















Mean 121.53 225.47 249.61 201.46 208.37 188.32 
SD 
43.75 57.84 131.13 101.97 105.88 57.92 
SEM 
14.58 19.28 43.71 33.99 35.29 19.30 
 
IL-8 (pg.mL) Vehicle 
normoxia 











2688.87 2673.21 2716.32 5258.47 








SEM 287.13 183.46 291.84 288.00 98.38 505.94 
 
Table II: Raw data from ELISA of pericyte cell culture medium. Note that these values are taken 
as an average from experimental repeats with cells at different passages and have not been 





























66.09 191.10 226.59 1037.36 
121.25 167.12 
SD 
11.46 80.32 71.53 359.27 
21.78 43.50 
SEM 

















Mean 98.5 253.6 249.69 232.61 273.47 190.55 
SD 
60.4 84.82 59.80 170.75 66.78 51.12 
SEM 
16.75 28.27 19.93 56.92 27.26 29.87 
 
Table III: Raw data from ELISA of astrocyte cell culture medium. Note that these values are 
taken as an average from experimental repeats with cells at different passages and have not 
















248.15 457.63 453.34 189.71 228.72 397.39 
SD 55.16 243.32 263.86 119.89 73.79 248.87 
















Mean 2304.50 3573.39 4756.84 3088.78 6861.55 3433.11 
SD 
1050.72 1150.08 1878.69 1663.37 4206.34 1614.60 
SEM 
















Mean 520.69 882.82 799.72 645.74 362.35 333.93 
SD 
342.50 448.88 422.61 295.39 72.88 85.87 
SEM 
139.82 183.25 172.53 120.59 29.75 35.06 
 
Table IV: Raw data from ELISA of human brain microvascular endothelial cell (HBMEC) cell 
culture medium. Note that these values are taken as an average from experimental repeats 









Background and purpose 
Cannabidiol (CBD) has demonstrated a plethora neuroprotective effects and previously 
our group showed CBD reduced blood-brain barrier (BBB) permeability in an in vitro 
model of ischaemic stroke. We aimed to investigate whether CBD’s acidic precursor, 
cannabidiolic acid (CBDA), also reduced BBB permeability and protected cells against 
oxygen-glucose deprivation (OGD) induced damage. 
 
Experimental Approach 
Human brain microvascular endothelial cells (HBMECs), pericytes, astrocytes and 
neurons were grown in a four-cell transwell style BBB model. Pericytes and neurons 
were also grown in monoculture. Oxygen-glucose deprivation (OGD) was used to 
model ischaemia. Medium was analysed for proinflammatory mediators and heat 
shock proteins post OGD. Propidium iodide staining was also conducted in neurons to 
evaluate neuronal cell death. Mechanisms of action were probed in pericytes using 
appropriate receptor antagonists. 
 
Results 
CBDA 3 M prevented an increase in permeability post OGD between 4 h (post OGD) 
and 24 h (p<0.05). CBDA (1 M) also protected neurons from OGD induced damage as 
shown by propidium iodide staining and by visual assessment using a light microscope 
(72 h post OGD). 
 
In pericyte monocultures, CBDA (10 nM- 1 M) attenuated increases in interleukin 6 
(IL-6) 24 h post 4 h OGD (p<0.01). CBDA did not modulate levels of VEGF, ICAM-1 but 




CBDAs ability to reduce IL-6 secretion. CBDA (100 nM) also reduced levels of 
HSP27(ps78) and HSP90 in neuronal monocultures. 
Conclusions and implications  
These data suggest that CBDA, like CBD, displays anti-inflammatory and 
neuroprotective properties, as well as modulating BBB permeability in a four-cell 
model. CBDA appears to mediate some of its anti-inflammatory effects in pericytes in a 
similar mechanism to CBD; via the 5-HT1A receptor. Overall, further research is 
warranted into CBDAs neuroprotective effects in in vivo models of ischaemic stroke 



































The development and maintenance of the BBB is governed by specialised cell types 
namely human brain microvascular cells (HBMECs), astrocytes and pericytes. 
Collectively they regulate the formation of tight junctions, barrier polarization, 
paracellular permeability and expression of transporter proteins, which are 
characteristic features of the BBB (Abbott, 2002; Abbott et al., 2010). The BBB also has 
significant interaction with surrounding cells, namely neurons and microglia, and 
altogether form the neurovascular unit (NVU) (Reviewed in Iadecola, 2017; McConnell 
et al., 2017). Crosstalk between neurons and the cells of BBB is essential for functional 
hyperaemia, BBB maintenance, immune responses and metabolic waste clearance 
(Nippert, Biesecker and Newman, 2018). In addition, pericytes are key players in 
regulating cerebral blood flow as well as tight junction formation and maintenance in 
HBMECS (Bell et al., 2010; Daneman et al., 2010).  
 
Ischaemia-reperfusion (IR) ensues significant damage upon the BBB, specifically 
oxidative stress, glutamate release and immune cell activation, which stimulate the 
release of pro-inflammatory cytokines, disruption of endothelial cell tight-junctional 
complexes, as well as increases in the expression of adhesion molecules. These 
pathological mechanisms increase BBB permeability and facilitate leukocyte infiltration 
into the CNS, perpetuating neuronal damage in the potentially salvageable penumbral 
region. Only two treatments, tissue plasminogen activator (tPA) and surgical clot 
removal, are licenced to treat ischaemic stroke (Minnerup et al., 2012). Recently it was 
reported in a study where patients were receiving thrombolysis treatment, good 
functional outcome decreased by 75% for every 1% increase in BBB permeability 
measured 5 days post stroke (Nadareishvili et al., 2019). Currently, there are no 
successful treatments to mitigate BBB permeability which can dramatically affect 
neurological outcome and functional recovery post stroke. 
 
Cannabidiol (CBD) does not activate the cannabinoid receptors CB1 and CB2 but can 




possesses significant anti-inflammatory, antioxidant and neuroprotective properties 
(Esposito et al., 2007; Ruiz-Valdepeñas et al., 2011) and studies have shown CBD 
protects against hypoxia induced neuronal cell damage (Alvarez et al., 2008; Castillo et 
al., 2010; Lafuente et al., 2011). At the BBB, CBD mediates its protective effects at least 
in part through the activation of TRPV2, A2A, PPARy and 5-HT1A (Mecha et al., 2013; 
Hind, England and O’Sullivan, 2016; Luo et al., 2019). Despite extensive interest in CBD, 
data on CBDs acidic precursor cannabidiolic acid (CBDA, particularly its neuroprotective 
effects, is extremely limited (Formato et al., 2020; Stone et al., 2020). CBDA has 
displayed efficacy as an anti-hyperalgesic, antiemetic, an antiepileptic, an anti-cancer 
agent and as an inhibitor and down-regulator of the cyclooxygenase enzyme, COX-2 
(Takeda et al., 2008; E M Rock and Parker, 2017; Rock, Limebeer and Parker, 2018; 
Anderson et al., 2019) Bolognini et al., (2013) showed that CBDA is 1000 times more 
potent than CBD as an antiemetic, via activation of 5-HT1A. Additionally, CBDA has been 
shown to activate various transient receptor ion channels, albeit with a lower potency 
than CBD (De Petrocellis et al., 2008). Given these data it is possible that CBDA acts 
similarly to CBD in other conditions, such as ischaemic stroke. Recently Anderson et al., 
(2019) characterised the pharmacokinetics and CNS penetration of acidic 
phytocannabinoids and the poor brain: plasma ratio of CBDA was positively improved 
by administration with a Tween 80 vehicle, highlighting that CBDA can penetrate the 
brain when administered in the right formulation.  
 
In light of the above, together with previous data generated by our group, we 
hypothesised that CBDA may also be protective at the BBB through a similar 
mechanism to CBD. The aim of this study was to assess the effects of pre-treatment 
with CBDA in pericyte and neuronal cell monocultures and an in vitro BBB model 
(Stone et al., 2018). BBB permeability was assessed using transepithelial resistance 
(TEER) and levels various cytokines and chemokines were assessed in cell culture 









HBMECs, astrocytes, pericytes and neurons were grown in a contact four-cell model in 
their respective media (ScienCell, UK). HBMECs were seeded in the apical side of 
collagen coated 3.0 µm pore polytetrafluoroethylene membrane Transwell inserts (12 
well type; Corning Costar, USA). Astrocytes and pericytes were seeded as a mixed 
culture on the underside of the insert. Neurons were cultured on poly-L-lysine coated 
coverslips which were placed on the cell culture well bottom. For full methodology see 
Stone et al., (2018). Cells were grown to confluency and the resistance across the 
membrane was measured using STX-3 chopstick electrodes linked to an epithelial 
voltohmeter (World Precision Instruments, UK). These measurements were used to 
evaluate barrier integrity. For monoculture experiments pericytes and neurons (P3-P5 
and P1 respectively, ScienCell, UK) were cultured until confluency in 24 well cell culture 




To simulate ischaemic conditions, medium was replaced with glucose free RPMI 
medium (Gibco, UK) containing increasing concentrations of cannabidiolic acid (CBDA) 
or cannabidiol (CBD), alongside a vehicle control (0.01% acetonitrile or ethanol) and 
then placed in an anoxic bag (BD, anaerobe) for 4 h plus an additional 20 minutes to 
ensure anaerobic conditions (Hind et al., 2015;2016). For normoxic conditions, the 
same concentrations were applied but these were prepared in normal pericyte or 
neuronal medium (Sciencell, UK) and maintained in normal oxygenated conditions. 
After 4 h OGD, medium was aspirated and replaced with normal pericyte or neuronal 
medium containing the relevant concentrations of CBDA or CBD for a 20 h reperfusion 
period. At 24 h, medium from both conditions (OGD and normoxia) was sampled and 
cells were lysed with RIPA buffer containing protease and phosphatase inhibitors. 






Pericytes (P3-P5) were cultured until confluency in 24 well cell culture plates. For OGD 
conditions the medium was replaced with glucose free RPMI medium (Gibco, UK) 
containing relevant antagonists, AM251 (100 nM), AM630 (100 nM), GW6471 (100 
nM), GW9962 (100 nM), (S)-WAY 100135 (300 nM), O1918 (1 µM), capsazepine (1 
µM), CID16020046 (1 µM), SB366791 (1 µM). CBDA 1 M alone and a vehicle control 
(0.01% acetonitrile). After 15 minutes, CBDA 1 M was applied to the antagonist 
treated wells and then placed in an anoxic bag (0% O2) for 4 h (BD, anaerobe). After 4 
h, medium was replaced with normal pericyte medium containing the relevant 
antagonists and 15 minutes later CBDA 1 M was applied to the antagonist treated 
wells. 
 
At 24 h, medium from both conditions (OGD and normoxia) was sampled and cells 
were lysed with RIPA buffer containing protease and phosphatase inhibitors. Medium 




Medium samples were analysed for Interleukin-6 (IL-6) a pro-inflammatory mediator, 
intracellular adhesion molecule-1 (ICAM-1), interleukin-8 (IL-8), vascular endothelial 
growth factor (VEGF) using duo-set ELISA by affymetrix and R&D systems, UK. Data 
obtained from monolayer experiments were normalised to total protein using a 
bicinchoninic acid (BCA) assay (Sigma-Aldrich, UK). 
 
Propidium Iodide (PI) Staining  
 
At 72 h post OGD, neurons were washed with 1X PBS and incubated with a 100 μL/mL 
solution of PI prepared in PBS for 1-2 minutes at room temperature in the absence of 
light. PI is excluded from live cells but binds to double stranded DNA of dead or dying 
cells, thus the red staining is proportional to the number of dying cells. Images were 




fluorescence microscope (Nikon Eclipse 50i) with a 20x objective. Images were visually 




CBDA was obtained from Sigma, UK and CBD from Tocris, UK. CBDA was dissolved in 
100% acetonitrile and CBD in 100% ethanol to a stock concentration of 10 mM and 
were stored at -20 C. AM251, AM630, GW6471, capsazapine, GW9962, O1918, 
CID16020046, SB366791 (Tocris, UK) were dissolved in dimethyl sulfoxide as stock 
solutions of 10 mM. (S)‐WAY100635 was dissolved in deionised water. Antagonists 
were stored at -20°C and dilutions were made fresh as required. 
Statistical Analysis 
 
Data are represented as the mean ± S.E.M, data were assessed for normality using the 
D'Agostino-Pearson normality test and subsequently analysed using one-way ANOVA 
with Dunnett's post hoc analysis. All statistical analyses were conducted using 
GraphPad prism (7/8) (Version 7.01; GraphPad Software Inc.), comparing either vehicle 
normoxia or vehicle OGD with all other treatments. TEER and IL-6 data from BBB 
model were analysed using two-way ANOVA with Turky’s multiple comparisons test. A 













6.3.1 The effects of CBDA and CBD in a 4-cell BBB model  
Subjecting co-cultures to a 4 h OGD increased permeability, as shown by decrease in 
TEER (0 h-4 h), measured immediately post OGD (Figure 6.1 A, B). Pre-treatment with 
CBD displayed a trend to prevent permeability increases between 4 h and 24 h post 
OGD, but this did not achieve statistical significance (Figure 6.1A). There was a 
significant difference between treatment with 300 nM CBD and 1 µM CBD at 48 h and 
72 h. CBDA (300 nM-3 M) exhibited a trend to decrease permeability between 4 h 
and 24 h post OGD and was significant at 3 M (p<0.05; Figure 6.1B). There was a 
trend for CBD (3 M) and CBDA (1 M) to decrease levels of IL-6 at 24 h and 48 h but 
this did not reach significance (Figure 6.2A,B). 
 
CBDA prevented cell death in neurons present in the 4-cell model which had been 
subjected to 4 h OGD; as shown by fewer PI-stained neuronal nuclei vs vehicle control 







Figure 6.1. The effects of CBD (A) and CBDA (B) on permeability (transepithelial resistance, TEER in 
vitro model of the BBB post 4 h oxygen-glucose deprivation (OGD) and a subsequent 20 h 
reperfusion period. TEER was measured at the same intervals prior to medium change/ sampling. 
Compounds were applied prior to OGD, post OGD and at 24 and 48 h post OGD after TEER 
measurement and medium sampling (depicted by black arrows). Data are given as means with error 
bars representing S.E.M. n= 6 inserts based on 3 experimental repeats. Statistical analysis was 
conducted using a two-way ANOVA and multiple comparisons were adjusted for by Turkey’s 
statistical hypothesis test. * denotes a significant difference compared to control (p<0.05), $ 







Figure 6.2. The effects of CBD (A) and CBDA (B) on IL-6 secretion in an in vitro model of the BBB post 4 
h oxygen-glucose deprivation (OGD) and a subsequent 20 h reperfusion period. Medium was sampled 
before OGD, post OGD and at 24 h intervals before drug reapplication. Compounds were applied 
prior to OGD, post OGD and at 24 and 48 h post OGD after TEER measurement and medium sampling 
(depicted by black arrows). Data are given as means with error bars representing S.E.M. n= 6 inserts 
based on 3 experimental repeats. Statistical analysis was conducted using a two-way ANOVA and 
multiple comparisons were adjusted for by Turkey’s statistical hypothesis test. * denotes a significant 
difference compared to control (p<0.05), $ denotes a significant difference between 300 nM CBD and 















Figure 6.3. Fluorescence and light microscope images of neurons from the 4-cell BBB model stained 
with propidium iodide at 72 h post 4 h OGD. PI s excluded from live cells but can bind to double 
stranded DNA of dead or dying cells, thus red staining is proportional to the number of dying cells. 1 
μM CBDA (B, D) protected neurons against OGD induced cell death as shown in vehicle control wells 




6.3.2 Pericyte monocultures 
In pericytes, IL-6, VEGF and ICAM-1 levels, but not IL-8, rose significantly 24 h post 4 h 
OGD compared to the normoxia vehicle (p≤0.01; Figure 6.4A-D). Pre-treatment with 
CBDA (10 nM, 100 nM and 1 μM) significantly decreased IL-6 secretion in pericytes 24 
h post OGD compared to OGD vehicle (p<0.01; Figure 6.4A). 10 μM CBDA exhibited a 
trend for decreasing IL-6 but this did not reach significance. CBDA (10 nM- 1 μM) did 
not modulate levels of VEGF but exhibited a slight trend to further increase VEGF at 10 
μM (Figure 6.4B). CBDA (10 nM- 10 μM) had no effect on levels of elevated levels of 
ICAM-1 (Figure 6.4C), but significantly increased IL-8 at 10 μM (p<0.01; Figure 6.4D). 
  
BCA results showed that there was no significant difference in protein levels in OGD 
conditions 24 h post OGD between vehicle and CBDA treated cells (6.6).  
 
Application of 5-HT1A antagonist, WAY-100,635, under OGD conditions inhibited CBDA 
mediated reduction in IL-6 secretion in 24 h post OGD samples (p<0.01 normoxia 
vehicle vs WAY+CBDA 1 μM; Figure 6.5A). All other antagonists tested did not block 
CBDAs ability to reduce IL-6 secretion (Figure 6.5A,B), however PPAR⍺ anatagonist, 
GW6471, appeared to potentiate CBDAs effects (p<0.0001 vs vehicle OGD and p<0.05 













Figure 6.4. The effects of CBDA on pericyte cytokine signalling. CBDA attenuated IL-6 secretion (A) 10 µM 
CBDA increased VEGF secretion (B) but had no effect on ICAM-1 (C). 10 nM-1 µM (C) and increased secretion 
of IL-8 (D), n=6-10 from 3 experimental repeats. Data are given as means with error bars representing S.E.M. 
normalised to total protein and expressed as a % change from the normoxia vehicle (vehicle N). Data was 
analysed using a one-way ANOVA and multiple comparisons were adjusted for by Dunnett’s statistical 
hypothesis test. * denotes a significant difference compared to vehicle normoxia  (p<0.05), $ denotes a 





Figure 6.5. Effect of 1 µM CBDA on IL-6 secretion alongside a range of antagonists; AM251 (A; 100 nM), 
AM630 (A; 100 nM), capsazepine (A; 1 µM), GW6471 (A; 100 nM), WAY-100635 (A; 300 nM), O1918 (A; 1 
µM), GW9962 (B;100 nM), SB366791 (B; 1 µM) and CID16020646 (B; 1 µM). 5-HT1A antagonist WAY-
100,635 blocked the effects of CBDA on IL-6 secretion (A,B) n=6-10 from 3 experimental repeats. Data are 
given as means with error bars representing S.E.M. normalised to total protein and expressed as a % 
change from the normoxia vehicle (vehicle N). Data was analysed using a one-way ANOVA and multiple 
comparisons were adjusted for by Dunnett’s statistical hypothesis test. * denotes a significant difference 



















Figure 6.6. The effects of CBDA on pericyte monoculture protein levels 24 h post 4 h OGD, 
determined using a BCA. Data are given as means with error bars representing S.E.M. 
Data was analysed using a one-way ANOVA and multiple comparisons were adjusted for 
by Dunnett’s statistical hypothesis test, comparing to vehicle normoxia (vehicle N) or 















































6.3.3. Neuronal monocultures 
In neuronal monocultures, levels of heat shock proteins (HSP), HSP 27 (ps78) and HSP 
90⍺ increased in OGD samples vs normoxia control (p<0.05; Figure 6.7D,H). Levels of 
HSP27 (total) and HSP60 exhibited a trend for being increased post OGD but this did 
not reach significance (Figure 6.7A,B,E,F). CBDA (100 nM) significantly decreased 
HSP27 (ps78) and HSP90 (p>0.05) and exhibited a trend for decreasing HSP27 (total) 
(Figure 6.7B,D,H).CBDA also displayed a trend to decrease HSP60 at all concentrations 
(Figure 6.7F). CBD (100 nM, 1 µM) displayed a trend to decreases HSP27 (total) (Figure 
6.7A) but not HSP27(ps78). CBD also exhibited a trend to decrease HSP60 at 1 µM 
(Figure 6.7E) and HSP90⍺ at 10 nM and 1 µM, but this did not reach significance 
(Figure 6.7G). 
 
Levels of DNA damage markers were not significantly altered 24 h post OGD and were 
not affected by either CBDA or CBD treatment (Figure 6.8).  
 
Exposing neuronal monocultures to a 4 h OGD protocol significantly increased MCP-1 
in 24 h post OGD medium samples and exhibited a trend to increase NADH (Figure 
6.9). Neither CBDA nor CBD significantly decreased levels of NADH post OGD (Figure 
6.9A,B). CBD (100 nM, 1 M) and CBDA (1 M) significantly reduced levels of MCP-1 in 
24 h medium samples (p>0.05; Figure 6.9C,D).  
 
Whilst there was a trend for neuronal protein levels to decrease post OGD, this did not 









 Figure 6.7. The effects of CBDA and CBD on levels of heat shock proteins in neuronal monocultures post 
OGD. A-J A multiplex HSP protein assay (Milliplex™, 48-615MAG, EMD Millipore ) was used to detect 
changes in HSP levels (HSP-27 total, HSP 27, HSP 60, HSP 70 and HSP 90 respectively) in 24 h samples 
following treatment with CBDA and CBD (10 nM-1 μM) following a 4 h OGD protocol (n=5-6). Data are 
given as means with error bars representing S.E.M. normalised to total protein and expressed as a % 
change from the normoxia vehicle (vehicle N). Data was analysed using a one-way ANOVA and multiple 
comparisons were adjusted for by Dunnett’s statistical hypothesis test. * denotes a significant 






Figure 6.8. The effects of CBDA and CBD (10 nM-1 μM) on DNA damage proteins in neuronal 
monocultures post OGD. A multiplex DNA damage protein assay (Milliplex™, 48-615MAG, EMD 
Millipore) was used to detect changes in levels of ATR (Total), Chk1 (Ser345), Chk2 (Thr68), H2A.X 
(Ser139), MDM2 (total), p21 (Total), p53 (Ser15) respectively in 24 h medium samples following 
treatment with CBDA and CBD and an 4 h OGD protocol (A-N). Data are given as means with error 
bars representing S.E.M. (n=6 from 2 experimental repeats). Data was analysed by One-way 















Figure 6.9. The effects of CBDA and CBD (10 nM-1 μM) on neuronal monocultures subjected to a 4 h 
OGD protocol. Following treatment with CBDA and CBD an LDH assay was used to detect changes in 
NADH (A,B) and a multiplex cytokine panel was used to detect changes in MCP-1 (C,D) in 24 h medium 
samples following treatment with CBDA and CBD. Data are given as means with error bars 
representing S.E.M. (n=4 from 1 experimental repeat). Data were analysed by one-way ANOVA. 
Multiple comparisons were adjusted for by Dunnett’s statistical hypothesis test. * denotes a significant 
difference compared to vehicle normoxia (Vehicle N) (p<0.05), $ denotes a significant difference to 
vehicle OGD.  
Figure 6.10. The effects of CBDA on neuronal monoculture protein levels 24 h post 4 h OGD, 
determined using a BCA. Data are given as means with error bars representing S.E.M. Data was 
analysed using a one-way ANOVA and multiple comparisons were adjusted for by Dunnett’s 




6.4 Supplemental information 
  
Baseline (0h) post OGD (4h) 24 h post OGD 48 h post OGD 72 h post OGD  
Mean SD Mean SD Mean  SD Mean  SD Mean  SD 
Vehicle 
CBDA 
39.67 3.46 28.56 4.56 29.68 9.48 25.85 4.99 22.03 8.31 
CBDA 
300 nM 
41.72 3.45 32.01 8.20 32.76 8.22 27.53 5.04 26.32 6.93 
CBDA 1 
µM 
44.88 6.46 35.04 7.95 35.60 13.77 35.52 6.04 28.00 8.76 
CBDA 3 
µM 
34.25 7.90 35.00 5.45 34.72 11.72 33.23 5.78 25.11 5.57 
Vehicle 
CBD 
38.19 8.22 26.66 7.19 23.97 6.40 26.88 3.31 18.82 5.29 
300 nM 
CBD 
44.15 4.89 26.69 9.06 22.68 9.76 53.76 2.40 34.72 3.98 
CBD 1 
µM 
36.49 5.43 28.56 5.59 30.15 6.34 56.93 4.43 43.49 5.38 
CBD 3 
µM 
33.32 3.51 28.65 11.70 27.16 12.10 53.95 5.21 39.57 7.22 
 
Table V: Raw average transepithelial resistance (TEER) values measured in ohms per cm2 











CBDA 1 uM CBDA 10 
uM 
Mean 118.87 553.46 483.29 471.65 414.39 443.12 
SD 40.14 150.30 97.01 130.54 104.27 73.32 
 
Table VI: Raw data from VEGF ELISA of pericyte cell culture medium. Note that these values are 
taken as an average from experimental repeats with cells at different passages and have not 
been normalised to total protein. 
 








CBDA 1 uM CBDA 10 
uM 
Mean 121.53 225.47 249.61 201.46 208.37 188.32 
SD 
43.75 57.84 131.13 101.97 105.88 57.92 
 
Table VII: Raw data from IL-6 ELISA of pericyte cell culture medium. Note that these values are 
taken as an average from experimental repeats with cells at different passages and have not 















CBDA 1 uM CBDA 10 
uM 
Mean 
75.94 452.93 466.26 403.67 433.33 466.47 
SD 15.44 92.86 47.14 90.00 73.94 82.16 
 
Table VIII: Raw data from ICAM-1 ELISA of pericyte cell culture medium. Note that these values 
are taken as an average from experimental repeats with cells at different passages and have 
not been normalised to total protein. 
 



































Table IX: Raw data from IL-8 ELISA of pericyte cell culture medium. Note that these values are 
taken as an average from experimental repeats with cells at different passages and have not 




























BBB breakdown is one of the major consequences of ischaemic stroke and is 
accompanied with unwanted infiltration of noxious substances and peripheral immune 
cell into the brain, which perpetuates neuronal injury (Reviewd in W. Zhang et al., 
2020). Pathological processes that mediate BBB disruption post ischaemia have been 
found to be positively modulated by cannabidiol, including oxidative stress, 
mitochondrial dysfunction, inflammation, DNA and cellular damage (Iuvone et al., 
2004; Ryan et al., 2009; Pazos et al., 2013; Ceprián et al., 2017; Sun et al., 2017). In this 
study we demonstrate that like CBD, CBDA decreases BBB permeability when given 
prior to OGD. We also found CBDA displays anti-inflammatory effects in pericytes and 
exhibits neuroprotective properties in our BBB model and in neuronal monocultures. 
Our data add to the limited knowledge on the biological properties of CBDA and 
further investigation is needed into the neuroprotective properties of this compound, 
particularly in ischaemic stroke.  
 
Pericytes are pivotal in the regulation, maintenance and integrity of the BBB and 
pericyte loss has drastic consequences to the BBB (Nakagawa et al., 2007; Daneman et 
al., 2010). During ischaemia-reperfusion (IR), pericytes secrete a range of pro-
inflammatory mediators including IL-6, IL-8, ICAM-1 and VCAM-1 (Balabanov, 
Beaumont and Dore-Duffy, 1999; Pieper, Pieloch and Galla, 2013; Rustenhoven et al., 
2016). Specifically, elevations in ICAM-1, VCAM-1 and IL-8 post ischaemia are known to 
aid the adhesion and diapedesis of leukocytes across the endothelial barrier 
(Stanimirovic et al., 1997). VEGF also has a significant role in post stroke injury and 
recovery, with mixed conclusions on its role at the BBB. Interestingly, Zechariah and 
colleagues (2013) found that VEGF treatment prior to MCA occlusion reduced infarct 
volume and when pre-treated for 21 days VEGF promoted pericyte coverage of 
endothelial cells. To our knowledge this is the first study to demonstrate pre-treatment 
with CBDA attenuated levels of IL-6 in pericytes post OGD, which was blocked by 5-




CBDA acts as a 5-HT1A receptor agonist (Bolognini et al., 2013; E. M. Rock and Parker, 
2017), but contrast to findings from a recent study which showed CBDA increased IL-6 
and PPARγ protein levels in mouse prefrontal cortex (Alegre-Zurano, Martín-Sánchez 
and Valverde, 2020). CBD has been shown to attenuate VEGF secretion in experimental 
diabetes (El-Remessy et al., 2006) and in a BBB model subjected to OGD (Hind, England 
and O’Sullivan, 2016). However, in HBMEC monocultures under normal conditions, 
CBD was found to increase VEGF which was inhibited by PPARy antagonist GW9662 
(Hind, England and O’Sullivan, 2016). Interestingly, CBDA (10 µM) appeared to increase 
VEGF levels post OGD in pericytes, but this was not tested in our BBB model nor did we 
determine CBDAs mechanism of action. Rajesh et al., (2007) found that CBD decreased 
levels of ICAM-1 and VCAM-1 in endothelial cells under high glucose conditions and 
Hind and colleagues (2016) found CBD decreased levels of VCAM-1 in normoxic 
conditions, an effect also blocked by PPARy antagonist GW9662. Unlike CBD, in our 
model CBDA had little effect on ICAM-1 levels and did not decrease VEGF at any 
concentration tested. These data suggest that whilst CBDA and CBD share some 
pharmacological targets, CBDA does not modulate levels of the same proteins in 
pericytes under OGD conditions in the same manner as CBD in endothelial cells. Thus, 
it will be important for future studies to assess differences between CBD and CBDA on 
inflammatory cytokine secretion in multiple cell types and to fully elucidate CBDAs 
mechanisms of action. 
 
Preserving BBB integrity is vital to protect salvageable neuronal tissue and enhance the 
probability of positive neurological outcomes post ischaemia. In the present study 
CBDA (3 µM) reduced BBB permeability and prevented neuronal cell death in our BBB 
model post OGD. These findings build upon previous data from our group which 
showed that 10 M CBD was effective at decreasing BBB permeability in a co-culture 
BBB model, mediated through 5-HT1A and PPARy (Hind et al., 2016). Recently Mori et 
al., (2017) found that CBD improved cognitive function and preserved the number of 
nissel stained neurons in mice subjected to bilateral common carotid artery occlusion 




number of Iba-1 and GFAP positive cells. Future studies should assess whether CBDA 
can attenuate glial activation and other inflammatory markers, as well as investigate 
whether CBDA can modulate BBB permeability in vivo. 
 
HSPs are typically referred to as chaperone proteins, helping to stabilise existing 
proteins and prevent their degradation. Some HSPs are expressed constitutively, but 
many are induced as a result of cellular stress, for example during hypoxia or 
neurological disease (Latchman, 2005; Luo et al., 2010). Our data support that from an 
early study by Wagstaff and colleagues (1996) which found elevations in HSP70, HSP27 
and HSP60 mRNA 8 h and 24 h post middle cerebral artery occlusion (MCAO) in rats. 
Similarly, HSP70 and HSP90 were overexpressed in myocardial ischaemia-reperfusion 
injury (Nishizawa et al., 1996), which was later found to be triggered by elevations in 
reactive oxygen species (Nishizawa et al., 1999). Recently, Zhang et al., (2020) found 
that decreases in HSP90 expression reduced infarct volume, attenuated neuronal 
apoptosis, and reduced levels of pro-inflammatory cytokines IL-6, TNF-⍺ and IL-1β in a 
murine model of cerebral ischaemia reperfusion injury. On the other hand, HSP27 is 
considered to be protective against cellular stresses, namely thermal and ischaemic 
stress (Latchman, 2005; Stetler et al., 2008). Endothelial specific HSP27 overexpression 
was also able to attenuate I/R induced BBB disruption, but not the severity of the 
initial insult (Shi et al., 2017). We found that both CBD and CBDA modulated levels of 
several HSPs in neuronal lysates 24 h post OGD, with 100 nM CBDA significantly 
decreasing levels of HSP27 (total) and HSP90⍺. However, at the lowest and highest 
concentrations tested, CBDA appeared to increase HSP27, while still decreasing HSP90. 
CBD also showed a trend for decreasing HSP60 and HSP90 at the highest concentration 
tested, which is contrast with a study conducted by Scott and colleagues (2015) 
showing CBD 10 µM enhanced the expression of HSP40,60, 70 and 90 in glioma cell 
lines, suggesting that CBD appears to exhibit different effects depending on the 
pathology being investigated. Thus, it will be important for future studies to establish 
whether CBD or CBDA attenuate HSP levels in in vivo models of ischaemia and whether 




documented (Hampson et al., 1998; Borges et al., 2013; Schubert et al., 2019) and may 
be partly responsible for meditating the effects of CBD and CBDA on levels of heat 
shock proteins, as oxidative stress is a known regulator of HSP expression. Moreover, 
as modulation in HSP expression has been linked to alterations in pro-inflammatory 
mediators, this could be another route in which phytocannabinoids mediate their 
protective effects and warrants further investigation.  
 
The role of DNA damage and BBB disruption post ischaemia is not fully understood, 
however emerging evidence has shown that vascular endothelial cells and astrocytes 
are targets for oxidative DNA damage. Interestingly we did not see any significant 
changes in DNA damage proteins in neuronal monoculture lysates 24 h post OGD and 
neither CBD nor CBDA significantly affected the levels of these proteins. This may be 
due to the DNA damage response being activated earlier as irreversible damage has 




In this study we have shown that CBDA is able to decrease BBB permeability when 
given before an OGD, in a four-cell contact model consisting of HBMECs, astrocytes, 
pericytes and neurons. This was achieved at a lower concentration (3 µM) compared to 
CBD (10 µM) in a previous study (Hind, England and O’Sullivan, 2016). CBDA also 
decreased the secretion of IL-6 after a 4 h OGD protocol in pericyte monocultures and 
attenuated heat shock proteins in neuronal monocultures. To our knowledge, no study 
has assessed the effects of CBDA on BBB permeability and its ability to act as a 
neuroprotectant in a stroke model. We acknowledge that we have only looked at a 
select number of biological markers associated with IR injury and future studies should 
assess whether CBDA can modulate other aspects of post stroke injury, particularly in 
glial cells, as well as fully establish CBDAs mechanism of action. Overall, these pilot 
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The euphoric feeling described after running is, at least in part, due to increased
circulating endocannabinoids (eCBs). eCBs are lipid signaling molecules involved in
reward, appetite, mood, memory and neuroprotection. The aim of this study was
to investigate whether activities other than running can increase circulating eCBs.
Nine healthy female volunteers (mean 61 years) were recruited from a local choir.
Circulating eCBs, haemodynamics, mood and hunger ratings were measured before and
immediately after 30 min of dance, reading, singing or cycling in a fasted state. Singing
increased plasma levels of anandamide (AEA) by 42% (P < 0.05), palmitoylethanolamine
(PEA) by 53% (P < 0.01) and oleoylethanolamine (OEA) by 34% (P < 0.05) and improved
positive mood and emotions (P < 0.01), without affecting hunger scores. Dancing did
not affect eCB levels or hunger ratings, but decreased negative mood and emotions
(P < 0.01). Cycling increased OEA levels by 26% (P < 0.05) and tended to decrease
how hungry volunteers felt, without affecting mood. Reading increased OEA levels by
28% (P < 0.01) and increased the desire to eat. Plasma AEA levels were positively
correlated with how full participants felt (P < 0.05). Plasma OEA levels were positively
correlated with positive mood and emotions (P < 0.01). All three ethanolamines were
positively correlated with heart rate (HR; P < 0.0001). These data suggest that activities
other than running can increase plasma eCBs associated with changes in mood or
appetite. Increases in eCBs may underlie the rewarding and pleasurable effects of singing
and exercise and ultimately some of the long-term beneficial effects on mental health,
cognition and memory.
Keywords: endocannabinoids, anandamide, human, clinical, high, mood, singing and dancing
Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, anandamide; BBB, bloodbrain barrier; BDNF, brain derivedneurotrophic
factor; eCBs, endocannabinoids; LC-ESI-MS-MS, electrospray ionization liquid chromatography/mass spectrometry; OEA,
oleoylethanolamine; PEA, palmitoylethanolamine.
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INTRODUCTION
The classic ‘‘runners high’’ is described as the sense of well-being
and mood elevation associated with moderate distance running.
Other typical indicators include a decrease in anxious thinking
(anxiolytic), positive emotions/mood (euphoria), reduced pain
perception (analgesia) and a feeling of increased endurance
(Sparling et al., 2003; Dietrich and McDaniel, 2004; Tsatsoulis
and Fountoulakis, 2006; Raichlen et al., 2012). To explain
these positive effects post-exercise, attention was directed to
the endocannabinoid (eCB) system, and a number of groups
have found significant correlations between physical activity,
mood and elevated eCB levels. Interestingly, the majority of
studies have only observed significant rises in the first identified
eCB, anandamide (AEA; Sparling et al., 2003; Heyman et al.,
2012; Raichlen et al., 2013), whilst the reports analyzing
2-arachidonylglycerol (2-AG) levels post-exercise have been less
clear. Heyman et al. (2012) reported no change in circulating
2-AG levels after cycling. However, Brellenthin et al. (2017)
showed that 2-AG and AEA were significantly increased in
a study analyzing the effects of preferred (self-selected) and
prescribed (70%–75% of max) exercise on eCB levels and mood.
The eCB system consists of the cannabinoid receptors
1 and 2 (CB1 and CB2), eCBs, and the enzymes that are
responsible for their synthesis and breakdown (Devane et al.,
1992; Mechoulam et al., 1995; De Petrocellis and Di Marzo,
2009). AEA and 2-AG are partial agonists of CB1 and CB2,
whilst palmitoylethanolamine (PEA) and oleoylethanolamine
(OEA) share similar synthesis and degradation mechanisms,
without directly interacting with these receptors themselves
(Hansen et al., 2000; Okamoto et al., 2004). Instead, these
molecules interact with other receptors, primarily peroxisome
proliferator-activated receptor alpha (PPAR-a) and transient
receptor potential cation channel subfamily V member 1
(TRPV1; Ahern, 2003; Fu et al., 2003; Lo Verme et al., 2005a,b;
Karwad et al., 2017). eCB signaling mediates a number of
physiological and psychological processes including emotional
responses, cognition, memory, motor behavior, feeding and
energy consumption (Berger and Motl, 2000; Cota et al., 2003;
Cota, 2007; Brellenthin et al., 2017). Studies have also established
prominent roles of eCB signaling in the positive reinforcement
in reward driven activities such as masturbation, arousal, binge-
eating and social interactions in humans (Klein et al., 2012;
Monteleone et al., 2015, 2017; Fuss et al., 2017).
Singing and dancing, especially as a group activity, are
associated with positive mood in humans (Zajenkowski et al.,
2015; Pearce et al., 2016; Tarr et al., 2016; Schladt et al., 2017).
However, little has been studied to elucidate how these positive
emotions are mediated. Recently, Hahn et al. (2017) studied
the relationship between song practice and the eCB system in
European starlings. They found a significant positive correlation
between conditioned place preference (a measure of reward
and song production), the number of songs a bird produced
and the expression of CB1 in areas of the brain associated
with reward, primarily the ventral tegmental area. Therefore
suggesting a role for eCB signaling in singing and reward (Hahn
et al., 2017; Riters et al., 2017). In humans, singing has been
studied as a therapy for long-term disorders such as Alzheimer’s
(to improve cognition, memory and long-term pain), chronic
obstructive pulmonary disease, as well as to improve mood in
conditions such as anxiety and depression (Reagon et al., 2016;
Kang et al., 2017). Similarly, dancing has been explored as a
potential therapy for cognitive and emotional dysfunction in
conditions such as depression, dementia and Parkinson’s. In a
systematic review of 11 studies, Kiepe et al. (2012) found that
depression and psychological distress were reduced by dance
therapy in patients suffering from Parkinson’s, diabetes, breast
cancer or heart failure. Dance therapy in a group of 60 students
also significantly reduced depression over a period of 12 weeks
(Akandere and Demir, 2011). To date, no study has assessed
singing or dancing and whether they modulate eCB levels in
humans and whether that correlates to an improvedmood. Given
that mood is central in the measure of overall psychological well-
being, low intensity activities that can positively modulate mood
could be useful therapeutic tools in numerous conditions such
as depression, anxiety and stress, especially if a patient cannot
undertake moderate/higher intensity exercise.
The purpose of this study was to investigate whether activities
other than running can give you a measurable ‘‘high’’ through
changes in circulating eCBs levels. We examined activities that
are associated with euphoria (singing and dancing) as well as an
exercise regime other than running (cycling), with the hypothesis
that these activities would increase plasma eCB levels. Quiet
reading was used as a control condition. A secondary objective
of this study was to establish whether there was a link between




All procedures were approved by the University of Nottingham
Faculty of Health Sciences ethics committee, and were carried
out according to the declaration of Helsinki. Nine healthy
post-menopausal female volunteers (age range 55–67, mean
61 years) were recruited from a local choir as people who
enjoyed singing and exercise. The inclusion criteria were that
volunteers be non-smokers, in good physical health, accustomed
to singing in a group, and also enjoy exercise. Volunteers gave
written informed consent prior to participation. Themedications
taken included antihypertensives (n = 2), antacids (n = 2),
antidepressants/anti-anxiety medication (n = 2), HRT (n = 1),
and an inhaler for asthma (n = 1).
Subjects arrived fasted (feeding affects plasma eCB levels;
Monteleone et al., 2012) with no consumption of caffeine and
this was verbally confirmed on arrival at the study facility.
Participants were also asked to refrain from any exercise prior
to attending the laboratory. Volunteers were unaware of the
activity they were to perform on a given day until all baseline
measurements were made to avoid any anticipatory effects.
Study Days
Subjects came to the test site on four occasions between
8 am and 10 am in loose fitting sportswear. Each day,
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individuals were asked to complete two questionnaires before
and after completing the activity. A visual analog scale (VAS)
questionnaire was used to assess how hungry subjects were
feeling on a scale of 1–10, using the questions ‘‘how hungry
do you feel?’’, ‘‘how full are you?’’, ‘‘how much food could you
eat?’’ and ‘‘how strong is your desire to eat?’’. A positive and
negative affect schedule (PANAS) questionnaire was used to
assess subject’s mood before and after each activity using the
following scoring system: 1 = ‘‘very slightly or not at all,’’ 2 = ‘‘a
little,’’ 2 = ‘‘moderately,’’ 4 = ‘‘quite a bit’’ and 5 = ‘‘extremely;’’
Watson et al., 1988; Crawford and Henry, 2004). Positive affect
score was calculated by adding the positive emotional responses
and the negative affect score was calculated based on the addition
of the negative affect scores.
Blood pressure was measured by oscillometry with the
participant seated according to the British Hypertension Society
guidelines, and heart rate (HR) was taken prior to commencing
the activity and immediately after finishing the activity. Blood
pressure and HR measurements were taken as the average over
three (pre-activity) or 2 (post-activity) measurements. Blood
draws (approximately 5 mL) were taken before commencing
the activity and immediately after finishing the activity into
pre-chilled K2-EDTA (Ethylenediaminetetraacetic acid) tubes
and immediately placed on ice. After collection, blood was
centrifuged at 2,000 g for 15 min at 4 C, plasma was removed
and aliquoted, and immediately snap frozen in liquid nitrogen.
Samples were stored at  80 C until subsequent analysis.
After the baseline measurements were made, volunteers were
informed of the activity they were to perform. On day 1,
volunteers did a supervised 30 min dance exercise class preceded
by a 5 min warm up, to upbeat music. On day 2, volunteers did
30 min of supervised quiet reading (of boiler and dishwasher
catalogs) to classical music. On day 3, volunteers for 30 min choir
practice led by their choral director. On day 4, volunteers did a
30 min spin class (cycling) with a qualified instructor from the
University of Nottingham Sports facility, with a 5 min warm up
to upbeat music. All activities were performed as a group.
eCB Quantification
eCB analysis was based on the method as described by
Richardson et al. (2007). Samples were thawed and 100 µL
of internal standard of 2-AG-d8 (10 µM) and 15 µL of
AEA-d8 (28 µM) were added to a 0.4 mL aliquot of each
plasma sample or blank sample (0.4 mL water) vortexed briefly.
Ethyl acetate:hexane (9:1 v/v) was added to each sample and
subjected for a slow vortex (10 min) and centrifuged for
13,000 rpm, 10 min, 4 C. The supernatants were transferred
and the procedure was repeated. Supernatants were then
pooled and evaporated using a centrifugal evaporator.
Prior to analysis, each sample extract was reconstituted in
100 µL of acetonitrile (ACN). Standards for AEA, 2-AG, PEA,
OEA, N-(2-hydroxyethyl)-9Z-octadecenamide), arachidonyl
ethanolamide-d8 (N-(2-Hydroxyethyl)-5Z, 8Z, 11Z, 14Z-
eicosatetraenamide-d8, AEA-d8) and 2-arachidonyl glycerol-d8
(2-AG-d8, (5Z, 8Z, 11Z, 14Z)-5, 8, 11, 14-Eicosatetraenoic acid-
d8, 2-hydroxy-1-(hydroxymethyl)ethyl ester-d8) were purchased
from Cambridge BioSciences, UK.
Following sample preparation, 10 µL of final sample
extract was analyzed using liquid chromatography electrospray
ionisation mass spectrometry (LC-ESI-MS/MS). The HPLC
system used was a modular Shimadzu Vp series LC (Shimadzu,
Milton Keynes, UK), with pumps, chilled autosampler and
column oven. The HPLC column used was an ACE 3 C8
(100 ⇥ 2.1 mm, 3 mm) with guard column. The mobile phase A
was water with 1 g/L ammonium acetate and 0.1% formic acid
and mobile phase B was ACN with 1 g/L ammonium acetate
and 0.1% formic acid pre-dissolved in 10% H2O. The flow rate
was 300 µL/min. The MS system used was a SCIEX 4000 QTrap
triple quadrupole mass spectrometer (Sciex, Warrington, UK)
operated in electrospray positive multiple reaction monitoring
mode. Quantification was performed using Analyst 1.6 and
identification of each compound in plasma was confirmed by
LC retention times of each standard and precursor and product
ion m/z ratios. The peak area of each analyte is compared to a
known amount of standard to determine the amount of target
compound present.
2-AG in these samples were below the limit of quantification
with ourmethodology in the plasma samples and the data has not
been reported.
Statistical Analysis
Data is presented as a scatter plot with mean ± SEM. Data sets
were compared by paired Student’s t-test pre and post-activity.
Correlations between plasma eCBs levels and hunger ratings,
cardiovascular parameters or mood pre and post-activities were
analyzed by linear regression. A quality control check was
performed by a separate researcher on data entry.
RESULTS
All but one of the participants completed the study in full;
one participant was unable to finish the cycling activity and
did not have a final blood draw or complete the surveys. Thus
nine participates were in the final comparison, except for the
cycling activity where n = 8.
Haemodynamics
Thirty minutes of dancing significantly increased HR
(t(8) = 4.894, P < 0.01, Figure 1A) and decreased diastolic
blood pressure (t(8) = 2.764, P < 0.05, Figure 1I). Thirty
minutes of reading caused a small but significant reduction
in HR (t(8) = 3.736, P < 0.01, Figure 1B). Thirty minutes of
singing increased systolic blood pressure (t(8) = 5.66, P < 0.001,
Figure 1G). Thirty minutes of cycling significantly increased
HR (t(7) = 7.314, P < 0.001, Figure 1D) and decreased diastolic
blood pressure (t(7) = 2.567, P < 0.05, Figure 1L).
Hunger Scores
The only significant change in hunger and appetite scores were
observed after 30 min of reading when volunteers reported
a significantly higher desire to eat (Figure 2N). Volunteers
tended to have reduced hunger ratings after dancing, singing and
cycling (Figure 2), but this only reached near significance for
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FIGURE 1 | Changes in cardiovascular parameters (heart rate, HR; A–D), systolic blood pressure (E–H) and diastolic blood pressure (I–L) before and after 30 min
activity (dancing, reading, singing or cycling) in nine healthy female volunteers. Data is presented as a scatter plot with mean ± SEM. Data sets were compared by
paired Student’s t-test pre and post-activity (⇤P < 0.05, ⇤⇤P < 0.01 and ⇤⇤⇤P < 0.001).
the question ‘‘how hungry do you feel?’’ immediate post-cycling
(t(7) = 2.348, P = 0.0512, Figure 2D).
Mood Scores
Dancing decreased negative mood and emotions (t(8) = 3.671,
P < 0.01, Figure 3E), while reading decreased positive mood
and emotions (t(8) = 5.751, P < 0.001, Figure 3B). Only singing
was found to significantly improve positive mood and emotions
(t(8) = 4.951, P < 0.01, Figure 3C) and also tended to decrease
negative mood and emotions (eight out of nine volunteers
reported a lower NAS post-singing, Figure 3E). Cycling has no
effect on mood ratings.
Plasma Levels of Endocannabinoids
Dancing had no effect on circulating levels of eCBs measured
immediately the activity, although there was a trend for AEA and
OEA levels to be increased (Figures 4A,E). Thirty minutes of
reading significantly increased plasma OEA levels (t(8) = 4.586,
P < 0.01, Figure 4F) and tended to increase PEA levels
(t(8) = 2.02, P = 0.078, Figure 4J). Singing significantly increased
the plasma levels of all eCBs measurable; AEA (t(8) = 3.049,
P < 0.05, Figure 4C), OEA (t(8) = 4.81, P < 0.01, Figure 4G)
and PEA (t(8) = 3.319, P < 0.05, Figure 4K). OEA levels were also
increased after 30 min cycling (t(6) = 3.594, P < 0.05, Figure 4H).
At baseline (before activities started) across all 4 days, there
was a significant positive correlation between plasma OEA levels
and the rating for ‘‘how much food could you eat?’’ (r2 = 0.2226,
F = 9.16, P < 0.01) and positive mood and emotions (r2 = 0.1355,
F = 5.172, P < 0.05). Resting HR was positively correlated with
both plasma AEA (r2 = 0.3363, F = 16.72, P < 0.001) and PEA
(r2 = 0.169, F = 6.711, P < 0.05) levels.
Across all days and time points (pre- and post-activity),
plasma AEA levels were positively correlated with the rating for
‘‘how full are you?’’ (r2 = 0.0626, F = 4.472, P < 0.05, Figure 5A),
and plasma OEA levels tended to be positively correlated with
the rating for ‘‘how much food could you eat?’’ (r2 = 0.0404,
F = 2.821, P = 0.097, Figure 5B) and ‘‘how strong is your desire
to eat?’’ (r2 = 0.04624, F = 3.248, P = 0.076, Figure 5C) and with
increased ratings for positive mood and emotion (r2 = 0.1269,
F = 9.879, P < 0.01, Figure 5D). All three ethanolamines were
positively correlated with HR (AEA: r2 = 0.4394, F = 53.3,
P < 0.0001, Figure 5E; OEA: r2 = 0.2639, F = 24.37, P < 0.0001,
Figure 5F and PEA: r2 = 0.2093, F = 18, P < 0.0001, Figure 5G).
DISCUSSION
It is well reported that running is correlated with mood elevation.
These positive effects have been attributed to an evolutionary
trait, where positive re-enforcement ultimately led to increased
food foraging, survival and subsequent passing of relevant genes
to offspring and have recently been attributed, at least in part,
to increases in eCBs (Bramble and Lieberman, 2004; Raichlen
et al., 2012). Our study aimed to examine whether activities other
than running also increase eCBs and enhance mood. We have
shown for the first time that singing significantly increases levels
of AEA, OEA and PEA in healthy post-menopausal females and
Frontiers in Behavioral Neuroscience | www.frontiersin.org 4 November 2018 | Volume 12 | Article 269
Stone et al. Endocannabinoids in Cycling, Dancing and Singing
FIGURE 2 | Changes in hunger and appetite scores as assessed using a visual analog scale (VAS) (1–10) before and after 30 min activity (dancing (A,E,L,M),
reading (B,F,J,N), singing (C,G,K,O) or cycling (D,H,L,P) in nine healthy female volunteers. Data is presented as a scatter plot with mean ± SEM. Data sets were
compared by paired Student’s t-test pre and post-activity (⇤P < 0.05).
enhanced mood. Dancing (on mood) and cycling (on eCBs) also
had positive effects in this group. Although singing was the most
beneficial activity in this study, this is likely to reflect the fact
that the volunteers were recruited from local choirs and already
find this an enjoyable activity. These data provide biochemical
evidence of an increase in novel signaling messengers known
to improve mood, reduce stress and anxiety, enhance memory,
protect brain function and reduce pain.
Singing, in particular group singing, has been associated with
an increase in positive mood and improved immune function
in humans (Kreutz et al., 2004; Schladt et al., 2017). Choir
singing also enables social interactions, exhibiting a greater
benefit to mood than singing alone (Schladt et al., 2017). Our
results also demonstrate that singing increases mood, and also
for the first time that singing increasing circulating levels of
AEA, OEA and PEA. As AEA is a partial agonist of CB1
and has full agonist activity at TRPV1, an increase in the
levels of AEA post activity could therefore facilitate increases
in positive emotions, as well as anxiolytic and analgesic effects
(Chapman et al., 2009; Starowicz et al., 2012). Levels of OEA
post activity were correlated with a decrease in hunger and
desire to eat. This supports previous data that OEA attenuates
food consumption and increase lipolysis and energy expenditure
(Lo Verme et al., 2005a,b). In vivo studies conducted in mice
have also suggested beneficial neuroprotective effects of OEA,
this protective effect could potentially be translated to humans
and warrants further study (Galan-Rodriguez et al., 2009; Zhou
et al., 2012; Yang et al., 2015). An abundance of evidence
has supported PEA as a potential therapy for neurological
and inflammatory disorders, particularly those associated with
pain (Costa et al., 2008; Keppel Hesselink, 2012; Esposito
and Cuzzocrea, 2013). PEA has also been taken into clinical
trials, whereby 600 mg of PEA was shown to be effective
in various pain states, without exhibiting any safety issues
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FIGURE 3 | Changes in postive (PAS, A–D) and negative (NAS, E–H) mood and emotions before and after 30 min activity (dancing, reading, singing or cycling) in
nine healthy female volunteers. Data is presented as a scatter plot with mean ± SEM. Data sets were compared by paired Student’s t-test pre and post-activity
(⇤⇤P < 0.01, ⇤⇤⇤P < 0.001).
FIGURE 4 | Plasma endocannabinoid levels (AEA, anandamide, A–D; OEA, oleoylethanolamine, E–H; PEA, palmitoylethanolamine, I–L) before and after 30 min
activity (dancing, reading, singing or cycling) in nine healthy female volunteers. Data is presented as a scatter plot with mean ± SEM. Data sets were compared by
paired Student’s t-test pre and post-activity (⇤P < 0.05, ⇤⇤P < 0.01).
(Hesselink and Hekker, 2012). Therefore, it could be beneficial
to increase levels of PEA via activities such as singing, to
promote neuroprotection, analgesia and reduce inflammation.
It is also important to note that increasing OEA and PEA can
indirectly increase AEA responses by the entourage effect by
competitive inhibition of AEA degradation by fatty acid amide
hydrolase (FAAH; Di Marzo et al., 2001; Costa et al., 2008; Ho
et al., 2008). Overall, singing could be a valuable activity in
patient populations that suffer with dysfunctions in psychological
well-being and struggle to participate in aerobic/moderate
intensity exercise.
Cycling resulted in a significant increase in OEA, and in
a trend for increases in both AEA and PEA. These changes
corresponded with a decrease in participants desire to eat and
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FIGURE 5 | Correlations between plasma eCBs levels and appetite (A–C), mood (D) and HR (E–G) in healthy female volunteers when measured pre or
post-activities and analyzed by linear regression.
how hungry they felt. These data are consistent with results from
a previous study where plasma OEA levels were significantly
increased after 30 min of cycling in 16 male non-smokers with
a mean age of 22.9 years (Cedernaes et al., 2016). Our data did
not show that cycling positively affected mood (no increase in
PAS or decrease in NAS). Brellenthin et al. (2017) showed that
acute aerobic exercise (both prescribed and preferred) resulted
in positive mood outcomes in individuals capable of a range
of levels of physical activity, as well as showing modulation of
the eCB system. Interestingly, the group that undertook their
‘‘preferred exercise’’ had the best effect in reducing anxiety and
improving mood. In the present study, singing by participants
recruited from a choir support these observations, suggesting
that the eCB system is not only responsible for the motivation
for exercise (i.e., reward driven), but also the pleasure associated
with an activity that an individual enjoys. It would also have
been interesting if another group had been included (i.e. not
recruited from a choir) to directly assess the concept of preferred
vs. prescribed activity and to confirm that carrying out an activity
that is ‘‘pleasurable’’ to an individual is an important factor in
the psychological benefits of exercise and other related activities.
Subjects were also not asked to rate how much they enjoyed each
of the activities, this would have been an interesting endpoint to
assess to what degree the participant’s moods were influenced
by how much they liked a particular activity and should be
considered in future study. These factors would also have
provided further evidence to why individuals in this study failed
to experience positive mood changes or significant increases in
AEA post cycling; compared with the study by Heyman et al.
(2012) where increases in AEA were seen in well-trained cyclists,
who presumably enjoy cycling.
Exercise intensity may be another factor explaining the lack
of AEA increases in our participants. Brellenthin et al. (2017)
showed that the greatest increases in 2-AG and AEA were seen
in the higher intensity exercise group. Sparling et al. (2003) also
showed significant increases in AEA when participants reached
70%–80% max HR. According to Gulati et al. (2010), maximum
HR for women is calculated as 206 (0.88 ⇥ age of patient). As
the average age of our participants was 61 years, their average
maximum HR (max HR) is approximately 154 bpm, meaning
their 70%–80% max HR should be 107–123 bpm. Cycling was
the only activity that almost reached this (average 102 bpm
immediately post exercise) and dancing resulted in an average
HR of 95 bpm (immediately post exercise). This could suggest
that our activities may not have been intense enough to elicit
significant changes in circulating eCBs.
A number of studies have shown that dance is an effective
therapy in improving mood (including mild depression),
enhancing social interactions, boosting self-confidence, as well
as improving physical activity (Akandere and Demir, 2011; Kiepe
et al., 2012; Meekums et al., 2015). In one study, dancing caused
an increase in plasma serotonin levels and a decrease in negative
psychological symptoms in a group of 20 female adolescents
with mild depression, compared to 20 control subjects (Jeong
et al., 2005). We found post activity that there was a significant
decrease in negative emotions following 30 min of dancing. It
should be acknowledged that the decrease in negative emotions
could also be because this was the activity undertaken on day 1
and participants had higher NAS scores before starting the study.
Although there was a trend in increasing levels of AEA and
OEA levels post-activity, this did not reach significance. Our
results suggest that dancing did not effectively increase eCB levels
or improve mood, however this could be because they were
unfamiliar with the class, therefore not finding it as enjoyable as
singing as this wasmore familiar to them, or that the class was not
at a high enough intensity to produce changes in eCB levels. It
should also be noted that our participants were older than those
previously studied, and there could be an age-related decline in
the eCB response to exercise.
Reading was used as a control activity to assess baseline
eCB levels and mood. We found that reading was the only
activity that increased participants desire to eat but had little
impact on overall fullness or actual hunger and was correlated
to increases in OEA post activity. Reading also decreased the
ratings for positive mood and emotions. In hindsight, because
subjects were unaware of the task, the activity set-up looked
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like they were about to take an exam, which may have resulted
in unforeseen heightened anxiety levels. Recent studies have
implicated the eCB system as a possible mediator of hedonic
vs. homeostatic eating response to the consumption of food
(as a reward) as well as acute stress and anxiety (Matias et al.,
2006; Monteleone et al., 2015, 2017). Dlugos et al. (2012)
showed that AEA, PEA and OEA were all increased in serum
in response to stress. They also found that higher levels of
AEA at baseline, associated with decreased levels of anxiety.
Furthermore, a common phenomenon is that typically negative
emotions, particularly boredom, stress and depressive emotions
increase our desire to eat in order to increase positive emotions
(Koball et al., 2012; Yau and Potenza, 2013; Moynihan et al.,
2015). These factors could explain the elevated levels of OEA post
activity and lower PAS scores.
A limitation of our study is that participants already had
very low negative affect scores and high positive affect scores.
This suggests that the individuals that took part in the study
were generally happy and positive and there was therefore little
room for mood to be further improved. It would therefore be
interesting in future work to see the effects of these same activities
on individuals that exhibit depressive, or anxious behavior in
order to see greater differences in negative emotional responses.
Intensity of a physical activity has also been shown to influence
exercise induced increases in eCB levels. Raichlen et al. (2013)
built on previous work showing that eCBs follow a U-shaped
curve, with moderate level activity resulting in the biggest
increase in eCB levels (Berger and Motl, 2000). This trend in
eCB levels is also correlated with mood as the positive emotional
state post exercise is not experienced at very low or very high
intensities (Berger and Motl, 2000). As all the participants were
unfamiliar to the activities they carried out, a lot of their focus
would have been on ‘‘mastering’’ the class rather than actually
enjoying it in the moment.
It can also not be overlooked that this study only recruited
healthy female volunteers. Evidence from animal studies has
already shown distinct sexual dimorphism in the eCB system,
particularly in CB1 expression and activation (Reich et al., 2009;
Mateos et al., 2011; Dias-Rocha et al., 2018). Limited preliminary
evidence from human studies have also shown variations in the
eCB system between males and females (Cupini et al., 2006; Hill
et al., 2008). Thus future study should look to establish whether
the effects observed in this study translate to male participants as
well as females.
In conclusion, we found that activities other than running
(singing, dancing and cycling) can increase plasma eCB levels.
Singing was the only activity to increase plasma levels of AEA
and improve positive mood outcomes, suggesting that singing
in this group of volunteers was able to produce an endogenous
‘‘high.’’ This is interesting as the participants were recruited
from a choir, suggesting that the enjoyment of an activity may
influence their feeling of reward and the eCB response. This
preliminary evidence suggests that activities like singing could
be recommended to individuals suffering from mood disorders
such as anxiety and depression, as well as a potential therapy
for neurological and inflammatory disorders. Future research
should consider an individual’s preference to a particular activity,
as this could be an important factor in influencing the eCB
system, as well as being a factor in deciding appropriate
therapy.
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8. General Discussion 
 
In neuropathological conditions such as ischaemic stroke, Alzheimer’s and Parkinson’s, 
the BBB becomes compromised, exacerbating the detrimental effects these diseases 
have on CNS homeostasis (Rosenberg, 2012; Zhang et al., 2020). Key studies and 
comprehensive reviews have shown that CBD and Δ9-THC  display efficacy in a range of 
neurological disorders, including ischaemic stroke, as well as offering protection at the 
BBB (Cristino et al., 2020; Hayakawa et al., 2010). However, the neuroprotective 
properties of minor phytocannabinoids remain to be fully elucidated. In light of the 
results obtained from a systematic review conducted in Chapter 4 (Stone et al., 2020), 
we hypothesised that CBG and CBDV would also prove to be protective in ischaemic 
stroke. Experiments were performed to determine the effects of CBDV and CBG on 
cells of the NVU subjected to OGD (Chapter 5). CBDA has been found to exhibit similar 
biological properties to CBD and acts more potently than CBD as an antiemetic via the 
activation of 5-HT1A (Rock and Parker, 2013). Given these data and that of previous 
work from our group (Hind et al., 2016), we hypothesised that CBDA may also reduce 
BBB permeability, perhaps by the same mechanism as CBD. In Chapter 6, experiments 
were performed to assess CBDAs ability to modulate BBB permeability post OGD. In 
addition to the central thesis aims, a clinical study was conducted to investigate 
endocannabinoids and their ability to influence mood and is presented as an additional 
chapter (Chapter 7). Altogether, the results presented in this thesis add to the growing 
body of evidence on the anti-inflammatory and neuroprotective properties of 
phytocannabinoids, as well as the importance of endocannabinoids in exercise and the 
regulation of mood.  
 
To protect the brain, the BBB must remain impenetrable to harmful agents such as 
xenobiotics and peripheral immune cells, whilst enabling the selective transport of 
essential nutrients (Abbott et al., 2006, 2010). In ischaemic stroke, oxidative stress, 
inflammatory cytokine release and immune cell activation contribute to BBB 




exacerbating neuronal injury (reviewed in L and X, 2016). It is worth noting, however, 
that whilst BBB disruption is generally associated with a worse outcome for patients, it 
enables the possibility of greater drug penetration into the CNS (Borlongan and 
Emerich, 2003). Modelling the BBB in vitro is important tool to study the crosstalk 
between cells of the NVU under normal and pathological conditions. Following 
rigorous model development conducted in Chapter 3, we generated a model which 
incorporated four primary human cell types that constitute the NVU (Stone et al., 
2019), which was based on a previous model developed by our group (Hind, 2014). 
Results showed that our OGD model was effective to stimulate cellular responses 
associated with in vivo ischaemia-reperfusion injury.  
 
In Chapter 4 we conducted a systematic review to gather all available published data 
on minor phytocannabinoids (excluding 9-THC and CBD) and their neuroprotective 
effects. Evidence presented in our review found that CBDV and CBG exhibited anti-
inflammatory, antioxidant, anti-excitotoxic and anticonvulsant properties in various 
models of neurodegeneration (Stone et al., 2020). In agreement with this and 
supporting our hypothesis, in Chapter 5 we demonstrated that CBDV and CBG 
exhibited anti-inflammatory effects in astrocytes and HBMECs subjected to OGD. 
Specifically, both CBG and CBDV attenuated IL-6 secretion in astrocytes and to a lesser 
extent in HBMECs. These data are consistent with findings in other studies where CBG 
was found to decrease expression of IL-6 in an in vivo model of Huntington’s disease 
(Valdeolivas et al., 2015), while CBDV decreased IL-6 in a mouse model of colitis 
(Pagano et al., 2019). Interestingly, while CBDV and CBG did not affect levels of IL-6 in 
pericytes, CBDA decreased IL-6 in pericytes post OGD, suggesting that these 
compounds may exhibit different mechanisms of action in different cell types. 
 
IL-6 increases endothelial permeability, promotes TJ remodelling (Maruo et al., 1992) 
and is correlated with poor outcomes in ischaemic stroke patients (Hotter et al., 2019; 
Shaafi et al., 2014). As these compounds were found to attenuate IL-6 secretion, they 




direct effects of CBG, CBDV and CBDA on TJ expression and localisation have yet to be 
investigated.  
 
To our knowledge, this is the first study to report that CBDV reduced levels of MCP-1 in 
HBMECs and attenuated levels of astrocyte derived VEGF post OGD. In addition, we 
found that both CBDA and CBD were effective in decreasing levels of MCP-1, however 
this was only conducted in one experiment and would need to be repeated to confirm 
the validity of these data. Our data corroborate findings the literature; in a viral model 
of multiple sclerosis (MS) CBD was found to mitigate MCP-1 secretion in astrocytes 
(Mecha et al., 2013) and recently CBDV was found to attenuate MCP-1 in a model of 
colitis (Pagano et al., 2019). As CBDV and CBDA exhibit a similar chemical structure to 
CBD, differing in just a shortened propyl side chain and a carboxylic acid group 
respectively, it is not surprising that they share similar biological and pharmacological 
properties. Interestingly, both CBDV and CBDA did not affect levels of VEGF in 
pericytes, but CBDV attenuated levels of VEGF in astrocytes. Therefore, it would be 
valuable to determine whether CBDA can also attenuate VEGF levels in astrocytes post 
OGD. Given that MCP-1 is associated with microglial activation and increases in 
endothelial permeability (Stamatovic et al., 2005, 2009; Yang et al., 2011), these 
preliminary data suggest that CBDV and CBDA may help prevent immune over-
activation and endothelial permeability post OGD. As CBDV also reduced levels of VEGF 
and in another study was found to reduce intestinal permeability (Pagano et al., 2019) 
this compound may be particularly promising in preventing BBB disruption and future 
in vivo experiments should be undertaken to clarify this potential. 
 
In Chapter 5, we also investigated the effects of CBDV and CBG on cellular and DNA 
damage in astrocytes. Both compounds reduced cell damage, which for CBDV 
appeared to be partially blocked by antagonists for GPR55 and GPR18, but CBGs 
effects were not inhibited by any of the antagonists tested. CBG and CBDV have 
displayed antioxidant capabilities in preclinical models of neurodegeneration (Di 




were not clearly blocked by any of the antagonists tested, it was postulated that the 
non-specific antioxidant properties may be largely responsible for these effects. We 
next investigated whether CBG and CBDV would also protect against DNA damage in 
astrocytes. Interestingly, while CBG decreased levels of DDR proteins, including Chk1, 
H2AX and p53, elevated in astrocytes post OGD, CBDV increased levels of ATR, Chk1, 
H2AX, MDM2 and p53, but exhibited a trend for decreasing ATR and Chk1 at higher 
concentrations. In Chapter 6, CBDA and CBD were assessed for their ability to protect 
against DNA damage in neurons, but neither the compounds nor the OGD protocol 
altered levels of any of the measured DDR proteins. We concluded that this may be 
due to the DDR pathway being activated earlier in neurons compared to astrocytes 
because they are more susceptible to ischaemia associated damage (Becerra-Calixto 
and Cardona-Gómez, 2017; Chen et al., 1997; Ordy et al., 1993). Thus, it may be of 
interest to ascertain whether CBD or CBDA can influence the DDR pathway at earlier 
time points in neurons and in astrocytes.  
 
CBDs acidic precursor, CBDA, has a similar chemical structure and studies have shown 
these compounds share pharmacological traits (reviewed in Formato et al., 2020). 
Using the BBB model we developed in Chapter 3, we demonstrated for the first time 
that CBDA pre-treatment prevented changes in permeability caused by OGD. 
Moreover, we found CBDAs ability to reduce IL-6 in pericytes was mediated by 5-HT1A 
receptor activation (refer to Chapter 6). These data are similar to previous data 
generated by our group, showing CBD reduced permeability via PPARy and 5-HT1A  
(Hind et al., 2016; Mishima et al., 2005). In light of the above, it is likely that CBDA, like 
CBD, exerts its effects on BBB permeability partly by acting as an agonist of 5-HT1A, 
however unfortunately this was not confirmed in this study. Future studies should 
assess whether CBDA can also modulate inflammatory cytokine release and BBB 
permeability in in vivo models of ischaemic stroke, as well as clarify whether CBDAs 





In neuronal monocultures, we found that CBDA (100 nM) modulated levels of heat 
shock proteins, reducing HSP60, HSP90⍺ and HSP27 whilst exhibiting a trend for 
increasing HSP27 total, HSP60 and 90 at higher concentrations. The multifaceted roles 
of HSPs in ischaemia-reperfusion injury have been increasingly recognised (Leak et al., 
2013; Shi et al., 2017; E Zhang et al., 2020). Zhang and colleagues (2020) found that 
HSP protein expression and elevated levels of proinflammatory cytokines post 
ishcaemia-reperfusion injury were associated with downregulated phosphatidylinositol 
3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamysin (mTOR) 
signalling. In an in vivo model of MS, Giacoppo and colleagues (2017) reported that 
CBD was able to restore the PI3K/AKT/mTOR pathway, increasing phosphorlyation of 
PI3K, Akt and mTOR and was associated with decreases in pro-inflammatory 
mediators, enhanced BDNF expression and upregulation of PPARy. Given that CBDA 
modulated levels of HSPs and reduced proinflammatory cytokine release post OGD, it 
is possible that like CBD, CBDAs mechanism of action may involve manipulation of the 
PI3K/Akt/mTOR signalling pathway, but this remains to be investigated.  
 
Endocannabinoids have been implicated in neuronal plasticity and neuroprotection, as 
well as being elevated in neuropathological conditions (Hillard, 2008; Naccarato et al., 
2010). Specifically, AEA was found to protect neurons in a model of CNS inflammation 
(Eljaschewitsch et al., 2006), OEA (10 µM) reduced BBB permeability induced by a 4 h 
OGD protocol in vitro, and in vivo reduced infarct volume and attenuated neurological 
dysfunction mediated by PPAR⍺ activation (Hind et al., 2015; Zhou et al., 2012). In 
addition, administration of PEA was found to be protective in an in vivo model of 
traumatic brain injury (TBI) (Ahmad et al., 2012). In Chapter 7, we found that singing 
increased levels of AEA, PEA and OEA as well as improving positive mood and 
emotions. Levels of OEA were also linked with participants desire to eat, overall hunger 
and mood (Stone et al., 2018). Heyman et al., (2012) found that cycling increased levels 
of AEA, which was positively correlated with BDNF and Brellenthin et al., (2017) found 
AEA,2-AG, OEA and PEA were increased after aerobic exercise and for AEA and 2-AG 




data and that presented in our study, influencing levels of endocannabinoids through 
exercise and other activities such as signing could have significant benefits on neuronal 
plasticity, as well as potentially offer neuroprotection, but this remains to be fully 
investigated. Collectively, these data build on existing knowledge on the role of 
endocannabinoids in the regulation of appetite, mood and reward and highlight their 
therapeutic potential in neuroprotection and mental health. 
8.1 Study Limitations and directions for future study 
Despite the positive data on the neuroprotective properties of these compounds, this 
study is limited to their effects in vitro. Whilst primary human cells offer closer 
modelling to human physiology than animal derived cells or immortalised cell lines, 
they were likely taken from a mixture of donor sources namely surgical specimens, 
foetal tissues and post-mortem donors, which differ from healthy adult physiology. It is 
also important to recognise that ischaemic stroke occurs in elderly patients and it is 
well known that aged cells undergo marked changes in their phenotype (Cai et al., 
2017). Therefore, whilst the cells used in our four-cell model and monoculture 
experiments are more representative of the human BBB than immortalised cell lines or 
animal cells, they are unlikely to provide full representation of the pathophysiological 
environment present in ischaemic stroke patients. Therefore, it is paramount that 
future studies assess the neuroprotective properties of these compounds in aged 
animals and animals with comorbidities to confirm their clinical potential.  
 
Our method of measuring permeability, whilst producing stable readings, was not able 
to run continuously and therefore involved moving cultures in and out of incubators to 
measure TEER at specific time points. It would be interesting for future studies to 
possibly incorporate techniques such as electric cell-substrate impedance sensing 
(ECIS) to monitor changes in permeability post OGD and the effects of 
phytocannabinoids in real time (Anchan et al., 2019). The importance of cerebral blood 
flow and the effects of shear stress on endothelial cell physiology has been well 




flow and therefore the effects of shear stress were not accounted for. Thus, it may be 
necessary for future studies to develop a method incorporating flow to be more 
representative of BBB physiology. 
 
The influence of overactive microglia and peripheral immune cells in potentiating post 
stroke injury has been well characterised (Shigemoto-Mogami et al., 2018; Szalay et al., 
2016; Taylor and Sansing, 2013). Microglia have also been shown to express 
cannabinoid receptors including CB2 and GPR55 (Saliba et al., 2018). It is worth noting 
that CB2 mRNA expression levels are elevated post ischaemia and CB2 receptor 
activation has been shown to be protective, specifically reducing IL-6, LDH and 
glutamate-mediated neurodegeneration (Contartese et al., 2012; Wang et al., 2018; Yu 
et al., 2015). Our model did not incorporate microglia, nor did we assess the effects of 
CBDV, CBG or CBDA on microglial monocultures. Studies have shown CBG protected 
stimulated macrophages against oxidative stress via a CB2 dependent mechanisms and 
protected motor neurons against medium taken from lipopolysaccharide (LPS) 
stimulated macrophages (Giacoppo, Gugliandolo, et al., 2017; Gugliandolo et al., 
2018). Recently Zamberletti and co-authors (2019) found that CBDV restored CB2 
expression and reduced microglial activation in rats exposed to valproic acid (VPA). 
However, CBDA has not been investigated in the context of neuroinflammation or 
whether it can influence immune cell activation. Thus, it would be interesting to see if 
CBDV, CBG or CBDA modulate microglial activation in preclinical models of ischaemic 
stroke. 
 
Phytocannabinoids exhibit a complex pharmacology and future experiments are 
needed to generate a more comprehensive picture of CBDVs, CBGs and CBDAs 
biological effects and their corresponding mechanisms of action. It is worth mentioning 
that Pagano et al., (2019) found CBDVs ability to reduce intestinal permeability and 
inflammatory cytokine release was mediated by TRPA1 receptors, which were not 
probed in our panel of antagonists. Pires and Earley, (2018) found that mitochondrial 




whilst Araújo and colleagues (2017) found that LDH release induced by OGD in chick 
retina was reversed by TRPA1 antagonist, HC-030031. These points support the role of 
TRPA1 receptors in hypoxia and ischaemia and it is possible that CBDVs protective 
effects and perhaps CBG and CBDA, in our model may be due to their interaction at 
TRPA1 receptors, which should be investigated in future studies.  
 
Inflammation and oxidative stress facilitate the breakdown of TJs post ischaemia, 
significantly contributing to BBB breakdown. Future experiments could analyse 
changes in TJ expression post ischaemia by analysing mRNA levels in BBB insert lysates 
or by immunocytochemistry. The direct influence of phytocannabinoids on TJ 
expression and localisation could also be examined. Whilst we concluded that CBG and 
CBDVs protection against cell damage was likely to be due to their antioxidant effects, 
direct measurement of oxidative stress was not conducted and could be assessed in 
future study.  
 
Looking forward, the pharmacokinetics (PK) of minor phytocannabinoids also need to 
be fully established before confirming clinical translatability (Stone et al., 2020). CBD 
has shown great promise as a neuroprotectant, partly due to its tolerability and safety 
in humans and its ability to cross the BBB (Millar et al., 2018). We found that despite 
evidence of CBDs efficacy in various disorders, there was an absence of PK data on CBD 
particularly regarding CBDs bioavailability in man (Millar et al., 2018, 2019). Likewise, it 
is paramount for PK data on minor phytocannabinoids, CBDA, CBG and CBDV to be 
generated in order for these compounds to be fully considered as therapeutic options 
in man. Limited PK data on these compounds in rodents presented in Deiana et al., 
(2012) and Anderson et al., (2019) demonstrate that CBDA, CBDV and CBG readily 
penetrate the brain, corroborating their potential as clinical neuroprotectants. 
Currently, CBDV is in clinical trials for autism spectrum disorder (phase 2, clinical trial 
identifier: NCT03849456) and was taken into clinical trials for epilepsy but did not 
meet the primary end point in controlling focal seizures (clinical trial identifier: 




effects (SAEs) were low and reported adverse effects (AEs) were of mild to moderate 
severity, altogether suggesting CBDV was well tolerated in humans (dose-titrated up to 
800 mg per day)(Morano et al., 2020). Considering the novel data presented in this 
thesis, together with evidence from the aforementioned studies, CBDA, CBDV and CBG 
are promising neuroprotectants and should be explored further in in vivo models of 
ischaemic stroke and perhaps other neurological disorders.   
8.2 Overall conclusions 
This thesis examined the protective effects of phytocannabinoids on cells of the NVU 
and successfully developed a four-cell BBB model. Using an OGD protocol to simulate 
ischaemic stroke in vitro, pre-treatment with CBG, CBDV and CBDA attenuated multiple 
aspects of OGD induced damage, including elevated levels of proinflammatory 
cytokines, adhesion molecules, heat shock proteins, as well as cellular and DNA 
damage. Furthermore, CBDA reduced BBB permeability and protected neurons in a 
four-cell BBB model subjected to OGD. In addition, manipulation of the 
endocannabinoid system by activities such as singing may pose a novel therapeutic 
avenue in various neurological disorders. The results presented in this study, together 
with the existing literature, suggest CBDA, CBG and CBDV may offer protection in 
ischaemic stroke, particularly against IL-6 and VEGF/MCP-1 induced increases in BBB 
permeability and cell damage. Overall, these novel data add to the growing body of 
evidence on the biological effects of phytocannabinoids and their potential as 













Professional internship reflective statement 
Note to examiners: 
A mandatory 3-month placement for DTP PhD students was carried out between 
February and May 2019. A brief, reflective statement on the internship and the skills 
developed is included to enable readers to recognise the range of PhD training that 
was experienced as a BBSRC doctoral student. This professional internship was 
completely separate to the PhD studies and was undertaken to develop different skills 
that could be useful in future endeavours. 
 
I accepted an internship at the scientific consultancy company Blossom Medical, under 
the supervision of a wonderful mentor, Dr Andy Yates. During the three months I 
learned a variety of new skills including, drug marketing, legislation, R&D and business 
development. I gained knowledge of the cannabidiol (CBD) commercial market and 
companies responsible for CBD’s novel food legislation. I also learned about the centre 
of medicinal cannabis (CMC) which promotes the widespread access to cannabis-based 
medicines (CBMs), as well as the education of various regulatory bodies and medical 
professionals on medical cannabis use. 
 
I wanted to establish whether I would pursue a career outside of lab-based research, 
either in scientific business development or legislation. I also wanted to build my 
corporate skills, such as interacting in business meetings, professional conduct and 
liaising with individuals with a range of skills and backgrounds. Shadowing Dr Andy 
Yates enabled me to partake in all of these and gain insight into the variety of projects 
he was involved with as a scientific consultant. Also, there was a range in the urgency 
of the tasks I was set meaning I had to be quick to delve into a piece of work if 
something was required promptly- sometimes within 1-2hrs. This helped me to 






Whilst it was very insightful and invaluable experience, I did miss working in the lab 
and the practical side of science. I realised that I still wanted to increase my scientific 
skills and experience, possibly to pursue an academic career or a lab-based job in 
industry.  However, I did appreciate the different career possibilities outside academia 
and the variety of job opportunities for someone with the breadth of skills I have 
developed over the course of my PhD. Overall, I thoroughly enjoyed my professional 
internship, it enabled me to be part of life outside PhD study and academic life whilst 

























































A systematic review of cannabidiol dosing in clinical populations 
 
The following chapter is presented in its final manuscript format and is published in 
British Journal of Clinical Pharmacology (Millar et al., 2019). 
 
Statement of personal contribution: performed systematic search and retrieval of 
articles and data extraction which was conducted independently from SM. Helped in 
editing the manuscript, confirming findings and input in the discussion. 
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Aims: Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential
application in a wide‐variety of contexts; however, its effective dose in different
disease states remains unclear. This review aimed to investigate what doses have
been applied in clinical populations, in order to understand the active range of CBD
in a variety of medical contexts.
Methods: Publications involving administration of CBD alone were collected by
searching PubMed, EMBASE and ClinicalTrials.gov.
Results: A total of 1038 articles were retrieved, of which 35 studies met inclusion
criteria covering 13 medical contexts. Twenty‐three studies reported a significant
improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with
doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not pro-
vided in any publication. CBD was reported as well tolerated and epilepsy was the
most frequently studied medical condition, with all 11 studies demonstrating positive
effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within
randomised controlled trials). There was no signal of positive activity of CBD in small
randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease,
ocular hypertension, fatty liver disease or chronic pain. However, low doses (average
2.4 mg/kg/d) were used in these studies.
Conclusion: This review highlights that CBD has a potential wide range of activity
in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to
elucidate effective plasma concentrations within medical contexts are severely lack-
ing and highly encouraged.
KEYWORDS
cannabidiol, cannabinoid, dose, dosing, therapeutics
1 | INTRODUCTION
Cannabidiol (CBD) is a non‐intoxicating major constituent of the
Cannabis sativa plant that has been increasing in interest due to its
potentially diverse range of therapeutic properties and its favourable
safety and tolerability profile.1 Side effects are generally mild and
infrequent, such as sleepiness, diarrhoea or increased temperature.
It is also reported that clinically significant drug‐interactions pose a
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low risk.2 There is no evidence for dependency or abuse potential
with CBD use, as concluded by the World Health Organisation Expert
Committee on Drug Dependence.1 The purported effects of CBD
include analgesic, anti‐inflammatory, antioxidant, anxiolytic, anticon-
vulsant and cytotoxic effects, which are mediated through signalling
mechanisms including the cannabinoid receptor 1 (weak agonist),
the cannabinoid receptor 2 (inverse agonist), the serotonin 1a
receptor (5‐HT1A), G protein‐coupled receptor 55 (GPR55), G
protein‐coupled receptor 18 (GPR18) and the transient receptor
potential cation channel subfamily V member 1 (TRPV1) receptors,
amongst others.3
Clinically, CBD is being investigated in multiple disease states
including neurodegeneration, anxiety disorder, orphan childhood
diseases with a prevalence of <5 in 10 000 individuals (e.g. tuberous
sclerosis complex) and addiction (ongoing trials in cannabis and
cocaine craving).4-6 Epidiolex has recently become the first Food and
Drug Administration‐approved CBD medicine, indicated for use in
Lennox–Gastaut or Dravet syndrome (childhood epilepsy) by oral
administration. Sativex is an oromucosal spray containing both CBD
and δ‐9‐tetrahydrocannibinol, which is licenced in the EU and Canada
for the treatment of multiple sclerosis associated spasticity. At the
time of writing, there are 49 clinical trials registered on clinicaltrials.
gov investigating CBD alone (either not yet recruiting, recruiting or
active) and there have been at least a further 100 clinical trials
previously registered containing CBD, indicating a significant clinical
interest with an ongoing need to ensure that human volunteers
engaged in these trials are given doses that are optimised for efficacy
and safety. Surprisingly, none of the 49 currently registered trials have
explicitly included a study design to investigate the dose‐ranging
efficacy of CBD.
Hemp‐derived CBD is commercially available and is currently used
as a health and food supplement commonly for anxiety and pain
relief. This market represents a flourishing industry expected to rise
financially and globally.7 However, the blurred lines between CBD
as a licensed medicine and CBD as an over‐the‐counter remedy
contribute to the overall lack of understanding of what dose of
CBD may be considered therapeutic. This is further hampered by
the lack of standardisation in over‐the‐counter CBD products and
their unregulated labelled doses.
Despite the prevalence of CBD use and current hype, guidance
on dose recommendations has not advanced and is not clear, addi-
tionally hampered by the striking lack of accessible pharmacokinetic
and bioavailability data of CBD in humans.8 No published study to
date has reported the absolute oral bioavailability of CBD in
humans.8 Limited dose‐determination studies have left a paucity in
data surrounding desired plasma concentrations to achieve minimum
effective doses. Additionally, the lack of information on the role of
different formulations and routes of administration on absorption
are also apparent. The aim of this review was to comprehensively
collate all published data relating to CBD administration in clinical
populations to describe the range of CBD doses assessed across
different pathological states.
2 | METHODS
2.1 | Search strategy
The systematic review was carried out in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta‐
Analyses) guidelines. A systematic search of PubMed, EMBASE
(including MEDLINE) and clinicaltrials.gov was conducted to retrieve
all articles reporting CBD administration in clinical populations using
‘CBD or Cannabidiol’ as search terms. Searches were restricted to
‘humans’ and ‘clinical trials and case reports’ in PubMed and EMBASE,
with no restrictions on clinicaltrials.gov. The searches were carried out
by 8 August 2018 by 2 independent researchers.
2.2 | Eligibility criteria
The titles and abstracts of retrieved studies were examined by 2
independent researchers, and inappropriate articles were rejected.
Inclusion criteria were as follows: an original, peer‐reviewed published
paper that involved administration of CBD to a clinical population, or
reported on clinicaltrials.gov, and included an outcome measurement
to assess the efficacy of CBD i.e. improvement in disease. Exclusion
criteria were: administration in healthy participants only; CBD
administered in combination with other cannabinoids such as with δ‐
9‐tetrahydrocannibinol or as whole cannabis extracts; article not in
English; no stated concentration of CBD used; or no statistical results
reported. The reference lists of included studies were hand‐searched
for additional relevant studies.
What is already known about this subject
• Due to its favourable toxicity and side effect profile,
cannabidiol is under increasing investigation in the
commercial and medical industry to treat many clinical
indications.
What this study adds
• This study identifies the wide active dosing range of
cannabidiol (<1 to 50 mg/kg/d) within a variety of
medical conditions including epilepsy, anxiety and graft‐
vs‐host disease.
• This review indicates that studies that used higher doses
tended to have better therapeutic outcomes compared to
lower doses overall.
• This study identifies a strong existing need for dose‐
ranging clinical studies to be conducted in which plasma
concentrations can provide a better indication of the
therapeutic range of cannabidiol.
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2.3 | Data acquisition and analysis
The included articles were analysed, and the following data extracted:
sample size, clinical population/medical context; study design and
length; administration route of CBD; source of CBD; dose of CBD;
side effects; and primary outcome results. All data entry was checked
by an additional independent researcher. Risk of bias of the 15
randomised controlled trials was assessed using the 2011 Cochrane
Collaboration's tool for assessing risk of bias.
As this review included studies of participants of all ages (from
infants to adults), dosing is reported in mg/kg of body weight to
allow for comparison. Where not available as mg/kg (24 studies),
dose was converted for adults using an average adult body weight
of 62 kg.9 In only 1 publication, a case report on a child, an average
child weight of 40 kg had to be used to convert reported mg/d dose
into mg/kg/d.10
A positive effect of CBD was determined by the presence of a sig-
nificant improvement in primary end points(s) or outcomes reported
compared to placebo or baseline. A lack of positive effect was deter-
mined if no significant improvements were reported. Mixed findings
were reported for example in case reports wherein some patients
improved, others did not, or where a primary outcome was not speci-
fied (exploratory study) and in which some endpoints improved while
others worsened (1 study) or remained unchanged.
3 | RESULTS
The initial search yielded 1038 records, from which 896 abstracts
were reviewed, and 35 articles were included in the final analysis,
comprising a total number of 1223 participants. A flow chart of arti-
cle retrieval and selection is presented in Figure 1. Fifteen studies
were randomised controlled trials (RCTs), 8 were clinical trials but
not both randomised and controlled in design (for example open‐label
trials), and 12 articles were case reports/series. A description of each
study is presented in tables 1–3 according to study design. Results of
the risk of bias assessment of the RCTs are presented in Figure 2. A
component of blinding was included in 74% of the RCTs . No study
was reported with a high risk of selection bias, detection bias, or
reporting bias. Overall, most information was from studies at low risk
of bias. No study reported plasma concentrations of CBD. All studies
reported oral administration of CBD, either as an oral solution
(n = 11), capsules (n = 13), spray/sublingual (n = 4), or orally but
unspecified (n = 6).
Of the 15 RCTs, the range of doses investigated varied from
<1 mg/kg up to 20 mg/kg per day (average 9 mg/kg/d).11-19,21-25
Seven RCTs reported CBD efficacy (average dose 14 mg/kg/
d),11-13,16,19,20,24 7 studies describe neutral effects of CBD (average
dose 5 mg/kg/d)14,15,17,21-23,25 and 1 study showed both positive
and negative outcomes.18 In the remaining 8 clinical trials of various
FIGURE 1 Flow chart of study retrieval and
selection
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TABLE 1 Summary of included studies: randomised controlled trials
Study
Clinical
population Total n Design Trial length
















8 wk 1000 mg/d (16.7 mg/
kg/d)































171 Double‐blind, phase III,
RCT. Add‐on
therapy to AEDs.
14 wk 20 mg/kg/d Oral solution GW Monthly frequency of
drop seizures
decreased by a
median of 43.9% in
the CBD group,
significantly more













225 Phase III, double‐blind,
RCT. Add‐on
therapy to AEDs.
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STI No effect on cognition
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19 RCT 8 wk 20 mg/d (0.3 mg/kg/d) Orally,
sublingual



































62 Double‐blind, RCT 13 wk 200 mg/d (3.3 mg/kg/
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42 Phase II, double‐blind,
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8 wk Approx. 9 sprays/d,
equivalent of
















6 wk 10 mg/kg/d Oral
capsules
US NIDA CBD was ineffective No Similar between CBD
and placebo






















GW No differences in liver
triglyceride levels
No Similar between CBD
and placebo
aIf not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.
bSignificant compared to placebo/control (P < .05) unless stated otherwise.
*Registered clinical trial identifier: not published in any peer‐reviewed journal but results available from clinicaltrials.gov.
AEDs, anti‐epileptic drugs; CBD, cannabidiol; GW, GW Pharmaceuticals; HDL, high density lipoprotein; NA, not available; NIDA, National Institute on Drug Abuse; RCT, randomised controlled trial; SAD, social








TABLE 2 Summary of included studies: clinical studies
Study Clinical population Total n Design Trial length
CBD dose (mg) and
approx. mg/kg/da Route of admin. CBD source
Resultsb: Primary
endpoint(s) + effect Side effects
Rosenberg, 201726 Epilepsy, 1–30 y 48 Open label clinical
study
12 wk 2–5 mg/kg/d titrated
up to 50 mg/kg/d
or intolerance
Oral solution or by
gastric tube
GW Improvement in
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18 Prospective study 6–12 months 5 mg/kg/d titrated
up to 50 mg/kg/d
if tolerated

























Acute 400 mg (6.7 mg/kg) Oral capsule THC Reduced subjective
anxiety
Yes None reported
Hallak, 201030 Schizophrenia, adults 28 Placebo‐controlled
study
Acute 300 or 600 mg (5 or
10 mg/kg)









4 wk 150 mg/d, increased
by 150 mg each
week to a total of
400 mg/d
(6.7 mg/kg/d)










6 wk 100–600 mg/d,
increased weekly
(1.7–10 mg/kg/d)






aIf not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.
bSignificant compared to placebo/control (P < .05) unless stated otherwise.








TABLE 3 Summary of included studies: case studies
Study Clinical population Total n Design Trial length
CBD dose (mg) and
approx. mg/kg/da Route of admin. CBD source
Resultsb: Primary
endpoint(s) + effect Side effects
Kaplan, 201733 Refractory seizures in
Sturge–Weber
syndrome, children
5 Case‐series 14 wk 5–25 mg/kg/d Oral solution GW Decreases in seizure
frequency
Yes Mild
Warren, 201734 Brain tumour related
epilepsy, aged 17–
40 y
3 Case series 2–10 mo 10–50 mg/kg/d Oral GW Improvement in
seizure frequency
(n = 2) and severity
(n = 3)
Yes Diarrhoea






Acute and up to
48 weeks







Shannon, 201610 Anxiety and insomnia
in PTSD, child









Saade, 201536 Seizures, 10‐month
old infant
1 Case report 6 mo 25 mg/kg/d Oral solution GW Substantial reductions
in seizures
Yes None reported
Chagas, 201437 RBD in Parkinson's
disease, adults
4 Case series 6 wk 75 mg/d
(1.25 mg/kg/d)





Crippa, 201338 Cannabis dependency,
adult
1 Case report 10 d 300 mg/d increased to
600 mg/d (5–
10 mg/kg/d)
Oral capsule THC Absence of withdrawal
symptoms
Yes None reported
Zuardi, 201039 Bipolar disorder, adults 2 Case series 30 d 600 mg/d increased to
1200 mg/d (20 mg/
kg/d)
Oral STI and THC CBD was ineffective
for manic episode
No None observed
Zuardi, 199540 Schizophrenia, adult 1 Case report 4 wk 1500 mg/d
(25 mg/kg/d)







3 Case series 30 d 40 mg/d, increased to
1280 mg/d
(21.3 mg/kg/d)
















study design, 7 studies reported CBD positively (average dosing
23 mg/kg/d)5,26-29,31,32 and 1 study was neutral (8 mg/kg/d).30
Within the 12 case studies and case series, 9 described positive
effects of CBD (average dosing 16 mg/kg/d),10,33-38,40,43 2 were
neutral (average dosing 21 mg/kg/d)39,41 and 1 study described
mixed results (3 mg/kg/d).42
Epilepsy was the most frequently studied medical condition, with all
11 studies describing beneficial effects of CBD in reducing the severity
or frequency of seizures.12,13,16,24,26-28,33-36 Within the 4 conducted
RCTs (n = 531), an average dosing of 15 mg/kg/d was used where
CBD was administered successfully as an add‐on therapy to usual
anti‐epileptic drugs.12,13,16,24 Significant improvements were observed
compared to placebo as an add‐on therapy. Within the other 3 clinical
trials of prospective open‐label design (n = 203), CBD was adminis-
tered at an average dosing of 42 mg/kg/d and significant improve-
ments in quality of life and seizure frequency compared to baseline
were observed.26-28 3 case series and 1 case report (total n = 16)
reported beneficial effects of CBD on seizure frequency, duration
and severity with an average administered dose of 21 mg/kg/d.33-36
Seven studies were conducted in the context of schizophrenia and















































































































































































































































































































































































































































































































FIGURE 2 Risk of bias summary of the randomised controlled trials
included in the systematic review. Green indicates low‐risk bias, red
indicates high‐risk bias, and yellow indicates intermediate or unclear
risk
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of 15 mg/kg/d over 4 or 8 weeks reported positive reductions in psy-
chotic or psychiatric symptoms and a better side effect profile
(n = 130).11,19 One of these compared CBD against an active control
(amisulpride), and the other as an add‐on therapy to usual medication
compared to placebo as an add‐on therapy. However, a third RCT
employing CBD as an add‐on therapy did not report any improve-
ments in cognition or symptoms of schizophrenia after a lower aver-
age dose of 10 mg/kg/d over 6 weeks (n = 36).14 An acute dose of
5 or 10 mg/kg/d did not improve selective attention in a placebo‐
controlled trial of 28 schizophrenia patients.30 A number of case
studies have also been conducted by Zuardi and colleagues in this
medical context. In 2 patients with bipolar disease, 20 mg/kg/d was
ineffective in treating manic episodes.39 CBD was similarly unable to
improve symptoms in 3 schizophrenia patients, although 1 patient
described mild improvement.41 Another case report described
improvement in psychiatric ratings following an average dose of
25 mg/kg/d over 4 weeks.40
Results are mixed within Parkinson's disease studies. Within an
RCT in 21 patients, 1.25 or 5 mg/kg/d CBD had no effect on motor
and general symptoms. However, the 5 mg/kg/d dose improved
well‐being and quality of life scores.18 The remaining studies are case
studies in which CBD decreased psychotic symptoms and Parkinson's
disease ratings (n = 6; 7 mg/kg/d),31 improved rapid eye movement
sleep behaviour disorder (n = 4; 1 mg/kg/d),37 decreased dyskinesia
with 2 to 3 mg/kg/d doses (n = 1), but exaggerated Parkinson's disease
symptoms with 5 and 7 mg/kg/d doses.42
CBD did not change therapeutic outcome variables in a double‐
blind RCT in Huntington disease patients compared to placebo
(n = 15; 10 mg/kg/d for 6 weeks),23 but improved dystonia disability
in an open pilot study (n = 5; 10 mg/kg/d for 6 weeks),32 and improved
spasm frequency and severity in a case report in 1 patient with Meige
syndrome (7 mg/kg/d).43
Within the RCTs, CBD did not significantly change the primary
outcomes in diabetes (n = 62), Crohn's disease (n = 19), ocular hyper-
tension (n = 6), chronic pain (mostly neuropathic; n = 24), or fatty liver
disease (n = 25).15,17,21,22,25 However, an average dose of 2.4 mg/kg/d
(range 0.3–13.3 mg/kg/d) was used in these studies, which is very low
in the clinical and clinical trial setting compared to other studies. Low
doses (10 mg/kg) did, however, produce positive responses in
generalised social anxiety disorder (SAD) in a double‐blind RCT in 24
patients.20 Likewise, in another double‐blind placebo‐controlled study,
a dose of 6.7 mg/kg reduced subjective anxiety in 10 adults with gen-
eralised SAD.5 Additionally, in a case report in a child, 0.6 mg/kg/d
increased sleep quality and duration, and decreased anxiety secondary
to PTSD.10
Lastly, it was found that doses of 5 mg/kg/d prevented occurrence
of graft‐vs‐host disease in a phase II clinical trial (n = 48) and
5–10 mg/kg/d doses have been shown in a case report to remove
withdrawal symptoms from a patient with cannabis dependency.29,38
Within studies that compared CBD against a placebo or control
(n = 17 publications), only 1 compared CBD against an active control
(and a greater clinical improvement and side effect profile was
observed with CBD against amisulpride), 8 compared CBD against a
placebo (monotherapy), and 8 studies compared CBD as an add‐on
therapy (adjunctive to antipsychotic medication, antiepileptic medica-
tion, anti‐Parkinson medication or pain medication) against placebo.
Analysis of these data revealed that a greater proportion of studies
reported a beneficial effect of CBD in the add‐on therapy group
compared to the monotherapy group (n = 6 and n = 2 respectively).
However, higher doses were used overall within the add‐on therapy
group compared to the monotherapy group (average 11 and
6 mg/kg/d, respectively) and, due to such a small data set and hetero-
geneity of studies, we did not perform any further analysis.
4 | DISCUSSION
To our knowledge, this is the first study to compile and compare all
publications in which CBD was administered to clinical populations.
The aim of this systematic review was to better understand the range
of doses of CBD used in clinical studies. In total, 13 medical contexts
were included in this review amongst 35 studies including clinical trials
and case reports. A positive effect of CBD was reported in 66% of
studies, covering disorders including schizophrenia, SAD, epilepsy,
cannabis dependency and graft‐vs‐host disease, with doses ranging
between <1 and 50 mg/kg/d (i.e. <62–3100 mg/d for an adult).
Although we acknowledge that these results mix widely heteroge-
neous studies, it appears well founded to highlight the differences in
average dosing for positive effect studies against those without posi-
tive effects, which is confirmed when analysing studies per medical
context within each study design format. This suggests that CBD
potentially displays a wide therapeutic range, and variable minimum
doses are required for effect depending on primary outcomes
assessed and the population group. However, it is vital to note that
no conclusions can be drawn on the efficacy of CBD as larger phase
III and conclusive efficacy trials have not been conducted, with excep-
tion of epilepsy. A number of phase III clinical trials are registered on
clinicaltrials.gov, which should provide more evidence in the coming
years in the contexts of pain, anxiety, Crohn's disease, bipolar disorder,
Fragile X syndrome, epilepsy and more.
CBD is increasingly popular, both as a food and health supplement
and as a licensed medicine. Within this review, 51% of studies have
been published in the last 5 years (since 2013); however, the included
articles span over decades, with prominent publications first appearing
in the 1980s and early 1990s.24,40 Despite its long history of sole
administration to patients, there is surprisingly little published about
the pharmacokinetic properties of CBD, particularly its bioavailability,
making it difficult to estimate true effective doses.8 Historically, there
is a striking lack of dose‐ranging studies and, looking forward, there
are no registered trials on clinicaltrials.gov including specific dose‐
ranging investigations in their study design. Ideally, this review would
have compared plasma concentrations of CBD in order to more
accurately estimate therapeutic concentrations, but, due to the lack
of reporting, this was not possible.
Different effective plasma concentrations of CBD may be required
for achieving different endpoints across clinical populations, which is a
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recognised trait in a number of other drugs and diseases. For example,
aspirin (acetylsalicylic acid) is used at low doses for antiplatelet ther-
apy, and at higher doses as an analgesic agent.44,45 With CBD, lower
doses may be effective in anxiety relief, while higher doses may be
required for effective reduction in epileptic seizures. In studies where
there are good rationales for CBD use (e.g. Crohn's disease and
chronic pain46,47), neutral results may be secondary to subtherapeutic
dosing, and dose‐escalation trials with embedded pharmacokinetic
studies are the next logical step.15,22 Studies in this review using
higher doses concluded that CBD was generally well‐tolerated with
the most frequent side effects including drowsiness, nausea, somno-
lence, fatigue and vomiting.
Among the clinical trial records retrieved from clinicaltrials.gov,
only 60% of completed trials had results uploaded and available. This
may represent a significant publication bias and is suggestive of disre-
gard for the priority of publication of negative results, which is a well‐
recognised problem.48 Unfortunately, this may potentially skew the
findings presented in this review and so should be interpreted with
caution and is acknowledged as a limitation. We also acknowledge
that despite all routes of administration being oral, there may be fur-
ther bias introduced between studies as one dose cannot be directly
compared to another due to lack of standardisation of formulations
and pharmacokinetic activity, including differences in bioavailability
between an oral spray and an oral capsule.
Future studies should also consider the safety of drug interactions
with CBD. CBD is a known inhibitor of the cytochrome P450 (CYP)
system49 and can therefore increase plasma concentrations of medi-
cines already in use, in particular antiepileptic drugs. Indeed, this has
been reported in a number of publications investigating concomitant
use of CBD and antiepileptic drugs.50 Similarly, CYP inhibitors are
predicted to increase CBD plasma concentrations which should be
equally monitored. Where possible, further well designed trials with
CBD may disentangle whether CBD offers unique therapeutic poten-
tial in addition to benefits seen when used as an add‐on treatment.
5 | CONCLUSION
Although larger confirmatory and efficacy clinical trials examining dos-
ing in more detail for each medical context is required, this review sum-
marises that CBD appears to offer a wide‐range of activity between 1
and 50 mg/kg/d, and there was a tendency of studies with positive
outcomes to have used higher doses of CBD. We recommend pharma-
cokinetic dosing schedules in subsequent trials to consider this range
along with safety data and individual patient requirements. Finally,
we implore all completed trial results to be made readily available so
the research community can progress and learn from equally important
positive and negative outcomes for the ultimate benefit of patients.
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A Systematic Review on the
Pharmacokinetics of Cannabidiol in
Humans
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Background: Cannabidiol is being pursued as a therapeutic treatment for multiple
conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but
literature in humans is not sufficient. The aim of this review was to collate published data
in this area.
Methods: A systematic search of PubMed and EMBASE (including MEDLINE) was
conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans.
Results: Of 792 articles retireved, 24 included pharmacokinetic parameters in
humans. The half-life of cannabidiol was reported between 1.4 and 10.9 h after
oromucosal spray, 2–5 days after chronic oral administration, 24 h after i.v., and 31 h
after smoking. Bioavailability following smoking was 31% however no other studies
attempted to report the absolute bioavailability of CBD following other routes in humans,
despite i.v formulations being available. The area-under-the-curve and Cmax increase
in dose-dependent manners and are reached quicker following smoking/inhalation
compared to oral/oromucosal routes. Cmax is increased during fed states and in lipid
formulations. Tmax is reached between 0 and 4 h.
Conclusions: This review highlights the paucity in data and some discrepancy in
the pharmacokinetics of cannabidiol, despite its widespread use in humans. Analysis
and understanding of properties such as bioavailability and half-life is critical to future
therapeutic success, and robust data from a variety of formulations is required.
Keywords: pharmacokinetics, endocannabinoid system, bioavailability, CMAX, TMAX, half life, plasma clearance,
volume of distribution
INTRODUCTION
The Cannabis sativa plant contains more than a hundred phytocannabinoid compounds,
including the non-psychotomimetic compound cannabidiol (CBD) (Izzo et al., 2009).
CBD has attracted significant interest due to its anti-inflammatory, anti-oxidative and
anti-necrotic protective effects, as well as displaying a favorable safety and tolerability
profile in humans (Bergamaschi et al., 2011), making it a promising candidate in many
therapeutic avenues including epilepsy, Alzheimer’s disease, Parkinson’s disease, and
multiple sclerosis. GW pharmaceuticals have developed an oral solution of pure CBD
(Epidiolex R⃝) for the treatment of severe, orphan, early-onset, treatment-resistant epilepsy
syndromes, showing significant reductions in seizure frequency compared to placebo in
several trials (Devinsky et al., 2017, 2018a; Thiele et al., 2018). Epidiolex R⃝ has recently
Millar et al. Pharmacokinetics of Cannabidiol in Humans
received US Food and Drug Administration (FDA) approval
(GW Pharmaceuticals, 2018). CBD is also being pursued in
clinical trials in Parkinson’s disease, Crohn’s disease, society
anxiety disorder, and schizophrenia (Crippa et al., 2011; Leweke
et al., 2012; Chagas et al., 2014; Naftali et al., 2017), showing
promise in these areas. Additionally, CBD is widely used as a
popular food supplement in a variety of formats for a range of
complaints. It is estimated that the CBD market will grow to
$2.1 billion in the US market in consumer sales by 2020 (Hemp
Business, 2017).
From previous investigations including animal studies, the
oral bioavailability of CBD has been shown to be very low
(13–19%) (Mechoulam et al., 2002). It undergoes extensive first
pass metabolism and its metabolites are mostly excreted via
the kidneys (Huestis, 2007). Plasma and brain concentrations
are dose-dependent in animals, and bioavailability is increased
with various lipid formulations (Zgair et al., 2016). However,
despite the breadth of use of CBD in humans, there is little
data on its pharmacokinetics (PK). Analysis and understanding
of the PK properties of CBD is critical to its future use
as a therapeutic compound in a wide range of clinical
settings, particularly regarding dosing regimens and routes
of administration. Therefore, the aim of this systematic
review was to collate and analyse all available CBD PK




The systematic review was carried out in accordance with
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines (Moher et al., 2009). A systematic
search of PubMed and EMBASE (including MEDLINE) was
conducted to retrieve all articles reporting pharmacokinetic
data of CBD in humans. Search terms included: CBD,
cannabidiol, Epidiolex, pharmacokinetics, Cmax, plasma
concentrations, plasma levels, half-life, peak concentrations,
absorption, bioavailability, AUC, Tmax, Cmin, and apparent
volume of distribution. No restrictions were applied to
type of study, publication year, or language. The searches
were carried out by 14 March 2018 by two independent
researchers.
Eligibility Criteria
The titles and abstracts of retrieved studies were examined by
two independent researchers, and inappropriate articles were
rejected. Inclusion criteria were as follows: an original, peer-
reviewed paper that involved administration of CBD to humans,
and included at least one pharmacokinetic measurement as listed
in the search strategy.
Data Acquisition
The included articles were analyzed, and the following data
extracted: sample size, gender, administration route of CBD,
source of CBD, dose of CBD, and any pharmacokinetic details.
Where available, plasma mean or median Cmax (ng/mL) were
plotted against CBD dose (mg). Similarly, mean or median Tmax
and range, and mean or median area under the curve (AUC0−t)
and SD were plotted against CBD dose (mg). The source/supplier
of the CBD was also recorded. No further statistical analysis
was possible due to sparsity of data and heterogeneity of
populations used. All studies were assessed for quality using an
amended version of the National Institute for Health (NIH),
National Heart, Lung and Blood Institute, Quality Assessment
Tool for Before-After (Pre-Post) Studies with No Control Group
(National Institute for Health, 2014). A sample size of ≤10 was
considered poor, between 11 and 19 was considered fair, and≥20
was considered good (Ogungbenro et al., 2006).
Definitions of PK Parameters
Tmax: Time to the maximum measured plasma concentration.
Cmax: Maximum measured plasma concentration over the time
span specified.
t1/2: Final time taken for the plasma concentration to be reduced
by half.
AUC0−t: The area under the plasma concentration vs. time curve,
from time zero to “t.”
AUC0−inf: The area under the plasma concentration vs. time
curve from zero to t calculated as AUC0−t plus the extrapolated
amount from time t to infinity.
Kel: The first-order final elimination rate constant.
RESULTS
In total, 792 records were retrieved from the database searching,
24 of which met the eligibility criteria (Figure 1). Table 1
summarizes each included study. Routes of administration
included intravenous (i.v.) (n = 1), oromucosal spray (n = 21),
oral capsules (n = 13), oral drops (n = 2), oral solutions (n = 1),
nebuliser (n = 1), aerosol (n = 1), vaporization (n = 1),
and smoking (n = 8). CBD was administered on its own in 9
publications, and in combination with THC or within a cannabis
extract in the remainder. One study was conducted in children
with Dravet syndrome, while the remainder were conducted in
healthy adult volunteers (Devinsky et al., 2018b). Overall, the
included studies were of good quality (Supplementary Table 1).
However, many studies had small sample sizes. Additionally,
not all studies included both males and females, and frequent
cannabis smokers were included in a number of studies. Thus,
interpretation and extrapolation of these results should be done
with caution.
Cmax, Tmax, and Area Under the Curve
Within the 25 included studies, Cmax was reported on 58
occasions (for example within different volunteer groups or doses
in a single study), Tmax on 56 occasions and area under the curve
(AUC0−t) on 45 occasions. These data from plasma/blood are
presented in Figures 2A–C. The AUC0−t and Cmax of CBD is
dose-dependent, and Tmax occurs between 0 and 5 h, but does
not appear to be dose-dependent.
Frontiers in Pharmacology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 1365
Millar et al. Pharmacokinetics of Cannabidiol in Humans
FIGURE 1 | Flow chart for study retrieval and selection.
Oromucosal Drops/Spray
A number of trials in humans were conducted by Guy
and colleagues to explore administration route efficiency of
sprays, an aerosol, and a nebuliser containing CBD or CBD
and THC (CBD dose 10 or 20mg) (Guy and Flint, 2004;
Guy and Robson, 2004a,b). Oromucosal spray, either buccal,
sublingual, or oropharyngeal administration, resulted in mean
Cmax between 2.5 and 3.3 ng/mL and mean Tmax between 1.64
and 4.2 h. Sublingual drops resulted in similar Cmax of 2.05
and 2.58 ng/mL and Tmax of 2.17 and 1.67 h, respectively. Other
oromucosal single dose studies reported Cmax and Tmax values
within similar ranges (Karschner et al., 2011; Atsmon et al.,
2017b).
Minimal evidence of plasma accumulation has been reported
by chronic dosing studies over 5–9 days (Sellers et al., 2013;
Stott et al., 2013a). Cmax appears to be dose-dependent. A dose
of 20 mg/day resulted in a mean Cmax of 1.5 ng/mL and mean
AUC0−t of 6.1 h × ng/mL while 60 mg/day equated to a mean
Cmax of 4.8 ng/mL and AUC0−t was 38.9 h × ng/mL (Sellers
et al., 2013). In another study, Cmax increased dose-dependently
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from 0.4 to 1.2 and 2.2 ng/mL following 5, 10, and 20mg
single doses, respectively, and from 0.5 to 1.1 and 3.2 ng/mL,
respectively following chronic dosing over 9 consecutive days
(Stott et al., 2013a). There was a significant increase in time-
dependent exposure during the chronic treatment.MeanAUC0−t
for the single doses were 0.8, 4.5, 9.9, and 2.5, 6.7, and 20.3 for
the chronic dosing schedule, respectively. Tmax does not appear
to be dose-dependent, nor affected by acute or chronic dosing
schedules.
Stott et al. reported an increase in CBD bioavailability under
fed vs. fasted states in 12 men after a single 10mg dose of CBD
administered through an oromucosal spray which also contained
THC (Stott et al., 2013a,b). Mean AUC and Cmax were 5- and 3-
fold higher during fed conditions compared to fasted (AUC0−t
23.1 vs. 4.5; Cmax 3.7 vs. 1.2 ng/mL). Tmax was also delayed under
the fed state (4.0 vs. 1.4 h).
In children, Devinsky et al. reported mean AUC as 70, 241,
722, and 963 h × ng/mL in groups receiving 2.5, 5, 10, and 20
mg/Kg/day of CBD in oral solution (Devinsky et al., 2018b).
Oral Intake
Cmax and AUC following oral administration also appears to
be dose dependent. A dose of 10mg CBD resulted in mean
Cmax of 2.47 ng/mL at 1.27 h, and a dose of 400 or 800mg
co-administered with i.v. fentanyl (a highly potent opioid) to
examine its safety resulted in a mean Cmax of 181 ng/mL (at 3.0 h)
and 114 ng/mL (at 1.5 h) for 400mg, and 221 ng/mL (at 3.0 h) and
157 ng/mL (at 4.0 h) for 800mg, in 2 sessions, respectively (Guy
and Robson, 2004b; Manini et al., 2015). A dose of 800mg oral
CBD in a study involving 8 male and female cannabis smokers,
reported a mean Cmax of 77.9 ng/mL and mean Tmax of 3.0 h
(Haney et al., 2016). Although, an increase in dose corresponds
with an increase in Cmax, the Cmax between the higher doses of
CBD does not greatly differ, suggesting a saturation effect (e.g.,
between 400 and 800mg).
One hour after oral capsule administration containing 5.4mg
CBD in males and females, mean Cmax was reported as
0.93 ng/mL (higher for female participants than male) (Nadulski
et al., 2005a). A subset (n = 12) consumed a standard breakfast
meal 1 h after the capsules, which slightly increased mean
Cmax to 1.13 ng/mL. CBD remained detectable for 3–4 h after
administration (Nadulski et al., 2005b).
Cherniakov et al. examined the pharmacokinetic differences
between an oromucosal spray and an oral capsule with piperine
pro-nanolipospheres (PNL) (both 10mg CBD) in 9 men. The
piperine-PNL oral formulation had a 4-fold increase in Cmax
(2.1 ng/mL vs. 0.5 ng/mL), and a 2.2-fold increase in AUC0−t
(6.9 vs. 3.1 h × ng/mL), while Tmax was decreased (1.0 vs. 3.0 h)
compared to the oromucosal spray (Cherniakov et al., 2017a).
This group further developed self-emulsifying formulations and
reported again an increased bioavailability and increased Cmax
within a shorter time compared to a reference spray (Atsmon
et al., 2017a,b).
Intravenous Administration
The highest plasma concentrations of CBD were reported
by Ohlsson et al. following i.v. administration of 20mg of
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FIGURE 2 | (A) Mean or median Tmax (h) and range against CBD dose
(mg) (B) mean or median area under the curve (AUC0-t) (h × ng/mL) and
SD against CBD dose (mg) and (C) plasma mean or median concentration
max (Cmax; ng/mL) against CBD dose (mg). It was not possible to
present error bars for Cmax as SD and SEM were both reported in the
data. IV, intravenous; SD, standard deviation; SEM, standard error of the
mean.
deuterium-labeled CBD. Mean plasma CBD concentrations
were reported at 686 ng/mL (3min post-administration), which
dropped to 48 ng/mL at 1 h.
Controlled Smoking and Inhalation
After smoking a cigarette containing 19.2mg of deuterium-
labeled CBD, highest plasma concentrations were reported as
110 ng/mL, 3min post dose, which dropped to 10.2 ng/ml 1 h
later (Ohlsson et al., 1986). Average bioavailability by the smoked
route was 31% (Ohlsson et al., 1986). A nebuliser resulted in
a Cmax of 9.49 ng/mL which occurred at 0.6 h, whereas aerosol
administration produced Cmax (2.6 ng/mL) at 2.35 h (Guy and
Flint, 2004). In 10 male and female usual, infrequent cannabis
smokers, Cmax was 2.0 ng/mL at 0.25 h after smoking a cigarette
containing 2mg of CBD (Schwope et al., 2011). CBD was
detected in 60% of whole blood samples and in 80% of plasma
samples at observed Cmax, and no longer detected after 1.0 h.
A study in 14 male and female cannabis smokers reported
15.4% detection in frequent smokers with no CBD detected in
occasional smokers in whole blood analysis (Desrosiers et al.,
2014). In plasma however, there was a 53.8 and 9.1% detection
in the frequent and occasional groups, with corresponding Cmax
of 1.1 ng/mL in the frequent group, and below limits of detection
in the occasional group.
Half-Life
The mean half-life (t1/2) of CBD was reported as 1.1 and 2.4 h
following nebuliser and aerosol administration (20mg) (Guy and
Flint, 2004), 1.09 and 1.97 h following single oral administration
(10 and 20mg) (Guy and Flint, 2004; Guy and Robson, 2004b),
2.95 and 3.21 h following 10mg oral lipid capsules (Atsmon
et al., 2017a,b), between 1.44 and 10.86 h after oromucosal spray
administration (5–20mg) (Guy and Robson, 2004b; Sellers et al.,
2013; Stott et al., 2013a,b; Atsmon et al., 2017b), 24 h after i.v.
infusion, 31 h after smoking (Ohlsson et al., 1986), and 2–5 days
after chronic oral administration (Consroe et al., 1991).
Elimination Rate
Mean elimination rate constant (Kel [1/h]) has been reported as
0.148 in fasted state, and 0.155 in fed state after 10mg CBD was
administered in an oromucosal spray also containing THC (Stott
et al., 2013a,b). After single doses of 5 and 20mg CBD, mean
Kel (1/h) was reported as 0.173 and 0.123 (Stott et al., 2013a).
Following 20mg CBD administration through a nebuliser and
pressurized aerosol, mean Kel was reported as 0.98 and 0.43,
respectively, while 20mg CBD administered as sublingual drops
was reported as 0.37 (Guy and Flint, 2004).
Plasma Clearance
Plasma apparent clearance, CL/F (L/h) has been reported to range
from 2,546 to 4,741 in a fasted stated following 10mg CBD
administered via oromucosal spray (Stott et al., 2013a,c). This
value decreases to 533 following the same concentration in a fed
state (Stott et al., 2013b). A plasma apparent clearance of 3,252
and 3,783 was reported following 5 and 20mg single doses of
CBD via oromucosal spray (Stott et al., 2013a). Ohlsson et al.
reported plasma apparent clearance as 74.4 L/h following i.v.
injection (Ohlsson et al., 1986).
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Volume of Distribution
Mean apparent volume of distribution (V/F [L]) was reported
as 2,520 L following i.v. administration (Ohlsson et al., 1986).
Following single acute doses through oromucosal spray
administration, apparent volume of distribution was reported as
26,298, 31,994, and 28,312 L (Stott et al., 2013a).
DISCUSSION
The aim of this study was to review and analyse all available
PK data on CBD in humans. Only 8 publications reported
PK parameters after administering CBD on its own, and the
others were in combination with THC/cannabis. Only 1 study
reported the bioavailability of CBD in humans (31% following
smoking). From the analysis of these papers, the following
observations were made; peak plasma concentrations and area
under the curve (AUC) are dose-dependent and show minimal
accumulation; Cmax is increased and reached faster following i.v.,
smoking or inhalation; Cmax is increased and reached faster after
oral administration in a fed state or in a pro-nanoliposphere
formulation; Tmax does not appear to be dose-dependent; and
half-life depends on dose and route of administration. Overall,
considerable variation was observed between studies, although
they were very heterogeneous, and further work is warranted.
Human studies administering CBD showed that the AUC0−t
and Cmax are dose-dependent, and Tmax mostly occurred
between 1 and 4 h. Animal studies in piglets, mice, and rats
also all demonstrate a dose-dependent relationship between CBD
and both plasma and brain concentrations (Long et al., 2012;
Hammell et al., 2016; Garberg et al., 2017), suggesting that
human brain concentrations will also be dose-dependent. Ten
publications in this review reported the half-life of CBD which
ranged from 1 h to 5 days and varies depending on the dose
and route of administration. Very limited data was available for
detailed analysis on the elimination rate, apparent clearance or
distribution of CBD in humans.
Plasma levels of CBD were increased when CBD was
administered with food or in a fed state, or when a meal is
consumed post-administration. Oral capsules with piperine pro-
nanolipospheres also increased AUC and Cmax. This is also
demonstrated in animal studies; co-administration of lipids with
oral CBD increased systemic availability by almost 3-fold in
rats (Zgair et al., 2016) and a pro-nanoliposphere formulation
increased oral bioavailability by about 6-fold (Cherniakov et al.,
2017b). As CBD is a highly lipophilic molecule, it is logical
that CBD may dissolve in the fat content of food, increasing
its solubility, and absorption and therefore bioavailability as
demonstrated by numerous pharmacological drugs (Winter et al.,
2013). Thus, it may be advisable to administer CBD orally in a fed
state to allow for optimal absorption.
Only one study used intravenous administration of CBD
and reported PK details, which could be a beneficial route
of administration in some acute indications. Results from
other routes such as rectal, transdermal, or intraperitoneal
have also not been published in humans, although transdermal
CBD gel and topical creams have been demonstrated to be
successful in animal studies (Giacoppo et al., 2015; Hammell
et al., 2016). Interestingly, intraperitoneal (i.p.) injection of
CBD corresponded to higher plasma and brain concentrations
than oral administration in mice, however in rats, similar
concentrations were observed for both administration routes,
and brain concentrations were in fact higher following oral
compared to i.p. route (Deiana et al., 2012). No published data
exists on the tissue distribution of CBD in humans. Although
plasma levels of CBD do not show accumulation with repeated
dosing, it is possible that there may be tissue accumulation.
Only one study in this review was conducted in children
(n = 34) (Devinsky et al., 2018b). Children (4–10 years) with
Dravet syndrome were administered an oral solution of CBD and
AUC was reported to increase dose-dependently. It is important
to emphasize the statement that children are not small adults,
and there are many differences in their pharmacokinetic and
pharmacodynamic profiles. Absorption, excretion, metabolism,
and plasma protein binding are generally reduced in children
compared to adults, and apparent volume of distribution is
generally increased (Fernandez et al., 2011). These parameters
need to be explored fully for CBD in order to understand and
advise dose adjustments.
Within the adult studies, inter- and intra-subject variability
was observed in studies, and it remains to be seen whether
i.v. and other routes of administration that by-pass initial
metabolism will alleviate this issue. Interestingly, although each
of the subject’s weight was taken into account, none of the
studies addressed subject fat content as a factor in their exclusion
criteria; as muscle can weigh more than the same proportion
of fat. It is well-known that cannabinoids are highly lipophilic
compounds and accumulate in fatty tissue which can then be
released gradually (Gunasekaran et al., 2009). It may be of
benefit in future study to either put in place more stringent
exclusion criteria and measure subject fat content or assess
the possible accumulation of CBD in fatty tissue. Differences
in metabolism, distribution and accumulation in fat, and in
biliary and renal elimination may be responsible for prolonged
elimination half-life and variable pharmacokinetic outcomes.
CBD use is widespread and has been recommended for use
by the FDA in childhood-onset epilepsy. CBD also displays
therapeutic promise in other disorders such as schizophrenia
and post-traumatic stress disorder. If we are to understand the
actions of CBD in those disorders and increase the success
rate for treatment, these groups of patients and their distinct
characteristics must be assessed as they may not be comparable
to a healthy volunteer population.
A systematic review in 2014 concluded that CBD generally
has a low risk of clinically significant drug-interactions (Stout
and Cimino, 2014). A few studies in the current review
included examination of drug-drug interactions with CBD.
GW Pharmaceuticals performed a clinical trial investigating the
pharmacokinetic interaction between CBD/THC spray (sativex)
and rifampicin (cytochrome P450 inducer), ketoconazole, and
omeprazole (cytochrome P450 inhibitors) (Stott et al., 2013c).
Authors concluded overall that CBD in combination with the
drugs were well-tolerated, but consideration should be noted
when co-administering with other drugs using the CYP3A4
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pathway. Caution is also advised with concomitant use of CBD
and substrates of UDP-glucuronosyltransferases UGT1A9 and
UGT2B7, and other drugs metabolized by the CYP2C19 enzyme
(Al Saabi et al., 2013; Jiang et al., 2013). Manini et al. co-
administered CBD with i.v. fentanyl (a high potency opioid)
which was reported as safe and well-tolerated (Manini et al.,
2015). In a number of trials with CBD in children with severe
epilepsy, clobazam concentrations increased when CBD was co-
administered and dosage of clobazam had to be reduced in some
patients in one study (Geffrey et al., 2015; Devinsky et al., 2018b).
Gaston and colleagues performed a safety study in adults and
children in which CBD was administered with commonly-used
anti-epileptic drugs (AEDs) (Gaston et al., 2017).Most changes in
AED concentrations were within acceptable ranges but abnormal
liver function tests were reported in those taking valproate and
authors emphasized the importance of continued monitoring of
AED concentrations and liver function during treatment with
CBD.
Limitations of this review should be acknowledged. Different
population types including healthy and patient populations and
cannabis naïve or not were all grouped together which may
impede generalizability. The proportions of men and women in
each study were also not uniform, and it is still being elucidated
whether men and women have distinct pharmacokinetic profiles
with regards to cannabinoids (Fattore and Fratta, 2010). One
study suggested that the PK of CBD was different in their
female volunteers (Nadulski et al., 2005a). It should also be
mentioned that CBD is currently not an approved product with
a pharmacopeia entry so using different sources of CBD that are
subject to different polymeric forms, different particle sizes, and
different purities may also affect the PK profiles observed. It is
important for future work that researchers record the source of
the CBD material used so that results have the highest chance of
being replicated. Despite a thorough search of the two databases
chosen, the addition of more databases may have widened the
search to increase the number of results and hence improve the
reliability and validity of the findings. However, the review was
carried out by two independent reviewers, and searches generated
were analyzed separately and then compared.
In conclusion, this review demonstrates the lack of research
in this area, particularly in routes of administration other than
oral. An absence of studies has led to failure in addressing the
bioavailability of CBD despite intravenous formulations being
available. This is of critical importance due to the popularity
of CBD products and will help interpret other PK values.
Standardized and robust formulations of CBD and their PK data
are required for both genders, with consideration of other factors
such as adiposity, genetic factors that might influence absorption
and metabolism, and the effects of disease states.
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